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Abstract
The conversion of cholesterol into bile  acids in the live r forms 
a major pathway of cholesterol catabolism and elimination in mammals.
The main rate-lim iting enzyme of this pathway, cholesterol 7a- 
hydroxylase, is a microsomal enzyme which displays some of the character­
istics of a cytochrome P-450-dependent mixed-function oxidase. I t  can 
be hypothesised that a low activ ity  of this hydroxylase may be causal 
in producing hypercholesteraemia and the associated occurrence of 
coronary heart disease.
In the present study this hypothesis was tested using two animal 
models of hypercholesteraemia -  the STR/1N mouse, and the vitamin D and 
cholesterol-fed ra t. In both cases no consistent evidence for this 
proposal could be established.
The nature of cholesterol 7a-hydroxyl ase was examined in ra t liver  
microsomal preparations where typical mixed-function oxidase requirements 
for NADPH and atmospheric oxygen were demonstrated; evidence for a cyto­
chrome P-450 dependency was derived from carbon monoxide inhibition and 
the additive effect on enzyme activity produced by NADPH and NADH in 
combination.
Pretreatment of rats with various cytochrome P-450-dependent mono­
oxygenase inducers such as phenobarbitone and 3-methylcholanthrene did 
not increase cholesterol 7a-hydroxylase activ ity , although administration 
of compounds such as SKF-525A, cholesterol and cholestyramine were 
associated with increases in both cholesterol 7a-hydroxylase activ ity  and 
microsomal cytochrome P-450 content. Compounds such asornaphthoflavone 
and SKF-525A were found to inhibit both cholesterol 7a-hydroxylation and 
biphenyl 4-hydroxylation in microsomal preparations.
A cytochrome P-450 fraction and highly purified NADPH-cytochrome 
c (P-450) reductase, isolated from liv e r microsomal preparations of 
cholestyramine-pretreated rats, were used to reconstitute cholesterol 
7a-hydroxylase activity in the presence of phospholipid. Cholesterol 
7a-hydroxylase in the reconstituted system showed an absolute require­
ment for cytochrome P-450 and NADPH-cytochrome c reductase , and a 
partial requirement for phospholipid.
I t  is concluded that cholesterol 7a-hydroxylase is a cytochrome 
P-450-dependent mixed-function oxidase.
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CHAPTER ONE 
Introduction
1. The Nature and Function of Cholesterol
Cholesterol belongs to the steroid class of lipids which are 
characterised by the possession of a similar cyclic nucleus resembling 
phenanthrene to which a cyclopentane ring is attached, referred to as a 
cyclopentanoperhydrophenanthrene (Figure 1.1}. Cholesterol occurs 
in a ll body cells and is particularly high in nervous tissue, 
connective tissue, body fluids and muscle (Table 1 .1 ). In the body 
cholesterol is present either in the free form or esterified to any one 
of a number of long chain fatty  acids, a small fraction may also be 
sulphated or otherwise conjugated. The main function of cholesterol in 
the body is as a structural component of all cellu lar and intracellu lar 
membranes as well as of the plasma lipoproteins. I t  is also important 
as the starting material for metabolic pathways from which the bile acids 
and the steroid hormones are derived.
i) Cholesterol and Membrane Structure: A number Of theoretical models 
have been proposed to represent the structure of biological membranes, 
ranging from the classical bimolecular sandwich of Danielli & Davson (1934) 
to the fluid mosaic of Singer & Nicholson (1972). These models represent 
the spatial arrangement of the protein and phospholipid components, usually 
with the assumption that cholesterol and minor components f i t  into the 
matrix. The planar nature of the cholesterol molecule would certainly 
allow i t  to be accommodated. The role of cholesterol in membranes remains 
uncertain although the concept f ir s t  suggested by White (1908) that i t  
modifies phospholipid activity has received considerable support from 
a rt if ic ia l phospholipid membrane studies. Van Deenen et al_.(1972) and 
Phillips (1972) report that when cholesterol is spread together with a
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Figure 1.1. The Structural Formulae of Cyclopentanoperhydrophenanthrene 
and Cholesterol.
Table 1.1. The Approximate Distribution of Cholesterol in a 70 kg Man
(Sabine, 1977a).
Cholesterol
System Weight (g) Concentration Amount Percentage of
(% wet weight) (g) total body
cholesterol
Nervous
tissue 1,600 2.0 32.0 22
Connective lnn 
tissue
(including adipose 
& body fluids)
0.25 31.3 22
Muscle 30,000 0.1 30.0 21
Skin 4,200 0.3 - 0.7 16.0 11
Blood 5,400 0.2 10.8 8
Bone
Marrow 3,000 0.25 7.5 5
Liver 1,700 0.3 5.1 4
Alimentary
tract 2,500 0.15 3.8 3
Lungs 950 0.2 1.9 1
Kidneys 300 0.25 - 0.34 0.9 1
Adrenals 12 2.6 - 15 1.2 1
naturally occurring phospholipid at an air-water interface, there is an 
overall decrease in the mean molecular area of the phospholipid molecules. 
Moreover, the permeability of a r t if ic ia l phospholipid membranes to polar 
molecules and ions is lowered by the inclusion of cholesterol in these 
membranes (McElhaney et £l_., 1973). I t  is also known that cholesterol 
modulates the mobility or flu id ity  of phospholipids, an effect which 
depends on whether the membrane phospholipids are above or below their 
transition temperature (Lucy, 1974). Below the transition temperature 
the fatty acyl chains of the phospholipids are relatively rig id , in this 
state cholesterol exerts a disruptive influence which allows increased 
movement of these acyl chains. Above the transition temperature the 
steroid nucleus prevents the movement of the acyl chains so reducing 
f lu id ity . The transition temperature for any particular phospholipid 
depends on the head group, hydrocarbon chain length, and the extent of 
unsaturation (Oldfield & Chapman, 1972). Stier et al. (1976), working 
with rabbit live r microsomes, have recognised that certain membrane 
functional proteins are enclosed in lip id  haloes, and conclude that the 
lip id  serves a structural role in the orientation of such proteins in 
the membrane. Membrane flu id ity  could therefore be expected to effect 
this orientation and presumably the function of these proteins.
ii) Cholesterol and the Plasma Lipoproteins: The bulk of the cholesterol 
in the blood is associated in stable complexes of lip id , protein and 
carbohydrate referred to as lipoproteins which are classified into four 
major types according to their density, flotation rates and electrophoretic 
mobility (Table 1 .2 ). The major functions of these lipoproteins is the 
transport of lip id  material, which is otherwise mostly insoluble, around 
the body.
Table 1.2. Some Physical and Chemical Characteristics o f Human Plasma
Lipoproteins (Scanu et a l . ,  1974; Jain, 1975)
HDL
LDL
VLDL
- high-density lipoproteins,
- low-density lipoproteins,
- very-low-density lipoproteins.
Lipoprotein class
Chylomicrons VLDL LDL HDL
Hydrated
density
(g/ml)
Molecular
weight
Particle
diameter
( * )
< 0.95
109 -  1010
750 - 6000
Percentage composition:
Protein
Triglycerides
Phospholipids
Free Cholesterol
Cholesteryl
Esters
4
78
7.5
5
5.5
0.98 - 1.03 1.03 - 1.09
5-10 x 106
300 - 700
8
55
19
6
11
2 x 106
150 - 300
21
10
28
8
33
1 . 1  -  1 . 2
1-4 x 106
90 - 350
58
6
25
3
8
Chylomicrons are v irtua lly  absent in the fasting state, but arise 
from the gastrointestinal wall, and appear in the lymph and subsequently 
the blood shortly after the ingestion of a meal with the primary purpose 
of transporting absorbed fa tty  acids of chain length C^ or greater 
away from the intestine (Levy a t a K , 1971). The cholesterol content 
of these chylomicra is derived from that absorbed from the gut and that 
provided by endogenous synthesis in the intestinal mucosal cells .
Chylomicrons are cleared rapidly from the blood (Levy £ t  a K , 1971;,
Higgins & Fielding, 1975], the cholesterol content being cleared by the 
liv e r (Redgrave, 1970) and ultimately becomes distributed among the body 
tissues. Very-low-density lipoproteins (VLDL) are synthesised mainly 
in the liv e r, and to a lesser extent by the intestine, and their primary 
function seems to be both the transport of triglyceride from the live r  
to other tissues and the transport of absorbed cholesterol away from the 
intestine. On the basis of their composition and function VLDL are very 
similar to chylomicrons, and may be cleared in the same manner although 
their h a lf-life  is much longer (Windmueller et a l .,  1970; Levy et a l .,  1971). 
In humans the low-density lipoproteins (LDL) form the most abundant lipo­
protein class, unlike most other mammals, where high-density lipoproteins 
(HDL} predominate (Lewis, 1971). The LDL transport cholesterol to the 
tissues and constitute the main carrying component of the plasma for 
cholesterol derived from : hepatic metabolism of VLDL and chylomicron 
remnants; endogenous synthesis; and that released from the peripheral 
tissue stores. The main function presently ascribed to the HDL is in 
the transport of cholesterol mobilised from the peripheral tissues to the 
live r for metabolism and/or excretion (Glomset, 1968). The enzyme lecith in: 
cholesterol acyl transferase (LCAT), which catalyses the transfer of a fa tty  
acid moiety from lecithin to cholesterol -
LCATlecithin + cholesterol -----^  lysolecithin + cholesterol ester, is
thought to be particularly involved in this role of the HDL (Glomset, 1970).
2. Cholesterol Metabolism.
As with any dynamic metabolic system, the absolute amount of 
cholesterol existing within the body at any one time is the net balance 
between influx and efflux. The influx of cholesterol into the body pool 
is constituted by dietary absorption and endogenous synthesis, and efflux 
by catabolism and excretion.
i) cholesterol Absorption: Dietary fats, including cholesterol, enter
the duodenum as a coarse emulsion produced by the physical action of the 
stomach in mixing the gastric secretion with the ingested foods. In the 
duodenum and small intestine lumen this cholesterol mixes with endogenous 
cholesterol from the bile and desquamated mucosal cells , and with sterol 
newly synthesised by the intestine its e lf  (Dietschy & Wilson, 1970a).
All sterol ester bonds are hydrolysed at this stage by the enzyme 
cholesterol esterase, present in the pancreatic juice, such that only 
free cholesterol remains (Shiratori & Goodman, 1965). This cholesterol 
combines with bile salts, fatty  acids and monoglycerides to give in tra ­
luminal complexes, referred to as micelles, for absorption primarily in 
the proximal small intestine. Such micellar solutions of lip id  are 
rapidly absorbed, and represent the major pathway for cholesterol 
absorption, and probably a ll fats (Borgstrdm, 1962). The mechanism of 
absorption remains uncertain although the process does show passive diffusion 
characteristics (Sylven & Borgstrdm, 1968). Within the mucosal cell the 
absorbed cholesterol mixes with the endogenous cholesterol with some 80-90% 
becoming esterified before i t  passes into the lymph (Karmen et aK., 1963;
Blomstrand et al_., 1964; Mott, 1972]. In the lymph the cholesterol 
becomes incorporated into chylomicra and VLDL.
The amount of cholesterol absorbed varies according to numerous 
factors that include age and sex (Lutton & Chevallier, 1972a), species 
and the quantity of cholesterol ingested (Lutton, 1976), the nature of 
the dietary fatty acids and the rate of bile flow (Dietschy & Wilson, 
1970a). The size of the bile acid pool also has an effect. For example, 
measures which decrease pool size such as cholestyramine treatment or 
bile  duct ligation markedly lower cholesterol absorption, whilst the 
addition of taurocholate to the diet increases i t  (Siperstein et a l .,1962 
Lutton & Chevallier, 1972b* Lutton et 1973).
ii) cholesterol Synthesis: The ab ility  to synthesise cholesterol is 
shown by most tissues of the body, although i t  is the liv e r and intestine 
and to a lesser extent the skin that predominate in this capability 
(Dietschy & Siperstein, 1967; Dietschy & Wilson, 1968). The pathway of 
cholesterol synthesis, shown in outline in Figure 1.2, involves both the 
microsomal and cytosolic fractions of the c e ll, and utilises acetyl co­
enzyme A as the source of carbon atoms. The synthesis can be broadly 
divided into several stages, the f ir s t  of which is the formation o f 
mevalonate, a 6-carbon compound, from acetyl-CoA. This mevalonate is 
subsequently transformed into isoprene units, the building blocks of the 
steroid skeleton, with the loss of carbon dioxide. Six of these units 
condense to form the intermediate, squalene, which in turn gives rise to 
lanosterol, the parent steroid. Cholesterol is formed from lanosterol 
after several, further steps, including the loss of 3 methyl groups.
In this pathway the major rate-lim iting step is regarded to be the
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Figure 1.2. An Outline of the Pathway of Cholesterol Biosynthesis.
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formation of mevalonate from B-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA), a reaction catalysed by the microsomal enzyme HMG-CoA 
reductase [EC 1.1.1.34], (Siperstein & Fagan, 1966; Linn, 1967). This 
enzyme is subject to negative feedback control by cholesterol, in 
particular the hepatic activ ity  is inhibited mainly by cholesterol 
absorbed from the intestine (Rodwell et £l_., 1973). In the intestinal 
mucosa cholesterogenesis is in part regulated by intestinal cholesterol 
(McIntyre & Isselbacher, 1973), although i t  is more profoundly influenced 
by bile acids (Dietschy, 1968). In the ra t under normal conditions there 
is a pronounced daily fluctuation in the rate of cholesterogenesis by 
the liv e r , with amaximum at about the middle of the night and a minimum 
at midday (Back e t al_., 1969). This diurnal rhythm appears to be 
derived from a concomitant rhythm of HMG-CoA reductase (Rodwell et a l .,
1973). I t  is not known whether man possesses this rhythm. Other factors 
known to influence the rate of cholesterol synthesis include the nutritional 
status, in fasting cholesterogenesis declines (Tomkins & Chaikoff, 1952), 
and various hormones (Sabine, 1977b).
i i i j  cholesterol Elimination: The main route of cholesterol disposal
in the body is by way of its  metabolism to the bile acids, although in 
man a considerable amount of the sterol can be lost in the faeces which 
contain cholesterol from b ilia ry  excretion and desquamated epithelial 
cells , and that unabsorbed from the diet (Grundy & Ahrens, 1969; Dietschy 
& Wilson, 1970b). In the ra t, faecal cholesterol excretion is relatively  
low compared with that of bile acids (Lutton, 1976). Faecal cholesterol 
is subject to bacterial metabolism in the lower regions of the digestive 
tract with the bulk being converted to coprostanol and coprostanone 
(Ttosenfeld et aj_., 1954; Kudchodkar et al_., 1972); only a small amount of
the faecal cholesterol escapes unscathed and is excreted as such. Small 
quantities of cholesterol are also lost in the urine (Vela & Acevedo, 1969) 
and through the skin (Bhattacharyya et a l . ,  1972).
The metabolism of cholesterol to the steroid hormones, which occurs 
predominantly in the sex organs and adrenal cortex, is qualitatively of 
major importance to the mammal, but quantitatively i t  represents only a 
minor pathway of cholesterol loss. The principal reactions of steroid 
hormone biosynthesis from cholesterol following the splitting of the C-20 
to C-22 bond involve the addition or removal of hydrogens by dehydrogenases 
and the addition of oxygen by hydroxylases. Degradation of these steroids 
is facilita ted  primarily in the live r and kidney by similar sets of stereo- 
specific dehydrogenases and hydroxylases (Briggs & Brotherton, 1970). 
Metabolic products, such as 17-ketosteroids formed from the androgens, can 
be excreted as such but are more often conjugated as sulphates or 
glucuronides (Briggs & Brotherton, 1970). In man the main route of excretion 
of these products is in the urine, with disposal into the bile being a more 
minor route.
The origin of bile acids from cholesterol was f ir s t  demonstrated by 
Bloch et a K (1943), who showed that deuterium-labelled cholesterol was 
transformed into deuterated bile acid. Since then, investigations in 
several laboratories have contributed to the elucidation of the currently 
accepted pathway of bile acid synthesis shown in outline in Figure 1.3.
These studies have been extensively reviewed in the literatu re  (Danielsson 
& Einarsson, 1969; Danielsson, 1973; Danielsson & S jdvall, 1975). The 
conversion of cholesterol into bile acids involves the introduction of 
hydroxyl groups into the 7a- and 12a-positions of the sterol nucleus, the
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Figure 1.3. The Pathway for the Biosynthesis of the Primary Bile Acids.
inversion of the 38-hydroxyl group to the 3a-configuration via a 3-keto 
intermediate, reduction of the A5-double bond, and shortening of the side- 
chain by removal of a terminal three-carbon fragment. As a result of 
these modifications in the structure of cholesterol, the coenzyme A 
derivatives of the primary bile  acids, cholic and chenodeoxycholic acids 
are generated. These may then be conjugated through a peptide linkage to 
either glycine or taurine and secreted into the bile as the primary bile  
salts, taurocholic, glycocholic, taurochenodeoxycholic, or glycocheno- 
deoxycholic acids. Bile its e lf  is secreted into the duodenum in response 
to the release of cholecystokinin from the duodenal mucosa, a process 
activated by gastric emptying. The bile salts in the gut are responsible 
for both the e ffic ien t absorption of the fat-soluble vitamins, and the 
emulsification of fats allowing better enzymic digestion of the partia lly  
digested food materials entering the duodenum.
Further metabolism of bile salts within the intestine by bacteria 
of the gut microflora may also occur, comprising deconjugation to the free 
bile acid and 7a-dehydroxylation to form secondary bile acids such as 
deoxycholic acid from cholic acid and lithocholic acid from chenodeoxy­
cholic acid. Approximately 90% of all bile acids in the intestine are 
reabsorbed almost exclusively in the distal ileum where an active transport 
system has been identified (Harper, 1975). Reabsorbed bile  acids are 
returned to the live r via the portal blood as the last stage in their 
enterohepatic cycle. In man i t  has been estimated that there may be 6-10 
such circulations per day (Dietschy, 1972). Any secondary bile  acids 
returned to the liver may be rehydroxylated to the relevant primary bile  
acid and conjugated with glycine or taurine, as are any unconjugated bile  
acids that are returned, prior to re-excretion in the b ile . Only a small
fraction of the daily bile acid turnover is therefore lost in the faeces 
normally and is replaced by an equal amount synthesised from cholesterol 
to maintain pool size.
The f irs t  step in the sequence of reactions leading to the formation 
of bile acids is a 7a-hydroxylation of cholesterol to form cholest-5-ene- 
3g9 7a-diol or 7a-hydroxycholesterol (Danielsson & Einarsson, 1964 & 1966), 
a reaction catalysed by the liver microsomal enzyme cholesterol 7a- 
hydroxylase (EC 1.14.13.17). Interruption of the enterohepatic circulation  
of bile acids by either dietary cholestyramine-, an anion exchange resin 
that binds bile acids in the intestine, or producing a b ilia ry  fis tu la  
increases the rate of this reaction many fold (Shefer et al_., 1968; Boyd 
et al[., 1969; Johansson, 1971) whilst other reactions in the biosynthetic 
pathway are relatively unaffected (Danielsson et a l . ,  1967; Johansson, 
1970). Moreover, the demonstration that b ile  acid synthesis mainly 
undergoes regulation homeostatically by bile acids returning to the liv e r  
from the intestine (Shefer al_., 1969) and that the incorporation of 
[4 -llfC]cholesterol but not 7a-hydroxy[4-1IfC] cholesterol into b ile  acids 
is inhibited or stimulated in the presence or absence of the bile  acid 
pool respectively (Shefer et a l . ,  1970; Mosbach et al_., 1971) have 
established the role of the 7a-hydroxylase as the main rate-determining 
step in the pathway of bile acid synthesis.
The possibility that the homeostatic regulation of bile acid 
formation could also involve the activ ity  of HMG-CoA reductase cannot 
be discounted in view of the similar modulations in the activ ities  of 
this enzyme and cholesterol 7a-hydroxylase observed under several 
conditions. Both enzymes exhibit an identical diurnal variation in
activ ity  (Gielen £ t  al_., 1969; Backet al_., 1969; Mitropoulos et a l .,
1972; Danielsson, 1972] which is abolished by adrenalectomy (Gielen et a l . ,  
1975; Mitropoulos & Balasubramaniam, 1976) and hypophysectomy (Huber et a l .,  
1974; Mayer & Voges, 1972). They are induced by portacaval anastomosis 
(Boyd & Lawson, 1976; Balasubramaniam et a l . ,  1976), glucose feeding 
after starvation (Takeuchi -et al_., 1974), introduction of a b ilia ry  fis tu la  
or cholestyramine treatment (Myant & Eder, 1961; Danielsson et al_., 1967; 
Boyd et , 1969), and are repressed by fasting (Mayer, 1976) . Conceivably 
changes in the rate of cholesterol biosynthesis may a lter the substrate 
ava ilab ility  for bile acid formation, hence the parallel changes in the 
activ ities  of these enzymes and the possible regulatory role of HMG-CoA 
reductase. Certainly the preferential u tilisation  of newly synthesised 
cholesterol by cholesterol 7ct-hydroxyIase has been suggested (Balasub­
ramaniam et al_., 1973; Mitropoulos et al_., 1974; Bjdrkhem & Danielsson, 
1975), and would appear to account for about 50% of that utilised for bile  
acid synthesis (Bjdrkhem & Lewenhaupt, 1979). I t  has also been proposed 
that cholesterol derived from plasma HDL contributes to this substrate 
pool (Halloran et al_., 1978).
Alternatively, the feeding of cholesterol decreases HMG-CoA reductase 
activ ity  (Shapiro & Rodwell, 1972) but increases cholesterol 7a-hydroxylase 
activ ity  presumably by increasing the substrate ava ilab ility  with exogenous 
cholesterol (Mitropoulos et , 1973), although possible changes in 
enzyme concentration induced by cholesterol may also be important 
(Mitropoulos et aK , 1978). Furthermore, the increase in cholesterol 
7a-hydroxylase activ ity  produced by thyroxine treatment precedes the rise 
in HMG-CoA reductase also produced (Balasubramaniam et £l_., 1975a). I t  is 
therefore clear from these considerations that some confusion exists 
concerning the regulatory role of HMG-CoA reductase and substrate supply in 
bile acid synthesis.
3. The Association of Cholesterol with Atherosclerosis and Coronary
Heart Disease.
Coronary heart disease ranks as the major cause of death among 
present day Western Man, accounting for a quarter of a ll deaths in 
England and Wales (Registrar General's Statistical Review, 1971) and up 
to half of deaths in the United States of America (Gotto et al_., 1976).
The disease results from atherosclerosis of the coronary arteries, a 
condition defined by the World Health Organisation as "a variable 
combination of changes of the intima of arteries, consisting of focal 
accumulation of lip ids, complex carbohydrates, blood and blood products, 
fibrous tissue and calcium deposits, and associated with medial changes" 
(Krause et a l .,  1968).
The f irs t  indications of atherosclerosis appears in the f ir s t  
decade of l i fe  as fatty streaks, or spots, of the aorta and carotid 
arteries (Gresham, 1972), and consist of lip id  accumulated in tra- 
cellu larly by smooth muscle cells that assume a lip id  storage function, 
i .e .  foam cells. In later l i f e ,  fibrous plaques and lesions laden with 
lip id  (atheroma) appear which consist o f extracellularly accumulated 
lip id  and large amounts of collagen, elastin and various in te rs titia l 
glycoproteins synthesised by smooth muscle cells . Coronary heart 
disease, such as myocardial infarction, may then ensue due to vascular 
obstruction produced by the lesion its e lf  or by thrombosis of vessels 
already affected by atherosclerosis. The major lip id  of the atherosclerotic 
lesion would appear to be cholesteryl ester (Smith, 1965).
A number of hypotheses for the pathogenesis of atherosclerosis have 
been forwarded ranging from the lip id  in filtra tio n  hypothesis of
Virchow (1856), which suggests the lesion is promoted by intima! lip id  
accumulation from the plasiria, to the "response to injury hypothesis" of 
Ross & Glomset (1976) which imp!icates . damage imparted to vthe arterial 
endothelium by, for example, hyperlipidaemia or increased shear stress 
as seen in hypertension, to the monoclonal theory of Benditt & Benditt 
(1973) which suggests each lesion results from the focal proliferation  
of smooth muscle cells in the intima of the artery.
Population studies have established strong, consistent but independent 
relationships of serum cholesterol, blood pressure and cigarette smoking 
with coronary heart disease, as exemplified by the recent report of the 
Pooling Project Research Group (1978). In particular, patients with 
hypercholesteraemia have a greater risk of developing atherosclerosis 
and the associated, often fatal occurrence of myocardial infarction (Kannel 
et aJL., 1971; Carlson & Bdttiger, 1972; Wilhelmsen et al_., 1973; Keys, 1975). 
Elevation of plasma cholesterol, mainly of the LDL fraction, is assumed to 
increase the rate of cholesterol deposition in the tissues, including the 
arterial intima (Smith, 1965; Insull & Bartsch, 1966; Malmros,1976; Ross 
& Harker, 1976; Goldstein & Brown, 1977).. Conversely, reduction in plasma 
cholesterol may reduce the risk of death from coronary heart disease.
Attempts to decrease plasma cholesterol by diet or drugs are based on the 
supposition that a drop in the rate of cholesterol deposition may retard 
the development of atherosclerotic lesions. The more recent establishment 
of a high concentration of plasma HDL cholesterol as a negative risk factor 
in coronary heart disease (M iller & M iller, 1975; Gordon et al.;, 1977a & b) 
has directed current pharmaceutical interest towards the search for anti- 
atherosclerotic agents that elevate the plasma HDL fraction.
4. The Mtxed-Function Oxidases
The term mixed-function oxidase was introduced by Mason (1957) and 
refers to enzyme-catalysed reactions in which one atom of a molecule of 
oxygen is introduced into the substrate, the other being reduced to water 
by a reduced coenzyme, usually NADPH. In this reaction two electrons are 
consumed for each molecule of oxygen, and may be depicted thus:
RH + NADPH + H+ + 02  » ROH + NADP+ + H-O,
where RH is the substrate.
il The Hepatic Microsomal Drug-Metabolising Mixed-Function Oxidases:
The endoplasmic reticulum of the live r is known to contain a membrane- 
bound mixed-function oxidase system that utilises many endogenous and foreign 
compounds as substrates (Conney, 1967; G ille tte  £ t£ l_ ., 1972). This enzyme 
system has a haemoprotein referred to as cytochrome P-450 acting as the 
substrate- and oxygen-binding s ite , and a flavoprotein, NADPH-cytochrome 
P-450 reductase, which catalyses the transfer of electrons from NADPH to 
cytochrome P-450. Solubilisation, resolution and reconstitution o f this 
enzyme system was originally reported by Lu & Coon (1968) and Coon & Lu 
0  9691 who showed a requirement for these two components in substrate 
hydroxylation and that in addition a heat-stable, chloroform-soluble factor 
was also needed. This factor was subsequently identified as phospholipid 
(Strobe! eteT_.» 1970). The role of this lip id  is uncertain, but in 
reconstituted systems i t  is essential for electron transport from NADPH 
to cytochrome P-450 although i t  is not an electron carrier (Strobe! e t a l ., 
1970; Depierre & Dallner, 1975). Stier (1976) considers that these 
properties of the lip id  are the result of a structural role in which i t  
orientates the haemoprotein and its  flavoprotein reductase in a lip id  halo
that allows effic ien t electron transfer from NADPH. The scheme presented 
in Figure 1.4 shows the series of reactions generally thought to be 
involved in substrate hydroxylation by this system.
ii) Induction and Inhibition of the Microsomal Mixed-Function Oxidases:
Enzyme induction of the microsomal mixed-function oxidases occurs when their 
activ ity  becomes enhanced as a result of increased synthesis of the enzyme 
protein(s), and may be produced by repeated dosing with certain drugs or 
environmental chemicals (Parke, 1968). Three major classes of inducing 
agents of this system are recognised, and these are:
-  drugs and insecticides such as phenobarbitone and DDT,
-  polycyclic hydrocarbons such as 3,4-benzpyrene and 3-methylchol-
threne, and
-  catatoxic steroids such as pregnenolone 16a-carbonitrile.
High substrate concentration or a slow rate of substrate metabolism by these 
enzymes is currently considered the in itia tin g  fafctor in enzyme induction. 
Under such conditions the active site of the enzyme would be saturated by 
substrate for extended periods, which could lead to competitive inhibition  
of the enzyme with subsequent derepression of the genome for the enzyme to 
provide increased synthesis of the enzyme protein. In keeping with this 
concept substrates such as phenobarbitone that are metabolised slowly by 
this system are also found to be inducers.
Enzyme inhibition of the microsomal mixed-function oxidases may be 
competitive in nature as a result of substrate saturation of the active 
site that is considered to occur during enzyme induction, or may be non­
competitive in nature where the inhibitor binds to some allosteric site  
on the enzyme protein preventing substrate binding at the active s ite .
The methylenedioxyaryl compounds are particularly noted for their competitive 
inhibition of this system (Fu jii et aJL, 1970).
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Figure 1.4. The Proposed Mechanism of Microsomal Cytochrome P-450 
-Dependent Hydroxylations (Estabrook £ ta j_ ., 1971).
©  Association of substrate to oxidised cytochrome P-450; ©  Reduction 
of NADPH-cytochrome P-450 reductase by NADPH; ©  Reduction of cytochrome 
P-450-substrate complex by reduced NADPH-cytochrome P-450 reductase; @ 
Addition of oxygen to reduced cytochrome P-450-substrate complex; ©  Reduction 
of oxygenated-reduced cytochrome P-450-substrate complex by another electron, 
probably from reduced NADPH-cytochrome P-450 reductase; ©  Decomposition of 
oxygenated-reduced cytochrome P-450-substrate complex to yield hydroxylated 
substrate, oxidised cytochrome P-450 and water.
iii) The Heterogeneous Nature of Cytochrome P-450: Whether the numerous 
activities attributed to liver microsomal cytochrome P-450 resides in
one or more forms of this pigment has been the subject of much investigation. 
The diversity of substrates u tilised, the differences in their metabolism 
in various experimental animals and the variable enzyme activ ities  observed 
in microsomes of animals treated with various inducing agents suggest that 
a number of forms of microsomal cytochrome P-450 are present (Haugen et al_., 
1975). Purification of this haemoprotein to homogeneity has established 
the apparent occurrence of multiple forms that d iffer in their physical 
and chemical properties as well as in the agents which bring about their 
induction (Coon et al_., 1975; Imai & Sato, 1974; Guengerich, 1977; Lu &
West, 1978; Ryan et al_., 1979). Moreover, each of the various forms appear 
able to metabolise a ll of the substrates, but d iffer in their relative  
efficiencies of substrate turnover (Haugen et al_., 1975). Variation in the , 
proportions of the various cytochrome P-450 forms in a given microsomal 
preparation could explain the species, strain, sex and age differences
observed in microsomal metabolism (lu , 1977).
iv) The Metabolism of Lipids by the Hepatic Microsomal Mixed-Function
oxidases: The hepatic microsomal cytochrome P-450-dependent mixed-
function oxidase system is associated with the hydroxylation of a variety 
of lipids (Brenner, 1977), for example, i t  is capable of co- and a-hydroxy- 
lating fatty  acids. The co-hydroxylation of fatty acids is important as an 
alternative route of oxidative attack of the fatty acid molecule at the 
— CHg end of the molecule to give — ^ O H , followed by oxidation to — COOH 
to give the dicarboxylic acid provided by soluble enzymes of the cytosol
and NAD (jtobbin, 1961; Preiss & Bloch, 1964; Wada e t ^ K ,  1968b; Bjdrkhem
and Danielsson, 1970). Dicarboxylic acids so produced may then enter the
mitochondrial 3-oxidation pathway of fatty acid oxidation ultimately 
yielding succinyl-CoA, an important gluconeogenic intermediate and starting 
material for haem biosynthesis. a-Hydroxylation of fa tty  acids by the 
cytochrome P-450-dependent mixed-function oxidase system provides 2- 
hydroxy acids which are important in the synthesis of cerebrosides such 
as 2-hydroxylignoceric acid (Brenner, 1977).
This enzyme system plays a significant role in the metabolism of 
cholesterol. In cholesterol biosynthesis cytochrome P-450 has been 
implicated in the later stages of the pathway, particularly the mono­
oxygenation of squalene to form squalene-2,3-epoxide (Tai & Bloch, 1972).
The catabolism of cholesterol to b ile  acids involves the introduction 
of hydroxyl groups into the 6a, 63, 7a, 12a, 16a, 23, 24, 25 and 26 
positions all of which, with the exception of the 24- and 26-hydroxylations, 
are catalysed by this microsomal enzyme system (Bjflrkhem et a l . ,  1975;
Brenner, 1977).
This microsomal mixed-function oxidase system of the liv e r also plays 
an important role in the deactivation of steroid hormones such as testosterone 
which can undergo hydroxylation in the 23, 63, 7a and T6a-positions 
($ustafsson et al_., 1968). The 25-hydroxylation of vitamin Dg, the in it ia l  
transformation in the activation of this vitamin in the body is also performed 
by this enzyme system (Bhattacharyya & DeLuca, 1974; Madhok et al_., 1978).
vl Cholesterol 7a-Hydroxylase and its Relationship to the Microsomal
Cytochrome P-450-Dependent Mixed-Function Oxidase System: Cholesterol 
7a-hydroxylase has many features in common with the cytochrome P-450- 
dependent hydroxylating system in that i t  requires NADPH and molecular 
oxygen (Mi tton et al_., 1971), and is inhibited by carbon monoxide (Wada
e t ^ k 9 1968; Mitropoulos & Balasubramaniam, 1972). Moreover, this 
inhibition has been optimally relieved by irradiation with monochromatic 
light at 450 nm (Boyd et a l .,  1973). The participation of NADPH-cytochrome 
c (P-450) reductase in this hydroxylation has been shown in studies where 
an antibody to this reductase was found to inhibit the 7a-hydroxylation 
of cholesterol (Wada et £l_., 1969). I t  would therefore appear like ly  
that cholesterol 7ct-hydroxylase is a cytochrome P-450-dependent microsomal 
mixed-function oxidase.
The rate of substrate hydroxylation by the live r microsomal fraction 
in most cases appears to be determined by cytochrome P-450 concentration. 
For example, the hepatic microsomal metabolism of aminopyrine by oxidative 
demethylation increases concomitantly with the induction of cytochrome 
P-450 CErnster & Orrenius, 1965); similar findings have been reported for 
the metabolism of ethylmorphine (Balasubramaniam & Mitropoulos, 1975). 
However, changes in the activ ity  of cholesterol 7a-hydroxylase cannot 
always be correlated with either the concentration of cytochrome P-450 
or the activ ity  of its  flavoprotein reductase in hepatic microsomes. This 
effect is particularly well demonstrated in cases where the enterohepatic 
circulation of bile acids has been interrupted and also during the dark 
period of the diurnal cycle (Gielen et jH_., 1969; Mitropoulos et aiK, 1972; 
Balasubramaniam & Mitropoulos, 1975). In both cases the activ ity  of 
cholesterol 7a-hydroxylase is markedly increased over the basal level but 
no changes in cytochrome P-450, NADPH-cytochrome c reductase or ethyl­
morphine N-demethylase activities can be detected. The administration of 
phenobarbitone to rats has variable effects on cholesterol 7a-hydroxylase 
even though i t  repeatedly induces the components and activ ities  of the 
live r hydroxylating system, as considered in more detail in Chapter 6.
These observations, together with the proposed existence of 
cytochrome P-450 in multiple forms have led to speculation regarding 
the presence of a specific form of cytochrome P-450 that catalyses the 
7a-hydroxylation of cholesterol (Wada e t^ T .,  1969; Atkin et a l . , 1972).
I f  this form comprised only a small proportion of the total liver  
microsomal cytochrome P-450 then i t  would be d iff ic u lt  to measure any 
changes in the total cytochrome under conditions of induction or 
repression of this enzyme (Myant & Mitropoulos, 1977). Alternatively, 
the existence of an additional component in this system for the 
7a-hydroxylation o f cholesterol, such as a cholesterol specific carrier 
protein which controls the access of cholesterol to the active s ite , 
has been proposed (Brown & Boyd, 1974). Presumably modulations in the 
level of such a protein would mediate changes in enzyme ac tiv ity .
5. The Role of Lipids, Lipid Metabolism and Mixed-Function Oxidation 
in Cardiovascular Disease.
Strasser (1972) has listed over 30 factors related to the risk of 
cardiovascular disease ranging from age to hardness or softness of local 
water, and includes a number of facets of lipids and their metabolism, 
such as the nature of the dietary fats.
A close correlation between the nutritional intake of fats of the 
saturated type and the incidence of hypercholesteraemia and cardiovascular 
disease in man has been well documented (Keys, 1970; Kritchevsky, 1976; 
Turpeinen, 1979). Studies have also shown that the substitution of 
unsaturated fat for the saturated fat in the diet lowers the serum 
cholesterol level and decreases the risk of cardiovascular disease 
(Dayton et a l . ,  1962; H ill & Wynder, 1976; Turpeinen, 1979). In animals
ample evidence that diets containing saturated fat are more atherogenic 
than similar diets in which the fa t is unsaturated has also been reported 
(Kritchevsky, 1970; Kritchevsky et a l . , 1976). There is a good deal 
of controversy as to how dietary fat influences the plasma cholesterol 
level. Some workers have observed an increase in faecal b ile  acid and 
neutral steroid outputs in humans given polyunsaturated fats in the diet 
(Wood et a l .,  1966; Connor et al_., 1969) which would implicate an 
accelerated rate of cholesterol degradation to bile acids, particularly  
increased cholesterol 7a-hydroxyl ase activ ity , in this effect. Recent 
studies in the rabbit have supported this proposal (Gray, 1979). Others, 
however, have failed to show this and conclude that the hypocholesteraemic 
effect arises from a sh ift of cholesterol from the blood to the tissues 
(Avigan & Steinberg, 1965; Spri tz et , 1965).
The inclusion of unsaturatect fats in the diet of rats has been found 
to be necessary for maximum induction of cytochrome P-450 and hepatic 
drug metabolism after administration of phenobarbitone (Marshall & McLean, 
1971; Century, 1973; Lambert & W ills, 1977), and would suggest a necessary 
role for unsaturated fats in maintaining the functionality and responsiveness 
of the hepatic microsomal mixed-function oxidases. I t  may be that diets 
high in saturated fat depress hepatic microsomal mixed-function oxidase 
activ ity , such as cholesterol 7a-hydroxylation. Others, however, have 
found a lowering of hepatic microsomal cytochrome P-450 and drug-metabolising 
ab ility  in rats fed unsaturated fats (Norred & Wade, 1972; Lang, 1976).
Fibre in the diet acts not only as roughage but i t  also influences 
hypercholesteraemia and atherosclerosis. In 1964, Kritchevsky reported 
an anti-atherogenic effect of stock diet compared to a semi-synthetic diet
in rabbits fed saturated fa t, and subsequently showed that the non­
nutritive residue of the stock diet was responsible for this protective 
effect (Kritchevsky & Tepper, 1965). The la ter finding that certain 
types of fibre avidly bound bile  salts in vitro lead to the proposal 
that the hypolipidaemic role of dietary fibre arises from its  a b ility  
to sequester b ile  acids in the gut fac ilita tin g  their faecal excretion 
which in turn lowers the proportion of b ile  acids available for 
cholesterol absorption (Kritchevsky, 1974 & 1978). Cpnversely, a low 
dietary fibre intake would allow an increased absorption of cholesterol 
in the gut resulting in hypercholesteraemia and atherosclerosis.
Another possible mechanism might be impaired bile acid synthesis, 
particularly a low level of cholesterol 7a-hydroxylase activ ity , 
produced by excessive enterohepatic recirculation of b ile  acids that 
might result from a lack of retention of bile acids in the gut by the 
fib re.
A dietary deficiency of ascorbic acid has also been shown to 
predispose to hypercholesteraemia and cardiovascular disease (Ginter, 
1976; Turley et £l_., 1976), as well as to lowered live r mixed-function 
oxidase activity (Zannoni, 1977}. The hypercholesteraemia of the 
scorbutic state, primarily studied in the guinea pig, would not appear 
to arise from an increased synthesis of cholesterol (Weight et al_., 1974) 
6utrather from a depressed rate of cholesterol catabolism to bile  acids 
(Guchait, Guha & Ganguli, 1963; Ginter et a l . ,  1973). More recently, 
Bjdrkhem & Kaliner (1976) and Harris e t afl_. (1979) have shown ascorbate 
deficiency is associated with a depressed cholesterol 7a-hydroxylase 
activ ity , a finding which directly implicates this enzyme in the genesis 
of hypercholesteraemia.
Aims of the Present Study
The aims of the present study were three-fold:-
i)  to investigate the possible role of cholesterol 
7a-hydroxylase activity in hypercholesteraemia;
i i )  to elucidate the relationship between cholesterol 
7a-hydroxylase and the hepatic microsomal cytochrome 
P-450-dependent drug metabolising system; and
i i i )  to examine whether cytochrome P-450, its  flavoprotein 
reductase and phospholipid are required for the
7a-hydroxyl a ti on of cholesterol.
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Materials
Chemicals: NADPH, NAD, NADH, glucose 6-phosphate, glucose 6-phosphate
dehydrogenase, flavin mononucleotide (TMN), dilauroylphosphatidyl choline, 
dith io th re ito l, vitamin D2, 3-methylcholanthrene, cholesterol, cholesteryl 
ester (T in° leate ), o-phthalaldehyde, bovine serum albumin, 6-mercapto- 
ethylamine and trisChydroxymethyl}aminomethane (Tris) were a ll purchased 
from Sigma Chemical Co., London. NADP and cytochrome c were obtained 
from Boehringer-Mannheim Corporation, Lewes, Kent. Vitamin D3 was 
from Koch-Light Laboratories Ltd., Colnbrook, Bucks. A water dispersable 
preparation of vitamin D ,^ Duphasol, was a g if t  from Biorex Laboratories 
Ltd., London, and previously obtained from N.V. Philips-Duphar, Amsterdam, 
Holland. [4 -14C]Cholesterol, specific activ ity  54-57 mCi/toimol and 
radiochemical purity of at least 98%, was purchased from the Radiochemical 
Centre, Amersham; i t  was stored in benzene or toluene under nitrogen at 
4°C until required.
Tween 80, cholesterol, o-naphthoflavone, phosphomolybdic acid, 
Biphenyl, semicarbazide hydrochloride, acetyl acetone, Folin-Ciocalteu 
Phenol, sodium deoxycholate, dimethylformamide, phenobarbitone sodium, 
and EDTA were supplied by British Drug Houses, Poole* Dorset. 2- and 4- 
Hydroxybiphenyls, and safrole were from Hopkins & Williams, Chadwell 
Heath, Essex. Piperonyl butoxide was supplied by Phase Separations 
Ltd., Deeside, Flintshire. 2-Propylbenzimidazole and 2-methylbenz- 
imidazole were from the Aldrich Chemical Co., Ltd., Gillingham, Dorset.
All gases were supplied by the British Oxygen Company, Crawley, Sussex.
Emulgen 911, generously donated by Dr. G. Gibson, was previously 
obtained from the Kao-Atlas Co., Tokyo, Japan. DEAE-Cellulose (DE 52)
was purchased from Whatman Ltd., Maidstone, Kent. Hydroxyapatite 
(BiOrGel HTP) and Bio-Beads SM2 were supplied by Bio-Rad Laboratories, 
Richmond, USA. Chromatography columns (2.6 x 40 cm and 0.9 x 30 cm) 
and Sephadex G-25 (medium) were obtained from Pharmacia, Hounslow, 
Middlesex. 2 1,5 '-Adenosine diphosphate-agarose and 2 '-adenosine 
monophosphate were from International Enzymes, Windsor, Berkshire.
Cholestyramine (Bristol Laboratories, Slough), pregnenolone 16a- 
carbonitrile (Upjohn Co. Ltd., Crawley, Sussex), SKF-525A (Smith, Kline 
& French Laboratories Ltd., Welwyn Garden City, Herts.), metyrapone 
(CIBA Laboratories, Horsham, Sussex), dodecylimidazole (Beecham 
Pharmaceuticals, Tadworth, Surrey), ethylmorphine hydrochloride (May 
& Baker L td .,.Dagenham, Essex) and 7a-hydroxycholesterol (Professor G. 
Boyd, Edinburgh) were a ll received as g ifts .
Other Materials: Thixotropic gel powder (Cab-o-sil) and 2,5-diphenyl- 
oxazole (PPO) were supplied by the Packard Instrument Co., London. The 
t . l . c .  plates, coated with Silicagel G1500 and with or without fluorescent 
indicator, were purchased from Scheicher & Schttll, Dassel, West Germany. 
Glass and quartz spectrophotometer and fluorimeter cuvettes, visking 
dialysis tubing, and glass wool were from Scientific Supplies, London.
All syringes and needles were from G ille tte  Surgical,Is!eworth, Middlesex.
Animals: Male rats of the University of Surrey Wistar albino strain were
used and housed on an inert bedding (Sebitol from E.A. Lee, Staines, 
Surrey).
Three strains of mice were used, namely STR/1N, CF1 and C3H(he-Mg). 
Mice of the STR/1N strain were bred from 4 breeding pairs generously 
donated by Biorex Laboratories Ltd., this mice strain was previously
obtained from Dr. C.T. Hanson, National Institutes of Health, Bethesda, 
USA. All mice were housed on wood shaving bedding.
All animals were bred,and housed under constant conditions of 
humidity (50%), temperature (22°C) and lighting (0700-1900h ligh t period, 
1900-0700h dark period) in the University of Surrey Animal Unit. They 
were routinely allowed access to food (Spratt's Laboratory Services, 
Barking, Essex) and water ad libitum except where otherwise specified. 
Pregnant female STR/1N mice were given milk powder as an alternative d ie t.
Methods
Pretreatment of Animals: To produce experimental atherosclerosis 
Vitamin D2 (240,000 I.U ./kg) was given orally once daily for 5 days to 
250-300g rats either alone as a crystalline suspension in olive oil 
(2 ml/kg), or in combination with cholesterol (30 mg/kg) in olive o i l ,  
or as the water dispersable preparation Duphasol (4 ml water/kg) in 
combination with cholesterol in olive o i l .  A cholesterol in olive oil 
dosed group was also used. Similarly vitamin D^  (240,000 I.U ./kg) was 
given orally for 5 days as a crystalline suspension along with cholesterol 
in olive o i l .  In one study a pair-fed group was used where the rats 
received olive o il orally (2 ml/kg) once daily for 5 days plus dietary 
restriction to adjust their food consumption to the same level as that of 
a vitamin D2 plus cholesterol dosed group run in p ara lle l.
To induce the live r microsomal enzymes phenobarbitone sodium 
(_80 mg/kg) in isotonic saline (2 ml/kg), 3-methylcholanthrene (20 mg/kg) 
in corn oil (4 ml/kg), or safrole (150 mg/kg) in corn o il (2.5 ml/kg) 
were each administered intraperitoneally once daily for 3 days to 180-200g 
rats. Pregnenolone 16aT-carbonitrile (20mg/kg) was dosed orally as an
aqueous microcrystalline suspension containing 1 drop of Tween 80/10 ml 
to 150-170g rats twice daily for 3 days. SKF-525A (50 mg/kg) in isotonic 
saline (2 ml/kg] was given intraperitoneally to 180-200g rats by two 
separate regimes, f ir s t ly ,  once daily for 2 days, and secondly, as one dose 
lb prior to death.
Both cholesterol and cholestyramine were given in the diet to 
180-200g rats at a level of 1 % and 4% (w/w) respectively for 5 days. For 
the studies in chapter 7 cholestyramine was added to the diet of 240-260g 
rats in the same manner.
All rats were dosed between 0900-11OOh and killed 24h after the last 
dose with the exceptions of rats treated with pregnenolone 16a-carbonitrile, 
which were dosed between 1630-1700h in addition and killed 15h after the 
last dose, and rats treated with SKF-525A which were k illed  Ih after a 
single dose. Control rats were given the appropriate volume of the 
administration vehicle only. The food consumption and body weight of 
both test and control rat groups were monitored daily.
Preparation of Liver Fractions: Animals were killed by cervical dislocation 
between 0830-0930h and the livers removed immediately into ice-cold 0.1M 
Tris/HCl buffer, pH 7.4, containing 0.25M sucrose. Each live r was rinsed, 
blotted dry and weighed, finely scissor minced in 2 vol. Tris-sucrose 
buffer and homogenised with a Tri-R variable speed d r il l  (Camlab,
Cambridge} at low speed using two return strokes of a size C Potter- 
Elvehjem type, glass-teflon homogeniser (A.H. Thomas & Co., Philadelphia). 
The homogeniser was rinsed with a further 2 vol. Tris-sucrose buffer.
The resultant 20% Gw/v l homogenate was centrifuged at 18,000g for 20 min 
to prepare the post-mitochondrial supernatant. Further centrifugation
of this supernatant at 105,000 g av. for 60 min yielded a clear supernatant, 
which was discarded, and a microsomal pe lle t. This pellet was resuspended 
in its  original volume with 20 mM Tris/HCl buffer, pH 7.4, containing 
154 mM KC1 using a size B glass-teflon homogeniser as above. A washed 
microsomal fraction was prepared by recentrifuging the resuspended 
microsomes at 105,000 g av. for 60 min to re-sediment the microsomal pellet 
which was subsequently resuspended as before.
All preparative procedures were performed at 4°C. In the studies 
reported in Chapters 4, 5 and 6 blood was collected by heart puncture 
from the experimental animals under ether anaesthesia prior to k illin g .
Blood samples were allowed to clot for 2h at room temperature before the 
serum was spun off and stored at 4°C.
Liquid Scintillation Counting: The quantification of radioactivity in 
organic and aqueous samples was performed by liquid sc in tilla tion  counting 
with a correction for quenching made by the external standard channels- 
ratio method. The counting mixture consisted of 0.05 ml of sample, 4.0 ml 
of a detergent-containing sc in tillan t (0.55% w/v PP0 in toluene-metapol,
2:1 v/v] and 0.4 ml water contained in a transparent plastic m ini-vial.
All samples were counted in duplicate.
Determination of Cholesterol 7g-Hydroxylase Activity in Rat and Mouse Liver: 
Cholesterol 7a-hydroxylase activ ity  was measured using an incubation 
mixture which consisted of 200pmol potassium phosphate buffer, pH 7.4, 
containing 8-9 nmol [4-AI*C] cholesterol in Tween 80 suspension (1.5 mg/ml 
incubation) according to Van Cantfort et al_.(1975), 20-40 mg 18,000g live r  
supernatant protein or 8-10 mg microsomal protein, and 50|amol 8-mercapto- 
ethylamine. These constituents were preincubated at room temperature
for.TO min prior to commencing incubation by the addition of 5ymol NADP 
and 50pmol glucose 6-phosphate to give a total incubation volume of
4.05 ml. Microsomal incubations also contained 1.0 I.U . glucose. 
6-phosphate dehydrogenase. Incubation was continued at 37°C with shaking 
for 30 min and then terminated by the addition of 10 ml methanol. 
Cholesterol was extracted according to the method shown in Figure 2.1. 
Recovery of labelled sterol by this method was 90 + 2%.
The final organic extract was evaporated to dryness and the residue 
redissolved in 0.2 ml chloroform; about 20pl of this was chromatographed 
as a 1.0 cm band on a t . l . c .  plate in toluene-ethyl acetate (7:13, v/ v ) . 
Radioactive bands were localised by a radioactive thin-layer scanner 
(TLC Scanner 11, Berthold LB 2723) supported by colorimetric localisation 
of 7a-hydroxychoiesterol and cholesterol standards with 20% (w/v) phospno- 
molybdic acid in absolute ethanol. In some cases mouse cholesterol 
7a-hydroxylase activ ity  was so low that the 7a-hydroxycholesterol band 
had to be localised by autoradiography, when the t . l . c .  plate was exposed 
to an X-ray film in the dark for a period of about 1-2 weeks. The exposed 
film was developed in the dark for 3 min in developer solution, washed in 
diluted acetic acid and fin a lly  immersed for a further 3 min in fixer  
solution before being allowed to dry. 7a-Hydroxycholesterol was the only 
detectable metabolite of cholesterol under these conditions as illustrated  
by the typical thin-layer scan shown in Figure 2.2. The radioactive bands 
were removed for quantification by liquid sc in tilla tion  counting (LKB 1210 
Ultrobeta) using a thixotropic gel sc in tillan t (4% Cab-o-sil plus 0.55%
PP0 w/v in toluene). Correction for quenching was made by the external 
standard channels-ratio method.
A control incubation mixture containing denatured tissue fraction was
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Figure 2 .1 . Scheme for Extraction of Radioactive Sterols from the 
Cholesterol 7a-Hydroxylase Incubation Mixture.
Based on the procedure of Mitton et a l . (1971)
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taken through the same procedure of incubation, extraction, chromatography 
and counting to correct for any 7a-hydroxycholesterol formed non-enzymically.
Determination of Biphenyl 2- and 4-Hydroxylase A ctiv ities: A procedure
based on that of Creaven et ajL £1965) was used, comprising the following 
incubation system:-
2-Hydroxybiphenyl 4-Hydroxybiphen 
Test Blank Standard_________ Standard
Buffer [ml) 0.5 0.5 0.5 0.5
154 mM KCl [ml) 0.5 0.5
Cofactor solution [ml) 0.25 0.25 0.25 0.25
Substrate [ml) 0.25 0.25 0.25 0.25
Post-mitochrondrial 
supernatant [ml) 0.5 0.5 0.5 0.5
2-Hydroxybiphenyl _ . n c
standard [ml)
*
*4-Hydroxybiphenyl _ _ n c
standard [ml)
*
denotes added after completion of incubation.
Buffer: 50 mM Tris/HCl, pH 8.1.
Cofactor solution: each 0.25 ml contained 2 ymol NADP, 10 ymol glucose 
6-phosphate and 10 ymol MgCl .^ Microsomal incubations also included 1.0
I.U . glucose 6-phosphate dehydrogenase.
Substrate: 12 mM Biphenyl in 154 mM KCl containing 2.5% [w/v) Tween 80. 
Standards: 2-Hydroxybiphenyl 12 yg/ml in ethanol-water [1:9, v/v ) .
4-Hydroxybiphenyl 60 yg/ml in ethanol-water [1:9, v/ v ) .
After incubation at 37°C for 15 min the reaction was terminated by 
addition o f 0.5 ml 2M HC1. Substrate and standards were added as appropriate.
After addition of 8 ml n-heptane, a ll tubes were rotary extracted for 
15 min and then centrifuged at 2000 r.p.m. for 15 min to break any 
emulsion formed. Samples [2 ml) of the heptane layer were transferred 
to clean tubes, 5 ml of 0.1M NaOH added and the tubes rotary extracted 
for 15 min. Following centrifugation as before, the upper heptane layer 
was discarded.
Samples [2.0 ml) of the lower NaOH phase were pipetted into a 
fluorimeter cuvette and the pH brought to 5.5 by addition of 0.5 ml 
0.25 M succinic acid. 2- and 4-Hydroxybiphenyls were determined using 
a Perkin-Elmer MPF-3 spectrophotofluorimeter at 290 nm [excitation) and 
420 nmCemission), and 282 nm (excitation) and 340 nm [emission) 
respectively.
The 4-hydroxybiphenyl standard, and all test and blank samples were read 
at the wavelength maxima of Both 2- and 4-hydroxybiphenyls, since 4-hydroxy-
biphenyl, under the conditions employed, fluoresces slightly  at the 2- 
hydroxybiphenyl wavelength maximum. A correction factor for substraction 
from the 2-hydroxybiphenyl reading of a ll test and blank samples was 
derived as follows:-
4-hydroxybiphenyl reading ________X mav A u1/j w.vwu4r,uariwlX 4-hydroxybiphenyl
4-hydroxybiphenyl standard reading y roxybiphenyl standard reading a
X max 2-hydroxy - 
biphenyl.
Determination of Ethylmorphine N-Demethylase A ctivity: The incubation 
procedure, based on that of Holtzman et aJL [1968), described below was 
used. Formaldehyde subsequently produced by this N-demethylation was 
measured by the method of Nash [1953).
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Test Blank Standard
Buffer (ml) 0.7 0.7 0.6
Semicarfaazide (ml) 0.2 0.2 0.2
Cofactor solution (ml] 0.2 0.2 0.2
Substrate (ml) 0.2 0.2* 0.2*
Post-mitochondrial 
supernatant (ml) 0.5 0.5 0.5
*
Standard (ml) - -  0.1
r k
denotes added after completion of incubation.
Buffer: 300 mM Tris/HCl, pH 7.4.
Semicarbazide 2% (w/v) aqueous solution of semicarbazide hydrochloride,
pH 7.0.
Cofactor solution: each 0.2 .ml contained 2 ymol NADP, 20 ymol glucose 
6-phosphate, and 10 ymol MgCl .^ Incubations with microsomes contained
1.0 I.U . glucose 6-phosphate dehydrogenase in addition.
Substrate: 75 mM ethylmorphine hydrochloride.
Standard: aqueous formaldehyde approximately 5 ymol/ml, standardised 
using an extinction coefficient of 8 mM-  ^ cm"^  for the 
formaIdehyde-Nash reagent complex.
Incubation was for 10 min at 37°C . The reaction was stopped by the 
addition of 1.0 ml 15% w/v ZnSO^  after placing the tubes into ice. Substrate 
and standard were then added as appropriate, followed by 1.0 ml saturated 
Ba(0H}£ to all tubes and the contents vortex mixed. The precipitate was 
sedimented by centrifugation at 2000 r.p.m. for 15 min. Samples (2.0 ml) 
of the supernatant were pipetted into clean tubes and 2.0 ml of freshly 
prepared Nash reagent (0.4% v/v acetylacetone in 4M ammonium acetate) added.
The yellow colour was developed at 37°C for 40 min and then measured 
at 412 nm on a Cecil model CE 272 u.v. spectrophotometer (Cecil Instruments, 
Cambridge].
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Measurement of Cytochrome P-450 Concentration: Cytochrome P-450 was
measured according to the method of Omura & Sato (1964) using a Unicam 
SP 1800 u.v. spectrophotometer. An extinction coefficient of 91 mM”  ^
cnf  ^ was used to calculate the cytochrome P-450 concentration from the 
extinction difference between the peak and the baseline at 450 nm.
Determination of NADPH-Cytochrome c Reductase A ctivity: A method
derived from that of Williams & Kamin (1962) was used as described below.
Into two 1 cm pathlength glass cuvettes at ambient temperature the 
following additions were made:
50 mM potassium phosphate 
buffer, pH 7.6, containing 
1 mM KCN fmll
Sample Reference
1.7 1.8
( )
100 yM cytochrome c (ml) 1.0 1.0
Microsomal suspension (ml) 0.2 0.2
The reaction was in itiated by the addition of 0.1 ml 30 mM NADPH to 
the sample cuvette, mixed rapidly and the reaction immediately followed 
at 550 nm using the SP 1800 spectrophotometer.
The in it ia l velocity was taken as the measure of reductase ac tiv ity .
A molar extinction coefficient of 18.5 mM~^  cm"^  was used in the calculation 
of reductase activ ity .
Determination of Protein Concentration: Protein concentration was
generally measured by a method based on that of Lowry et aj_. (1951) 
comprising the following procedure:-
To a 0.5 ml aliquot of tissue diluted in 0.5M NaOH (Usually 1:20 
and 1:80 dilutions for microsomes and 18,000g supernatant respectively)
5.0 ml of freshly prepared Lowry reagent (Z% aq. sodium carbonate,
1% aq. copper sulphate, and 2% aq. sodium potassium ta rtra te , in 
the proportions 100:1:1, v/v ) ,  were added.
After at least 10 min 0.5 ml of Folin-Ciocalteu Phenol reagent 
^diluted 1:1 with water] was added and immediately vortex mixed. At 
least 30 min were allowed for the blue colour to develop before 
measuring the absorbance at 720 nm using the Cecil spectrophotometer. 
Samples were analysed with standards (0-150 yg bovine serum albumin 
in 0.5M NaOH) in duplicate.
Protein concentration was also measured by a method modified from 
the microbiuret procedure of Zamenhof (1957), as detailed below:-
To a 0.5 ml aliquot of diluted microsomes (1:2.5 to 1:10) 
containing 2 drops of 10% (w/v) aq. sodium deoxycholate, either 4.5 ml 
of biuret reagent (0.25% w/v aq. copper sulphate, 0.6% w/v aq. sodium 
potassium tartrate and 3.0% w/v aq. NaOH; stored in the dark) or 4.5 ml 
of turbidity reagent (as for the biuret reagent with the omission of 
copper sulphate) were added and the samples vortex mixed. The 
appropriate blanks (0.5 ml water) were treated in the same manner. At 
least 10 min were allowed before the absorbance of the biuret and turbidity  
tubes were measured at 540 nm using the Cecil spectrophotometer. The 
absorbance difference between the biuret and the turbidity tubes, corrected 
for the absorbance of the blank, was used to calculate the protein 
concentration from the formula -  0.05 absorbance units equivalent to 
1 mg protein (personal communication from Dr. G. Gibson).
Extraction of Cholesterol from Liver Samples: A procedure derived from 
that of Folch et al_. (1957) was applied in which 1.0 ml of either whole 
live r homogenate or 18,OOOg liv e r supernatant was homogenised in 19 ml of 
a chloroform-methanol mixture (2:1, v/ v ) . The extract was filtered  
through glass wool, the f ilt ra te  washed with 4 ml of water and centrifuged 
to break any emulsion. The upper phase was then discarded and the lower 
phase evaporated to dryness. Total liv e r extracts were reconstituted 
with 0.5 ml absolute ethanol whilst 18,000g extracts were taken up in 
a small volume of chloroform. The recovery of cholesterol, determined 
using [4-lifC] chol esterol, was 91 +4%.
Separation of Free and Esterified Cholesterol in the 18,000g Liver 
Supernatant Extract: The free and esterified cholesterol fractions were
separated by chromatography of the concentrated extract on fluorescent 
s ilica  gel t . l . c .  plates in petroleum ether (b.p. 40-60°C)-diethyl ether 
(7:3, v/v ) .  Bands corresponding to cholesterol and cholesteryl ester 
^cholesterol lino leate), mean Rp values 0.15 and 0.60 respectively, were 
localised under u.v. ligh t and removed into tubes. Standards of 
cholesterol and cholesteryl ester were taken through the chromatography 
procedure to correct for recovery losses (generally 5-10%) . Cholesterol 
was measured directly in these s ilica  gel fractions.
Determination of Cholesterol: The concentration of cholesterol in samples 
(0.1 ml) of serum and liver extract, and also in the 18,000g supernatant 
free and esterified cholesterol - s ilica  gel fractions was measured by 
the method of Rude! & Morris (1973). Since this procedure employed a 
saponification step the cholesteryl ester fraction was determined with the 
free cholesterol. Samples along with a range of cholesterol standards 
(0-300 iig in absolute ethanol) were analysed in duplicate.
Titration of Vitamin Binding to Rat Liver Microsomes: Washed live r  
microsomes from untreated rats (_250-300g) at ambient temperature and a 
concentration of 2 mg protein/ml were evenly distributed between two quartz 
spectrophotometer cuvettes in the test and reference positions of a Cary 
219 spectrophotometer (Varian Associates, Palo Al to, California, USA).
A corrected baseline was recorded between 350-500 nm before vitamin 
binding was titra ted . Vitamin {0-30 yM) was added in dimethyl-  
formamide to the test cuvette and an equal volume of dimethylformamide 
added to the reference cuvette, and the resultant spectrum recorded as 
before for this and successive additions. The total volume of dimethyl- 
formamide added to each cuvette did not exceed 10 y l . Values for the 
binding constant, Kg, were determined from linear regression analysis 
of the peak plus trough distances corrected for baseline deviation.
Addition of Vitamin to Liver Microsomal Enzyme Incubation Preparations:
A range of vitamin concentrations (0-1 mM) were added in either
5 or 10 yl dimethylformamide to the washed live r microsomal preparations used 
in the determinations of cholesterol 7a-hydroxylase, biphenyl 4-hydroxylase
and ethylmorphine N-demethylase activ ities . Control incubations containing 
only dimethylformamide were also performed. These incubation mixtures were 
preincubated at 37°c for 30 min before each reaction was started by the 
addition of a NADPH generating system and the substrate. Incubation and 
product measurement were performed as previously described. Untreated 
rats (250-300g) were used to prepare the washed live r microsomal fraction.
Addition of Cytochrome P-450 Inhibitors to Liver Microsomal Enzyme 
Incubation Preparations: Each inhibitor (100 yM) was added in, 10 yl
dimethylformamide to the washed microsomal preparations for the determination 
of cholesterol 7a-hydroxylase and biphenyl 4-hydroxylase a c tiv itie s . Blank
incubations containing only dimethylformamide were also performed.
No preincubation was used, and the incubations were performed and 
analysed as previously described.
Statistics: Results were expressed as the arithmetic mean _+ the
standard deviation; significant differences between the means were
established using Student's t-te s t (* denotes P< 0.01, **
denotes P < 0.001). Linear regression analysis was performed to
determine the value for K of vitamin D0 binding to liv e r microsomes.s 2
These statistical analyses were performed on an O livetti P652 
programmable calculator (O livetti Ltd., London).
The Procedure for the Purification of Cholesterol 7a-Hydroxylase 
Activity from Rat Liver Microsomes:
i) Preparation of the Microsomal Fraction; A 33% (W/v) live r  
homogenate from 270-290g rats, pretreated with cholestyramine,was 
prepared by prior perfusion of each live r with isotonic saline to 
remove haemoglobin and then homogenised in Tris-sucrose buffer 
0 0  mM Tris/acetate, 0.25 M sucrose, pH 7.4) as previously described. 
The homogenate was centrifuged at 600g for 10 min, and then at 18,000g 
for 20 min to yield the post-mitochondrial supernatant from which a 
washed microsomal fraction was isolated as before using 10 mM Tris / 
acetate buffer, pH 7.4, containing 154 mM KC1, 1 mM EDTA and 1 mM 
dithiothreitol as the washing buffer. Washed microsomal pellets were 
overlaid with washing buffer and stored frozen at -20°C overnight. 
These pellets were thawed on the ice the following morning, 
resuspended in washing buffer to a volume of 70-80 ml and the protein 
level estimated by the biuret procedure. Samples were removed for
measurement of Lowry protein and cytochrome P-450 concentrations, 
and of NADPH-cytochrome c reductase and cholesterol 7a-hydroxylase 
activ ities .
iil The Solubilization of Cholesterol 7a-Hydroxylase Activity:
Cholesterol 7a-hydroxylase activ ity  was solubilised at a biuret 
protein level of 6 mg/ml from the microsomal fraction under nitrogen 
with 1% CV/v l Emulgen 911 in .0.1M Tris/acetate buffer, pH 7.4, 
containing 25% CV/v ) glycerol, 1 mM EDTA and 1 mM dithiothreitol by 
gentle stirring for 30 min. This solution was subsequently centrifuged 
at 105,000g for 60 min and the supernatant subjected to DEAE-Cellulose 
column chromatography. Samples were removed for measurement of Lowry 
protein and cytochrome P-450 concentrations, and of NADPH-cytochrome 
c reductase and cholesterol 7a-hydroxylase activ ities .
iiil DEAE-Cellulose Column Chromatography: DEAE-Cellulose 00091 
equilibrated in solubilising buffer {3 x 400 ml) was packed into a
2.6 x 30 cm column and further equilibrated with at least 200 ml of 
solubilising buffer. The supernatant was then loaded onto this column 
and washed with 200 ml of solubilising buffer, and the eluting fractions 
collected {LKB 2070 Ultrorac][. Cytochrome P-450 contaminated mainly 
by NADH-cytochrome bg reductase was eluted under these conditions. 
Fractions containing cytochrome P-450 were identified by measuring their 
absorbance at 418 nm, fractions with an absorbance higher than 0.45 
were pooled as the main cytochrome P-450 band and subsequently dialysed 
against 25 mM sodium phosphate buffer, pH 7.25, containing 25% glycerol 
0.2% Emulgen 911 (2 x 31[ for 60h before further column chromatography 
on hydroxyapatite. Tubing for dialysis was prepared by prior boiling 
in.several changes of water and cooled.
NADPH-cytochrome P-450GcIreductase {FPtI and cytochrome b5 
remaining on the DEAE column were eluted by a linear KC1 gradient 
(0-0.35 M in 200 ml solubi1ising buffer). Under these conditions 
cytochrome bg elutes in it ia l ly  closely followed by the FPy band, the 
eluted fractions were tested for FP-j- activ ity  and the appearance of 
cytochrome b,- was monitored at 413 nm. FPj active fractions were 
pooled and dialysed against 10 mM potassium phosphate buffer, pH 7.7, 
containing 25% glycerol, 0.1% Emulgen 911,0.02 mM EDTA and 0.2 mM 
dithiothr.eitol for 48h prior to further a ffin ity  chromatographic 
steps.
i v) Hydoxyapatite Column Chromatography: HydrOxyapati te Obtai ned
in 10 mM sodium phosphate buffer, pH 6.8, was packed into a 2.6 x 14 cm 
column and equilibrated with at least twice the bed volume of cytochrome 
P-450 dialysis buffer. The cytochrome P-450 pool was then loaded and 
the column washed with 300 ml of 50 mM sodium phosphate buffer, pH 7.25, 
containing 25% glycerol, 0.2% Emulgen 911 to remove NADH-cytochrome b^  
reductase activ ity . Cytochrome P-450 was eluted as an intense red 
band with 200 mM sodium phosphate buffer, pH 7.25, containing 25% 
glycerol, 0.2% Emulgen 911. The appearance of this cytochrome P-450 
band was monitored at 418 nm. Detergent was removed from this cytochrome 
P-450 fraction by treatment with Bio-Beads SM2.
v) Bio-Bead Detergent Removal: Bio-Beads SM2 (100g) were prepared by 
gentle stirring for 15 min in i l i t r e  of methanol and collected by 
filte rin g  through a glass scintered funnel. The beads were further 
washed with 2 litre s  of methanol followed by 3 litres  of water and then 
stored under water until required.
Prepared Bio-Beads were packed into a 2.6 x 35cm column and 
equilibrated with 200 ml of 50 mM sodium phosphate buffer, pH 7.25, 
containing 25% glycerol. The cytochrome P-450 pool was then loaded 
and the column washed with the same equilibrating buffer. The 
eluting cytochrome P-450 fraction was identified and pooled according 
to the presence of the characteristic pinkish-red colour.
vil Affinity Chromatography of the DEAE-FP ^ Fraction: ADP-agarOSe
a ffin ity  chromatography of the DEAE-FPy fraction was performed 
essentially as described by Yasukochi & Masters 0976) . 2 ',  5 1 -ADP-
agarose { 2 x 5  mlj was packed into a 0.9 x 14 cm column and equilibrated 
with 200 ml of the FPy dialysis buffer, as previously used. The FPy 
pool was then loaded and the column washed with 50 ml of the equilibrating 
buffer containing in addition 2 yM FMN. The column was further washed 
with 100 ml of 200 mM potassium phosphate buffer, pH 7.7, containing
25% glycerol, 0.1% Emulgen 911, 0.4 mM EDTA, 0.2 mM d ith io th re ito l,
\
and 2 yM FMN,and then washed with 30 ml of equilibrating buffer containing 
2 yM FMN. The FPy fraction was eluted in 50 ml of equilibrating buffer 
containing 2 UM FMN and 0.7 mM 2 1-AMP.- Eluted fractions containing 
FPy were identified and pooled according to the possession of a 
typical straw-yellow colour. AMP and detergent were removed from this 
preparation by gel f iltra t io n .
vii) Gel Filtration of f p ,^: Sephadex G-25 (_50g), pre-swollen by boiling 
for Ih in water and cooled,was packed into a 2.6 x 32 cm column and 
equilibrated with 200 ml of 50 mM sodium phosphate buffer, pH 7.25, 
containing 25% glycerol. The FPy fraction was then applied and the 
column washed with equilibrating buffer. FPy was recognised and pooled 
in the eluted fractions as above.
viii) Storage of the Purified Components: A 2.0 ml volume O f  
either the cytochrome P-450 or FPy final preparations was placed into 
a 5 ml glass vial and closed to the a ir with a rubber stopper. Each 
vial was gassed with nitrogen for 3 min through the stopper and then 
sealed with a clamped aluminium fo il cap. Vials were frozen at -4 0 °C .
ix) Sodium Dodecyl Sulphate Disc Gel Electrophoresis: Sodium 
dodecyl sulphate disc gel electrophoresis of the final cytochrome 
P-450 preparation was kindly performed by Mr. T.R. Fennell according 
to the method of Laemmli 0970) using a slab gel apparatus. The 
details of this method appear elsewhere (Fennell et a!.., 1979).
x) General considerstions: All manipulations were performed at 
4°C to minimize the loss of ac tiv ity . During chromatography and 
subsequent operations the fractions were protected from ligh t as 
much as was possible. All columns were gravity fed. Samples of the 
cytochrome P-450 and FPy pools derived throughout this procedure were 
taken to measure the respective yields. Detergent and other chemicals 
present in the purification buffers interfered with the protein 
estimation, and this effect was corrected by the inclusion of the 
appropriate buffer blanks in the estimation. In the final purified  
fractions these interfering effects were corrected by precipitation of 
the protein in the proportion 1:1 with 15% (w/v) trichloroacetic acid 
on ice,the precipitate sedimented and the supernatant decanted. The 
precipitated pellet was resuspended by homogenisation in 0.5M NaOH
for protein estimation.
The Procedure for the Reconstitution of Enzyme A ctiv ity :
i) Cholesterol 7a-Hydroxylase Activity: The Complete reconstituted
system, based on that of Haugen et a l .0975) ,  comprised 60 yg sonicated
dilauroylphosphatidylcholine, 4 nmol cytochrome P-450, 6 Units FPy 
(1 Unit = 1 ymol cytochrome c reduced/min), 100 yg sodium deoxy- 
cholate, 30 ymol MgC^, either 9 nmol [4 -llfC]cholesterol or 90 nmol 
cholesterol (composed of 9 nmol [4 -14C]cholesterol + 81 nmol unlabelled 
cholesterol) in Tween 80/potassium phosphate buffer (200 mM, pH 7.4) 
suspension, and 2 ymol NADPH in a final volume of 2.0 ml. Incubations 
were performed at 37°C for 15 min and 7a-hydroxycholesterol was 
determined as before. Incubations in which certain components were 
omitted contained a volume of water equivalent to the volume of the 
component omitted.
i i ) Ethylmorphine N-Demethylase Activity: The same reconstitution
system as above was used except that 15 ymol of ethylmorphine hydro­
chloride was added instead of cholesterol in Tween 80/phosphate buffer 
suspension, and 100 ymol of Tris/HCl buffer, pH 7.4, was also added.
Incubation was at 37°C for 10 min, and the mixture was then treated
as previously described for the determination of formaldehyde.
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CHAPTER THREE
Characterisation Studies with Rat Liver Cholesterol 
7a-Hydroxylase
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Introduction
Measurement of Cholesterol 7a-Hydroxy1ase Activity in Rat Liver: The
addition of a lip id  substrate to an aqueous medium in a form which is 
fu lly  accessible to the enzyme often creates problems in the interpretation 
of the data obtained; cholesterol 7a-hydroxylase is no exception (Bjflrkhem 
& Danielsson, 1975). Despite this d ifficu lty  a number of different 
techniques to measure cholesterol 7a-hydroxylase activity in liv e r samples 
have been reported, each one having merits and disadvantages, as reviewed 
by Myant & Mitropoulos (T977).
The isotope incorporation procedure, which formed the basis of the 
method used in this project, was the f ir s t  to be derived and is s t i l l  in 
current use 03ersdus et al_., 1969; Boyd et ail_., 1969; Carlson e t al_., 1978). 
In principle the technique relies on the conversion of radio!abelled 
cholesterol , [ llfC]cholesterol, into 7a-hydroxy[IlfC]cholesterol during 
incubation with a live r microsomal suspension at 37°C in the presence of 
NADPH and oxygen; the rate of 7a-hydroxy[llfC]cho1esterol formation being 
related directly to the activ ity  of cholesterol 7a-hydroxylase in the 
microsomes. Isolation of the radioactive sterols by a combination of 
solvent extraction and thin-layer chromatography followed by quantification 
using liquid scin tilla tion  counting enables the rate of 7a-hydroxy[llfC] 
cholesterol formation to be derived. This procedure does have two main 
drawbacks, f irs t ly  there is the d ifficu lty  of equilibration of the 
exogenously added substrate with the endogenous substrate pool mentioned 
above; and secondly, i t  requires lengthy manipulations.
Characterisation of Rat Liver Cholesterol 7a-Hydroxy1ase Activity: The rat
live r cholesterol 7a-hydroxylase enzyme system has been the subject of 
numerous characterisation studies by workers in several laboratories.
These investigations have made many important contributions to the under­
standing of the nature of the hydroxylase, although the mechanism of 
the reaction remains to be discovered.
Cholesterol 7a-hydroxylase has a marked substrate specificity (Boyd 
e t ^ K ,  1974; Arthur et a l ., 1975)_ suggesting a very specific sterol binding 
site which is sensitive to side-chain structure, planarity of nucleus and 
the presence of an equatorial or quasi-equatorial hydroxyl group at C^  
CAringer, 1978). Choiesteryl esters are not substrates for this reaction 
CKatayama & Yamasaki, 1968; Math£ e t£ l_ ., 1972; Balasubramaniam et a l . ,  1975b) 
and the enzyme preferentially uses newly synthesised cholesterol (Bjdrkhem 
& Danielsson,1975). The substrate pool of cholesterol 7a-hydroxylase has 
been calculated to correspond maximally to one third of the total cholesterol 
normally present in the microsomal fraction (Bjdrkhem & Danielsson, 1975).
More recently, the use of analytical centrifugation on sucrose density 
gradients of radiolabelled microsomal cholesterol fractions has enabled 
Balasubramaniam and coworkers (1978) to confirm the existence of a specific 
submicrosomal substrate pool for this enzyme. Cholesterol 7a-hydroxylase 
has been shown to have a for cholesterol of lOOyM (Gielen et 1968). 
Boyd et a l . (1973) report a for oxygen of about 20pM for this enzyme, 
that the reaction has an activation energy of 22 kcal/mol and that the 
enzyme shows product inhibition by 7a-hydroxycholesterol. The activ ity  can 
be enhanced in vitro by thiol-containing substances, and -SH blocking agents 
and heavy metals inhibit the activity (Van Cantfort & Gielen, 1975). These 
workers also report several steroids to be potent inhibitors vn _vvtro, among
them pregnenolone, 7-ketocholesterol and 7-dehydrocholesterol. Abroad 
pH optimum within the range pH 7 to 8 has been demonstrated for this 
enzyme (Mi tton et 1971).
In view of these previous investigations a characterisation study of 
this enzyme in the Wistar rat was undertaken both to further evaluate the 
nature of the enzyme system and the enzymic reaction, and also as a 
preliminary step to la ter investigations.
The Interaction of Carbon Monoxide with Cytochrome P-450: The existence in 
live r microsomes of a haem pigment which when reduced would complex with 
carbon monoxide to give a difference spectrum with an absorbance peak at 
450 nm was f ir s t  observed by Klingenberg (1958) and Garfinkel (1958), and 
was subsequently named cytochrome P-450 (Omura & Sato, 1962). I t  was not 
until la ter that the role of this cytochrome as the terminal oxidase for 
the hepatic microsomal mixed-function oxidases was realised. This discovery 
was derived in it ia l ly  from experiments which demonstrated inhibition by 
carbon monoxide, and inhibition-reversal by irradiation with monochromatic 
ligh t at 450 nm (Cooper et aK , 1965). Since then these crite ria  of carbon 
monoxide inhibition and release of inhibition by irradiation with lig h t at 
450 nm have been used to identify cytochrome P-450 mediated reactions.
The possible participation of cytochrome P-450 in cholesterol 7a- 
hydroxylation was evaluated in the present work by the a b ility  of carbon 
monoxide to inhibit this hydroxylation.
The Characteristics of the Mixed-Function Oxidases: The mixed-function 
oxidase enzymes catalyse reactions in which two independent activ ities  
are recognised, reduction of one atom of an oxygen molecule to water by a 
reduced coenzyme (usually NADPH) coupled to hydroxylation of the substrate
with the other atom. During this reaction two electrons are consumed, 
such that the overall reaction may be written —
AH + NADPH + H+ + 0„   k AOH + NADP+ + H„0
where AH is the substrate. Enzymes of this class therefore have an 
obligate requirement for oxygen and a two electron donor such as NADPH. 
Extensive reviews of this subject are available (Mason, 1957& 1965).
The nature of cholesterol 7a-hydroxylase as a mixed-function 
oxidase was examined in the present studies by testing f irs t ly  the 
a b ility  of the enzyme to function under anaerobic conditions and secondly, 
its  requirement for NADPH.
Electron Donors in Cytochrome P-450 Catalysed Hydroxylations: Cytochrome 
P-450-dependent microsomal mixed-function oxidations are generally thought 
to involve the reaction sequence proposed by Estabrook et al_. (1971) in 
which NADPH acts as the electron donor. However, the possibility has been 
raised that NADH can also act as a donor for the second electron (Hildebrandt 
& Estabrook, 1971; Estabrook et al_., 1971), a proposal supported by the 
observations that NADH addition to a microsomal fraction fo rtifie d  with an 
NADPH-generating system increases substrate hydroxylation to a greater 
extent than can be accounted for by the metabolism in the presence of NADPH 
alone (Cohen & Estabrook, 1971).
The microsomal 7a-hydroxylation of cholesterol was examined for these 
electron donor features to further evaluate any sim ilarity between this 
system and that of the cytochrome P-450 mediated hydroxylations.
Materials and Methods
Materials: All chemicals, solvents and gases were obtained as described
in Chapter Two.
Male rats weighing 180-200g were used in a ll characterisation 
studies.
Determination of Cholesterol 7g-Hydroxylase Activity in Rat Liver: The
activ ity  of cholesterol 7a-hydroxylase was measured in it ia l ly  by an 
isotope incorporation technique based on the methods of Bersdus e t £]_.
(1969) and Mitton et £]_. (1971) as described below.
A 20% (w/v) rat liv e r homogenate was prepared as described (Ch. 2) 
and centrifuged at 20,000g for 15 min at 4°C to prepare the fraction 
used for the determination of cholesterol 7a-hydroxylase ac tiv ity . The 
incubation mixture, of total volume 5.10 ml, comprised 2.0 ml 0.1M 
potassium phosphate buffer, pH 7.4, 0.05 ml 1M $-mercaptoethylamine,
2.0 ml 20,000g live r supernatant, and 0.05 ml acetone containing 8-9 nmol 
[4-1IfC]cholesterol. These constituents were preincubated at room temperature 
for 10 min prior to commencing incubation following the addition of Bprnol 
NADP, and 50pmol glucose 6-phosphate in water. Glucose 6-phosphate 
dehydrogenase (1.0 I.U./incubate) was added to microsomal and other 
cellular fractions not possessing this enzyme activ ity . Incubation was 
continued at 37°C with shaking for 60 min. The reaction was stopped, and 
the radioactive sterols isolated and quantified by the procedure detailed 
previously.
To improve this procedure optimisation was undertaken as detailed below 
to derive the method given in Chapter Two which was subsequently used for 
all further investigations.
i) The Subcellular Fractionation of Activity: The activ ity  Of 
cholesterol 7a-hydroxylase was determined in the subcellular fraction 
from rat live r homogenate prepared according to the scheme in Figure 
3.1. The mitochondrial plus lysosomal pellet was washed by resuspension 
in the homogenising buffer using hand homogenisation, and re-sedimented.
The microsomal pellet was resuspended in 154 m;M KC1 containing 0.02 M 
Tris/HCl buffer, pH 7.4, by gentle homogenisation. Singly or doubly 
washed microsomes were prepared by this resuspension procedure followed 
by re-sedimentation. A quantity of each fraction, which was equivalent 
to the same amount of original liv e r, was taken for measurement of 
cholesterol 7a-hydroxylase activ ity .
Cholesterol 7a-hydroxylase activity was highest in the 18,000 super­
natant, with relatively l i t t l e  activ ity  in the 18,000 g pelle t or the 
mitochondrial and lysosomal fraction, and even less in the whole homogenate 
(Figure 3 .2). Further investigation to optimize the centrifugation force 
for the supernatant preparation revealed that 18,000 g was optimal 
(Figure 3 .3 ). Fractionation of the 18,000 g supernatant showed that the 
activ ity  resided in the microsomal fraction with nil activ ity  in the
105,000 g supernatant. Preparation of the microsomal pellet and of the 
subsequently washed microsomes was accompanied by a decrease in enzyme 
activ ity .
i i ) The Effect of Protein Level on Cholesterol 7g-Hydroxylase Activity:
The effect of protein concentration on the cholesterol 7a-hydroxylase
activ ity  of the live r 18,000 g supernatant was determined over the range 
10-100 mg. To achieve this protein range a 50% rat live r homogenate was 
prepared and diluted with homogenising buffer to also give 25, 20, 10 and 
5% homogenates from which 18,000 g supernatants for measurement of
Whole homogenate
Pellet
Nuclei + other 
cellular debris
£
Microsomal
Pellet
centrifuged at 600g for 10 min
Supernatant
Centrifuged at 18,000g 
for 20 min
Supernatant Mitochondrial &
Lysosomal Pellet
Centrifuged at 
105,000g for 60 min
105,000g 
Supernatant or 
Soluble Fraction
Figure 3 .1 . Scheme for the Preparation of Rat Liver Homogenate 
Subcellular Fractions.
All manipulations were performed at 4°C.
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3 determinations (expressed as % activ ity  measured in
18,000 g supernatant). 18,000 g supernatant cholesterol 
7a-hydroxylase activ ity  = 8.8 ±J2.0 pmol/g liver/m in.
A, Whole Homogenate;
B, 18,000g Supernatant;
C, ^Mitochondria + 'Lysosornes;
D, 105,000g Supernatant;
E, 105,000g Pellet Unwashed Microsomes);
F, Single Washed Microsomes;
G, Double Washed Microsomes.
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Figure 3.3. The Effect pf Centrifugation Force on Cholesterol
7a-Hydroxylase Activi ty
cholesterol 7a-hydroxylase activ ity  were then prepared. Figure 3.4 shows 
that this activity  increased linearly with protein concentration to 
about 20 mg protein/incubation preparation, the activ ity  was increased 
further by raising the protein to 40 mg hut concentrations higher than 
this were accompanied by a gradual decrease in ac tiv ity . A protein 
concentration of 20-40 mg was subsequently used in a ll 18,000 g super­
natant incubations.
To assess the effect of protein concentration on microsomal cholesterol 
7crhydr0xylase activ ity  a series of microsomal suspensions diluted in 
resuspension buffer were prepared from a concentrated suspension (about 
20 mg microsomal protein/ml} to give a range from 2-16 mg protein added 
in 2.0 ml to each incubation preparation. Microsomal cholesterol 7a- 
hydroxylase activ ity  increased linearly with the amount of protein added/ 
incubation up to about 10 mg (Fi9ure 3 .5); a microsomal protein concentration 
of about 8 mg was routinely used for the microsomal measurement.
i i i i  The Stability of Cholesterol 7g-Hydroxylase Activity: The decay Of 
enzyme activ ity  with time C0-48hJ in an 18,000 g supernatant preparation 
kept at 4°C was determined (Table 3 .1 ). The activ ity  in a sample of the
preparation frozen for 48h at -10°C was also measured.
This investigation demonstrated that cholesterol 7a-hydroxylase 
remained reasonably stable to storage in this preparation, freezing at -10°C
for 48h enhanced the activity whereas at 4°C fu ll activ ity  was only retained
for 6h.
14ivl The Time Course for the Enzymic Conversion to 7a-Hydroxy [4- C]cholestei
The enzymic conversion of [4 -ltfC]cholesterol to 7a-hydroxy[4 -IIfC]cholesterol 
by an 18,000 g supernatant preparation was followed in incubations stopped
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Figure 3 .4 . The Effect of 18,Q00g Protein Level on Cholesterol 
7a-Hydroxylase Acti vi ty ..
1.0g wet wt. liver = 97.6 mg 18,000g Protein.
Each point is the mean of two determinations.
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Figure 3 .5 . The Effect of Microsomal Protein Level on Cholesterol 
7a-Hydroxyl ase A ctiv ity .
1.0g wet weight liver = 21.2 mg microsomal protein. 
Each point is the mean of two determinations.
Table 3.1. The S ta b ility  o f Cholesterol 7a-Hydroxylase A c tiv ity
in 18,000 g Supernatant
Each point is the mean + S.D. of two determinations
d A°r n*\ Cholesterol 7a-Hydroxylase ActivityPeriod at 4 C (h) ( , 7a. hydroxyf 4. i ^  cholesterol/
g liver/h )
0 5.1 0.6
2 5.3 + 0.4
4 5.8 + 0.3
6 5.8 + 0.4
8 4 .6 + 0 . 2
24 4.6 + 0.3
48 4.0 + 0.2
-10°C 
for 48h 6.3 + 0.5
at various times over a 240 min period (Figure 3 .6 ). The conversion 
was rapid for the f ir s t  30 min of the incubation, continued at a slower 
rate from 30-60 min, and reached a plateau after 60 min. An incubation 
time of 30 min was adopted for a ll further studies.
v) The Optimization of NADPH Generating System Level: A number Of 
NADPH generating system levels, as detailed in Table 3.2, were tested 
on the activity of cholesterol 7a-hydroxylase in 18,000 g supernatant 
to determine the optimal level required. A generating system level of 
5 ymol NADP and 50 umol glucose 6-phosphate was found to be optimal 
(Table 3.2) and was therefore used for a ll subsequent studies. For
the microsomal determinations i .0 I.U . glucose 6-phosphate dehydrogenase 
was used in addition.
vi) The Optimization of NADPH Concentration for the Microsomal Determination
The optimal NADPH concentration for the measurement o f microsomal cholesterol 
7a-hydroxylase activ ity  was assessed over the NADPH concentration range of 
0-10 mM added in 1.0 ml water. The activity was observed to increase as the 
NADPH incubate concentration increased up to 6 mM, further increases in 
NADPH concentration did not achieve any higher enzyme activ ity  (Figure 3 .7 ).
An NADPH concentration of 6 mM was therefore taken to be optimal for the 
microsomal determination.
14
vii) The Effect of Solubilization Mode of [ 4 -  c ] Cholesterol for Incubation: 
The determination of cholesterol 7a-hydroxylase activ ity  requires that the 
exogenous radio!abelled substrate added to the incubation equilibrates with 
the microsomal substrate pool for this enzyme. Acetone has been previously 
utilised as the vehicle (Einarsson & Johansson,1968a; Mitton e t  £l_., 1971), 
although more recently the use of Tween 80 has been preferred (Van Cantfort
et a l . ,1975a; Carlson et a l . ,  1978).
Ch
ol
es
te
ro
l 
7c
i-H
yd
ro
xy
l 
ase
 
A
ct
iv
ity
(pm
ol 
7a
rh
yd
ro
xy
[4
-1
IfC
]c
ho
le
st
er
ol
/g
 
liv
er
/m
in
)
-  65 -
4.0
3.0
2.0
1.0
0 60 12030
Period of Incubation (min)
Figure 3.6. The Time Course for the Enzymic 7a-Hydroxylation of 
[4-1IfC]Cholesterol in 18,000g Supernatant.
Each point represents the mean + S.D. for two 
determinations.
Table 3.2. The E ffect o f NADPH Regenerating System Concentration on
Cholesterol 7orHydroxylase Activity in 18,000 g Supernatant
Each point represents the mean + S.D. for 2 determinations. 
Additions were made in 1.0 ml water.
NADPH Regenerating Cholesterol 7a-Hydroxylase Activity
System (pmol 7a-Hydroxy[4-llf C] cholesterol/
g liver/min)
None 0.3 + 0.1
2.5 ymol NADP +
25 ymol glucose 6-phosphate 5.1 + 0 . 4
5 ymol NADP +
50 ymol glucose 6-phosphate 6.3 + 0.7
10 ymol NADP +
100 ymol glucose 6-phosphate 6.5 + 0.4
t  ■ , , 1_______________ I ■ „. ... I_______________ I_______________ L_
2 4 6 8 10
NADPH Concentration (mM)
Figure 3 .7 . The Effect of NADPH Concentration on Microsomal 
Cholesterol 7a-Hydroxylase A ctivity.
Each point represents the mean S.D. for 3 
determinations.
£4-llfC]Cholesterol added in Tween 80 suspension.
In this study the use of these two solubilizers were examined, in 
each case 9 nmol [4-1%C]cholesterol was added to an incubation either 
in 0.05 ml acetone or in Tween 80, 1.5 mg/ml of incubation according to 
Van Cantfort e t a l. (1975a}. The results of this investigation (Table 
3.3} showed Tween 80 to be a more e ffic ien t alternative than acetone. 
Consequently, Tween 80 was used for solubilization in a ll subsequent 
incubations.
Table 3.3. The Effect of Solubilization Mode of [4-ltfC]Cholesterol
for Incubation 
Mean + S.D> for 2 determinations given in each case.
Mode of [4-llfC]Cholesterol Cholesterol 7a-Hydroxylase Activity
Solubilization (pmol 7a-hydroxy[4-ll*C]cholesterol/ 
g liver/min)
Acetone, 0.05 ml 5.8 + 0.2
Tween 80, •o+1COCO1.5 mg/ml incubate
viiil The Effect of Substrate Concentration on Cholesterol 7CL-Hydroxylase
Activity: The variation in cholesterol 7a-hydroxylase activ ity
over a range of exogenously added [4 -llfC]cholesterol concentrations, 
introduced into the incubations using Tween 80, was investigated. No 
effect was observed on the measurable activ ity  over the concentration range 
0.4 to 3.6 yM (Table 3 .4}.
Table 3.4. The Effect of [4-ltfC]Cholesterol Concentration on Cholesterol
7g- Hyd roxy 1 a s e Ac t i  v i ty
Mean + S.D. for 3 determinations given in each case (P > 0.05 
in each case).
[4 -1!*C]Cholesterol Concentration Cholesterol 7ct-Hydroxylase Activity  
(UM) (pmol 7a-Hydroxy[4-1IfC]cholesterol/
g 1iv e r/h )
0.4 11.4 + 0.9
0.9 11.2 + 0.4
1.8 11.0 + 0.4
2.7 11.5 + 0.7
3.6 11.2 + 0.2
The addition of further concentrations of exogenous non-labelled
cholesterol along with a constant radiolabelled cholesterol level (9 nmol)
in Tween 80 to cholesterol 7a-hydroxylase incubations were found to
decrease the percent conversion to 7a-hydroxy[4-14C]cholesterol (Table 3 .5 ).
This effect would seem to be the result of dilution of the radiolabelled
cholesterol.
Table 3.5. The Effect of Extra Exogenous Cholesterol on Cholesterol
7a-Hydroxylase Activity
[4 -llfC] Cholesterol concentration = 2 yM in each case.
Each point represents the mean + S.D. for 2 determinations.
Cholesterol Concentration Cholesterol 7a-Hydroxylase Activity
(pmol 7a-HydroxyI4^lfC]cholestero!(pi) /g liver/min)
2 7.3 + 0.3
50 6.2 + 0.0
100 6.2 + 0.0
200 5.8 + 0.1
300 5.4 + 0.1
Exogenously added substrate, consisting entirely of [4-1IfC]cholesterol, 
of 1.8 yM (9 nmol) was selected for addition to a ll further incubations 
being most suitable for detection purposes.
ix) The pH Optimum of Cholesterol 7a-Hyjdroxyla.se Activity: The effect
of incubation pH on the activ ity  of cholesterol 7a-hydroxylase was 
investigated using 18,000 g supernatant over the pH range 6.0-8.0 using 
0.1 M potassium phosphate buffer. Cholesterol 7a-hydroxylase exhibited
a pH optimum within the range 7.2-7.8 (Figure 3 .8 ), with considerable 
activ ity  remaining at pH 8.0. An acidic pH proved unsuitable for enzyme 
activ ity . An incubation pH of 7.4 was consequently adopted for the 
enzymic determination.
x) The Diurnal Rhythm of Cholesterol 7a-Hydroxylase Activity: The 
measurement of cholesterol 7a-hydroxylase activ ity  in rats at four time 
points during a 24h period confirmed the existence of a diurnal rhythm 
in the activ ity  of this enzyme with a maximum around the middle of the 
dark period and a minimum during the light period (Figure 3 .9 ), as 
originally shown by Gielen et a l . (1969).
The existence of such a cyclic variation in enzyme activ ity  necessitated 
killing  animals at the same time on each day of experimentation. Through­
out these studies a ll animals were killed between 0830-0930 h.
The Effect of Carbon Monoxide and Nitrogen Atmospheres on Cholesterol 
7a-Hydroxylase A ctivity; The effect of carbon monoxide and nitrogen-rich 
atmospheres on microsomal cholesterol 7a-hydroxylase activ ity  were separately 
examined. A nitrogen atmosphere was used to determine the effect of 
anaerobic conditions on this enzyme. The normal incubation procedure was 
adopted with the incubation mixtures being gassed for 30 s with either
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carbon monoxide or nitrogen before the reaction was started by addition 
of the NADPH regenerating system and the tubes stoppered. The control 
tubes were incubated open to the a ir . A boiled tissue blank for each 
gaseous condition was used.
The NADPH Requirement of Cholesterol 7a-Hydroxylase, and the Effect of 
NAD and NADH: The absolute requirement for NADPH, and the a b ility  of
either NAD or NADH to support the enzymic 7a-hydroxylation of cholesterol 
was determined with washed microsomes using the normal incubation 
conditions without the addition of an NADPH-regenerating system. The 
NADPH requirement was evaluated by comparing the relative effects of 
6 mM NADPH, and various concentrations of NAD and NADH on cholesterol 
7a-hydroxylase activ ity . A boiled tissue blank for each cofactor system 
was also set up.
Results
The Effect of Carbon Monoxide and Nitrogen-Rich Atmospheres on Cholesterol 
7g-Hydroxyl ase Activity: In the presence of a carbon monoxide rich atmosphere
the activ ity  of cholesterol 7crhydroxylase was found to be markedly diminished 
from that measured in a ir  (Table 3 .6 ). Anaerobic conditions, as provided 
by a nitrogen rich atmosphere, also substantially lowered the aerobic 
activ ity  of this enzyme (Table 3 .6}.
The NADPH Requirement of Cholesterol 7g-Hydroxylase, and the Effect of 
NAD and NADH: The NADPH concentration of 6 mM provided the highest
cholesterol 7g-hydro*ylase activ ity  of the various cofactor systems tested 
(Table 3 .7}. In the presence of 6 mM NADH an activity 30% of this was 
measured whereas with 6 mM NAD no activ ity  could be detected.
The combination of 6 mM NADH with a sub-optimal concentration of 
NADPH gave cholesterol 7a-hydroxylase activ ity which was greater than 
that observed in the presence of this NADPH concentration alone, 
although this activ ity  could be accounted for i f  the activ ities  of 
these components rneasured singly were added (Table 3 .7 ). No such 
effect was exhibited in the presence of an optimal NADPH concentration 
and 6 mM NADH in combination, nor with any of the NADPH combinations with 
NAD. In fact these la tte r combinations with NAD produced a lowering 6f 
activ ity .
Table 3.6. The Effect of Carbon Monoxide and Nitrogen-Rich Atmospheres 
on Cholesterol 7g-Hydroxylase Activity in vitro  
Mean + S.D. for 3 determinations given in each case.
Cholesterol 7a-Hydroxylase Activity
( pmo1 7a-Hydroxy[4 -14 C]cho1estero1/ 
g liver/min)
Air
Carbon Monoxide 
Nitrogen
6.2 + 0.4 
0.5 + 0.1 
0.8 + 0.1
Incubation
Atmosphere
Table 3.7. The E ffect o f NAD and NADH on Cholesterol 7a-Hydroxylase
Activity in vitro  
Mean + S.D. given for 3 determinations in each case.
Cofactor Cholesterol 7a-Hydroxylase Activity
System (pmol 7a-Hydroxy[4-;l*C]cholesterol
/g liver/min)
Zero 0.3 + 0.1
6 mM NADPH. 5.8 + 0.8
2 mM NADPH 2.7 + 0.4
6 mM NADH 1.6 + 0.2
6 mM NAD 0.0
5.6 + 0.26 mM NADPH + 6 mM NADH
6 mM NADPH + 
6 mM NAD
2 mM NADPH + 
6 mM NADH
2 mM NADPH + 
6 mM NAD
2.3 + 0.4
4.0 + 0.5 
0.3 + 0.1
Discussion
Cholesterol 7a-hydroxylase was found to be a microsomal enzyme, the 
activ ity  of which is highest in the 18,000 g liv e r supernatant, in agreement 
with the findings of Boyd et al_. (1969). The lower activ ity  in the microsomal 
fraction compared to the 18,000 g supernatant would suggest the loss of a 
v ita l components) of this enzyme system during the microsomal preparative 
procedure, possibly into the cell flu id fraction (105,000 g supernatant). 
Mitton et £l_. (1971) have shown that the 18,000 supernatant activ ity  can 
be partia lly  restored in the microsomes by re-addition of cell flu id , and 
s t i l l  further by the addition of either thiol-containing substances or the 
thermostable factors from the boiled cell flu id . They suggest that these 
effects arise from the lowering of microsomal cholesterol auto-oxidation 
to various products, particularly 7-ketocholesterol a substance known to be 
a potent inhibitor of cholesterol 7a-hydroxylase (Van Cantfort, 1972). I t  
would therefore seem probable that the higher activ ity  of cholesterol 7a- 
hydroxylase present in the 18,000 g supernatant resulted from the presence 
of a thermostable component(s) which was heeded to prevent the formation 
of inhibitory auto-oxidation products, and that this component(s) became 
separated during microsome preparation. The low activity in the whole 
homogenate would seem to be the result of either enzyme inhibition or more 
like ly  to extensive non-specific binding of the I^Clcholesterol to cellu lar  
debris reducing the amount available for equilibration with the microsomal 
pool.
The in vitro inhibition of cholesterol 7a-hydroxyl ase by carbon monoxide, 
demonstrated by several workers (Wada_et_al.,  1968; Boyd et a l . ,  1969; 
Mitopoulos & Balasubramaniam, 1972), was confirmed. This e ffect, together 
with the re-activation of cholesterol 7a-hydroxylase by reversal of the 
carbon monoxide inhibition with monochromatic ligh t at 450 nm, shown by 
Boyd & coworkers (1973), indicated the probable participation of cytochrome 
P-450 in this enzymic reaction.
Cholesterol 7a-hydroxylase exhibited the characteristics of a true 
mixed-function oxidase, as classified by Mason (1965), in that i t  required 
aerobic conditions and the provision of a saturating concentration of 
NADPH for expression of fu ll activ ity  in v itro , confirming previous 
literature reports (Shefer £ t  ail_., 1968; Boyd et a l ., 1969; Mitropoulos 
& Balasubramaniam, 1972).
I t  was shown that the 7a-hydroxylation of cholesterol in vitro  
could be supported to a limited extent (30%) by NADH alone. Moreover,
NADH produced an additive effect on this hydroxylation when combined 
with a sub-optimal concentration of NADPH. These findings are consistent 
with the concept of NADH' as an alternative donor of the second electron 
in cytochrome P-450 catalysed hydroxylation reactions (Hildebrandt & 
Estabrook, 1971; Cohen & Estabrook, 1971; Es tab rook et al_., 1971), which 
further implicates cytochrome P-450 in this hydroxylation. The effect of 
addition of NADH to NADPH in supporting cholesterol 7a-hydroxylation was 
in marked contrast to the inhibitory effect recently noted by Mellon et a l . 
(1978) but was in agreement with the earlier results of Bjdrkhem &
Danielsson (1973).
No additive effect was obtained with NADH and an optimal concentration 
of NADPH in combination since the activity of cholesterol 7a-hydroxylase 
would have been maximised by the NADPH alone. The addition of NAD either 
alone or in combination with NADPH resulted in a lowering of the enzyme 
activ ity , an effect which probably arose from the activation by NAD of 
the microsomal dehydrogenase which uses NAD as a cofactor to dehydrogenate 
7a-hydroxycholesterol in the bile acid synthesis pathway.. This would 
consequently remove some of the 7a-hydroxyI4-IlfC]cholesterol formed to 
manifest an apparent decrease in cholesterol 7a-hydroxylase ac tiv ity .
- 78 -
CHAPTER FOUR
Liver Mixed-Function Oxidase Activity and Cholesterol 
Metabolism in the Obese, A rthritic  STR/1N Strain of Mouse
Introduction
I t  is well recognised that adjuvant-induced a rth ritis  is connected 
with impaired live r drug-metabolising mixed-function oxidase activ ity  
and depletion of the hepatic cytochrome P-450 content (Morton & '
Chatfield, 1970; Whitehouse & Beck, 1973; Cawthorne et j f h , 1976;
Mathur et a K , 1978). Atkin and coworkers (1972) using the adjuvant 
arth ritis  model in the rat to examine the relationship between 
cholesterol 7a-hydroxylase activity and the hepatic microsomal 
cytochrome P-450 content, found that although cytochrome P-450 was 
decreased, this had no effect on cholesterol 7a-hydroxylase activ ity  
or plasma cholesterol concentration.
The occurrence of severe spontaneous osteoarthritis of the knees, 
a genetically determined disease in mice, particularly of the STR/1N 
strain, was f irs t  reported by Sokoloff (1956) and Sokoloff & Jay (1956). 
This susceptibility to osteoarthritis was found to be polygenic, of 
recessive inheritance, and without major sex linkage (Sokoloff et a l . ,  
1962^. Mice of the STR/1N strain were also discovered to be genetically 
obese and hypercholesteraemic (Sokoloff et aT., 1960; Yamamoto et a l ., 
1963) although these conditions were genetically dissociated from the 
occurrence of the*degenerative jo in t disease in these mice (Sokoloff 
et al_., 1962).
In view of the suggested involvement of cytochrome P-450 in the 
7a-hydroxylation of cholesterol and the key role of this enzyme in 
cholesterol catabolism i t  may be hypothesised, in contradiction to the 
findings of Atkin etj*l_. (1972), that a decreased liver microsomal 
cytochrome P-450 content in these STR/1N mice produced by the a rth ritic
lesion causes a lowering of cholesterol 7a-hydroxylase activ ity  which 
in turn contributes to the accumulation of the hypercholesteraemia.
A study was therefore in itiated with these mice to ascertain i f  
there was any association of these pathological phenomena with deficiencies 
in liver cytochrome P-450 and cholesterol 7a-hydroxylase activ ity .
Materials and Methods
Materials: All materials and mice were obtained as described in
Chapter Two.
Methods: Male and female STR/IN mice were studied at three ages, weanling 
(3 weeks), sexual maturity (6-7 weeks), and aged (16 months). CF1 
Albino and C3H (he-Mg) mice, which are not characterised by any pathological 
abnormalities, were used as controls. In these mice the following parameters 
were measured: body and liver weights, liver microsomal protein and cyto­
chrome P-450 concentrations, and NADPH-cytochrome c reductase, cholesterol 
7a-hydroxylase, and biphenyl 2- and 4 -hydroxylase activities by the methods 
described previously in Chapter Two. Biphenyl 2- and 4-hydroxylase 
activities were not determined in the weanling mice. Serum and liv e r  
cholesterol, and 18, QOOg: supernatant free and esterified cholesterol 
concentrations were measured in the sexually matured and aged mice only.
Results
STR/1N mice of all three groups and both sexes had higher body weights 
than their C^ H counterparts, but there was no significant difference from 
the CF1 mice (Tables 4.1, 4.2 and 4 .3 ). On this basis the STR/1N mice 
showed no gross signs of obesity. In respect of liver weights no consistent 
differences between the three strains of mice were apparent.
The weanling STR/1N mice showed no significant difference from the 
other two strains of mice with regard to live r cytochrome P-450 content 
and NADPH-cytochrome c reductase ac tiv ity , but the male mice of the 
STR/1N strain showed a higher cholesterol 7a-hydroxylase activity  
(Table 4 .1 ).
The sexually mature STR/1N mice exhibited significantly lower 
hepatic cytochrome P-450 and microsomal protein concentrations and 
lower biphenyl 4-hydroxylase activities than the CF1 controls, and 
lower cholesterol 7crhydroxylase activities than either the CF1 or C^ H 
controls (Table 4 .2 ).
The aged STR/1N mice again had lower cytochrome P-450 concentrations 
than the CF1 and C^ H control mice, especially in the males (Table 4 .3 ).
A lower biphenyl 4-hydroxylase activ ity  in the STR/1N mice was also 
apparent. Biphenyl 2-hydroxylase activ ity  (ctyochrome P-448 activ ity ) 
was lower in the STR/1N mice than in the CF1 animals, but cholesterol 
7a-hydroxylase, in the females only, was even higher in the STR/1N strain  
than in the two control strains.
Raised serum cholesterol concentrations in the STR/1N mice were 
evident both at the stage of sexual maturity and in aged animals; in 
most cases these concentrations were double those of the control mice 
(Table 4 .4 ). With the exception of the aged STR/1N mice both sexually 
mature and aged male mice exhibited higher serum cholesterol concentrations 
than the females.
Liver concentrations of cholesterol were similar in both sexes of 
all three mice strains, but higher in the aged mice than in the sexually 
mature animals (Table 4 .4 ). The concentrations of free and esterified
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cholesterol present in the 18,Q00g supernatant fraction o f liver  
homogenate were again similar in a ll three strains of mice although 
the esterified cholesterol concentration was higher in the aged mice 
(Table 4 .5}.
Discussion
In this study sexually mature and aged mice of both sexes of 
the STR/1N strain were observed to have a depleted hepatic drug- 
metabolising monooxygenase activ ity , as characterised by lower
activ ities of biphenyl 4-hydroxylase and lower microsomal cytochrome 
P-450 concentrations. These findings confirm the observations in 
rats of both Morton & Chatfield (jl970) and Atkin and coworkers (1972) 
that adjuvant-induced arth ritis  depletes the drug-metabolising potential 
of the liv e r. In these rats the decreased rates of drug metabolism 
have been shown to parallel a decrease in hepatic cytochrome P-450 
concentration accompanied by a concomitant appearance of cytochrome 
P-420 in the liv e r microsomal fraction [Mathur et _al_., 1976 & 1977).
This appearance of cytochrome P 4^20 suggests the destruction of 
cytochrome P-450 which may result from damage to the microsomal membranes 
and the associated components of the mixed-function oxidase system by 
superoxide and other products of autoxidation formed as a response of 
the immune system to the adjuvant [Mathur et a l .,  1978). Indeed, this 
autoxidation and membrane damage could lead to changes in the synthesis 
of the microsomal membranes and enzymes from which the degenerative jo in t  
lesions could arise. The occurrence of this pathological lesion in the 
STR/1N mice may develop from a number of causes that include: impaired 
synthesis of cytochrome P-450, decreased s tab ility  of this haemoprotein,
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increased rate of degradation, a higher level of spontaneous autoxidation 
with consequent damage of the endoplasmic reticulum and changes in the 
lysosomal membranes and enzymes which are synthesised thereon.
Increases in live r cytochrome P-450 concentration and in cholesterol 
7a-hydroxylase activ ity  occurred in all three strains of mice as they 
developed from weanlings to sexually mature animals. However, in the 
sexually mature STR/1N mice these rises are smaller than in the two 
control strains of mice. With increasing age, the activ ity of cholesterol 
7a-hydroxylase in the STR/1N mice also increased to almost equal those 
seen in the other two strains despite the persistent lower levels of 
hepatic cytochrome P-450 in the aged STR/1N mice. These findings give 
only limited support to the proposed dependance of cholesterol 7a- 
hydroxylation on cytochrome P-450 (Boyd ejt a l,., 1973; Bjtirkhem et aT ., 
1975). No consistent changes in the 18,000g supernatant free cholesterol 
concentration, taken as a measure of the substrate pool size of cholesterol 
7a-hydroxylase, could be detected to suggest altered substrate ava ilab ility  
as the cause of the observed differences in cholesterol 7a-hydroxylase 
activ ity .
The lower activ ity of cholesterol 7a-hydroxylase observed at sexual 
maturity in the STR/1N mice may to some extent be in it ia l ly  associated 
with the hypercholesteraemia observed in these mice, since the higher 
cholesterol 7a-hydroxylase activities seen in the other two strains of 
mice were accompanied by normal blood cholesterol levels. However, 
although the aged STR/1N mice exhibited increased activ ities of this 
enzyme, which were approximately equal to those observed in-the other 
two mice strains, the serum cholesterol concentration continued to be 
raised. Moreover, even though the cholesterol 7a-hydroxylase activ ity
of female STR/1N mice increased more than two-fold from sexual maturity 
to old age, the blood cholesterol concentration further increased by 
nearly one hundred per cent. A contributing role for cholesterol 7a- 
hydroxylase under-activity in the development of hypercholesteraemia 
was therefore not firmly established. Alternatively, an increased 
biosynthetic rate may have been responsible for the hypercholesteraemia.
-  90 -
CHAPTER FIVE
Aspects of Experimental Atherosclerosis in the Rat
-  91 -
Introduction
The use of large doses of vitamin D2 and cholesterol to induce 
atherosclerosis in the rat, an animal noted for its  resistance to this 
condition, was f irs t  reported by Altman (1973) and Testa _et £l_. (1975). 
Histologically such regimes generate atheromatous lesions, centred 
mainly in the aorta and coronary arteries, that are characterised by 
extensive calcification and lip id  accumulation (Bajwa et al_., 1971; 
Altman, 1973). Moreover an associated occurrence of hypercholesteraemia 
with this atheroma was observed (Aubert et al_., 1974; Testa et a l . ,
1975; Douglas et al_., 1977), so contributing to the potential usefulness 
of this animal model in the pharmacological evaluation of anti-athero- 
sclerotic agents. The origin of this hypercholesteraemia is uncertain 
although Huang & Coworkers (1977), in studies using an atherogenic 
regime, containing vitamin D3 and fa t in swine, suggest that i t  is 
probably the result of increased absorption from the gut. Another 
possibility which might contribute is a low rate of cholesterol 
catabolism, due particularly to inhibition of cholesterol 7a-hydroxylase.
The metabolic activation of vitamin D3 (cholecalciferol) in the 
body involves its  conversion to more polar hydroxylated metabolites 
by the sequential action of liver and kidney enzymes (DeLuca, 1977).
The in it ia l transformation in this process is the 25-hydroxylation of 
cholecalciferol which is catalysed in the liver microsomal fraction 
(Bhattacharyya & DeLuca, 1.974; Madhok et al_., 1978) by a cytochrome 
P-450 dependent mixed-function oxidase enzyme (Del vin et al^., 1978; 
Bjorkhem et cH_., 1979). Evidence for the interaction of cholecalciferol
- 92 -
and 25-hydroxycholecalciferol with the cytochrome P-450 oxidase system 
was earlier demonstrated in vitro by Cinti & coworkers (1976) using 
both spectral binding studies and experiments in which the cytochrome 
P-450-mediated enzyme aminopyrine N-demethylase was inhibited by these 
compounds. Furthermore, these workers found that vitamin D congeners 
such as vitamin D2 (Figure 5.1) would also exhibit similar characteristics 
in v itro , indicating that vitamin D2 was also capable of interacting with 
the microsomal cytochrome P-450 oxidase system.
In view of the like ly  involvement of cytochrome P-450 in the 
7a-hydroxylation of cholesterol, referred to in Chapter One, i t  seemed 
possible that vitamin D2 could also interact with cholesterol 7a-hydroxylase 
bringing about a drop in cholesterol catabolism to explain the occurrence 
of hypercholesteraemia in rats treated with the afore-mentioned atherogenic 
regime.
To c larify  this proposal the effects of this atherogenic regime in 
the rat were determined with respect to the hepatic microsomal drug and 
cholesterol metabolising systems, and the serum and live r cholesterol 
concentrations in vivo. The effects of vitamin D2 on these enzyme 
systems and the binding of this compound to rat live r microsomes were 
also evaluated in v itro .
Materials and Methods
Materials: All materials were as previously specified in Chapter Two.
The Effect on Rat Hepatic Mixed-Function Oxidation and Cholesterol 
Metabolism of the Administration of Various Vitamin D- and Cholesterol-
Containing Regimes: Studies in three separate experiments were
o-  93 -
at
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CHj
Vitamin D2 (ergocalciferol) Vitamin D3 (cholecalciferol)
Figure 5.1. The Structural Sim ilarity Between Vitamins D? and P3.
carried out in which vitamin D and cholesterol were administered to 
groups of rats as follows:
Expt. 1) Control, cholesterol, vitamin D2 » and vitamin D2 
plus cholesterol;
Expt. 2) Control, and Duphasol (a water-dispersable preparation 
of vitamin D2 ) plus cholesterol;
Expt. 3) Control, and vitamin D3 plus cholesterol.
All rats in these groups were dosed as previously described.
On completion of each study (day 6) determinations were made of 
body and live r weights, serum and liver cholesterol concentrations, 
and various parameters of hepatic mixed-function oxidation that 
included microsomal .cytochrome P-450 and protein concentrations, 
ethylmorphine N-demethylase, biphenyl 2- and 4-hydroxylase, cholesterol 
7a-hydroxylase, and NADPH-cytochrome c reductase activ ities , by the 
methods detailed in Chapter Two.
The Relative Effects of Vitamin D? plus Cholesterol Administration 
and of Pair-Feeding on Cholesterol Metabolism and Hepatic Microsomal 
Cytochrome P-450 Concentration in Rats: To correct for the starvation
effect seen in the rats given vitamin D plus cholesterol a pair-fed 
group of rats were used in addition to vitamin D2 plus cholesterol 
and control groups; rats were dosed and fed as specified in Chapter 
Two . At the end of the dosing period the effect of these variousr. 
treatments were determined on the body and liver weights, on the serum 
and live r concentrations, and on both hepatic cholesterol 7 a -hydroxylase
a c t iv ity  and cytochrome P-450 concentration as before.
The Effect of Vitamin P9 Addition in vitro on Hepatic Mixed-Function 
Oxidase A ctivity: The possible in vitro effects of vitamin D2 on the
activities of cholesterol 7a- and biphenyl 4-hydroxylases, and ethyl- 
morphine N-demethylase were determined as previously described.
The Binding of Vitamin D2 in vitro to Rat Liver Microsomes: The binding
of vitamin D2 to rat liver microsomes in vitro was titrated  as detailed 
earlier.
Results
The Effect of Vitamin D2 and Cholesterol Administration on Hepatic 
MiXed-Furtction Oxidation and Cholesterol Metabolism in Rats: Rats in 
both the vitamin D2 and vitamin D2 plus cholesterol groups exhibited a 
mortality of between 0-18%, no deaths in either of the other two groups 
were recorded. Moreover the former two groups gradually consumed less 
food than the control or cholesterol groups as the dosing study 
progressed (Figure 5 .2). These observations coincided with substantial 
body weight losses in the vitamin D2 and vitamin D2 plus cholesterol 
groups compared to an increasing body weight in the other two groups 
(Figure 5.3. and Table 5 .1). Furthermore, this table shows that rats 
of the two former groups when compared to controls had decreased live r  
weights, microsomal protein and cytochrome P-450 concentrations, and 
NAOPH-cytochrome c reductase, biphenyl 4- and cholesterol 7a-hydroxylase, 
and ethylmorphine N-demethylase activities which were significant in 
most cases. These rats also had significant elevations in their serum 
cholesterol concentration but no change in liv e r cholesterol concen­
tration. Rats of the cholesterol group on the other hand possessed
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Figure 5.2. The Food Consumption of Control, and Vitamin D? and 
Cholesterol Dosed Rats During the Dosing Period.
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significantly increased live r weights, microsomal protein concentrations 
NADPH-cytochrome c reductase activities and live r cholesterol concen­
tration but with no serum cholesterol concentration change in relation  
to the controls. The results were expressed in this and the following 
in vivo studies per total liver to obviate the effect of differing  
live r weights between groups.
The Effect of Duphasol + Cholesterol Administration on Hepatic Mixed- 
Function Oxidation and Cholesterol Metabolism in Rats: Rats dosed with
Duphasol plus cholesterol showed a mortality of 18%. The food 
consumption of this group fe ll much more rapidly from control to zero 
levels in about 96h (Figure 5.4.) compared to about 120h for the 
previous vitamin D2 plus cholesterol regime. Similarly a substantial 
body weight loss occurred in the Duphasol plus cholesterol dosed 
animals as the study progressed (Figure 5.5) such that by the end 
of the dosing period their body weight was significantly lower than 
the controls as shown in Table 5.2. Moreover this table shows the 
former group possessed significantly decreased live r weights, microsomal 
protein and cytochrome P-450 concentrations, and NADPH-cytochrome c 
reductase, ethylmorphine N-demethylase and biphenyl 4-hydroxylase 
activities from the control values. The activity of cholesterol 
7*-hydroxylase in this Duphasol plus cholesterol dosed group was also
lowered but not significantly so. The mean serum cholesterol concen­
tration of this group was increased although there was no change in 
liver cholesterol concentration from the controls.
The Effect of Vitamin PQ + Cholesterol Administration on Hepatic 
Mixed-Function Oxidation and Cholesterol Metabolism in Rats: Rats on
the vitamin D3 plus cholesterol regime showed a much higher mortality
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Figure 5.4. The Variation of Food Consumption in Control, and
Duphasol + Cholesterol Dosed Rats During the Dosing Period.
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Figure 5.5. The Variation in Body Weight in Control, and Duphasol + 
Cholesterol Dosed Rats During the Dosing Period,
a - a  Control
Duphasol + Cholesterol
Table 5.2. The E ffect o f Duphasol + Cholesterol Administration on
Hepatic Mixed-Oxidation and Cholesterol Metabolism in Rats. 
Figures in parentheses refer to the number of rats/group.
* P < 0.01; **  P < 0.001.
CONTROLS
(6)
DULPHASOL + 
CHOLESTEROL 
DOSED (6)
Body weight (g) 283 +12 215+13* *
Liver weight (g) 11.0 +0 . 7 8.0 + 0.4**
Microsomal protein 
(mg/total liver) 304 + 18 194+21* *
Cytochrome P-450 
(nmol/total liver) 295 + 46 113 + 38**
NADPH-Cytochrome c reductase 
(ymol/total liver/min 15.8 + 2.6 6.9 + 1.1**
Cholesterol 7a-hydroxylase 
(pmol/total liver/min) 93 + 36 49 + 35
Ethylmorphine N-demethylase 
(ymol/total liver/min) 2.0 + 0.2 1.0 + 0 .4**
Biphenyl 2-hydroxylase 
(nmol/total liver/min) 4.6 + 1.6 6.0 + 3.3
Biphenyl 4-hydroxylase 
(ymol/total liver/min) 0 . 26+0 . 03 0 . 13+0 . 0 4 * *
Serum cholesterol 
(mg/dl) 61 + 5 105+50
Liver cholesterol 
(mg/total liver) 25.1 + 2.0 22.0 + 1 . 7
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of 75% than was experienced with the other vitamin D regimes. Further­
more this regime lead to an even quicker drop in food consumption from 
control to zero levels in about 72 h (Figure 5.6)  compared to the 
other vitamin D regimes. Once again a marked body weight loss became 
apparent in the vitamin D plus cholesterol-dosed animals as the 
dosing period progressed (Figure 5 . 7 ) .  Similar to the findings of 
the other two studies decreases in body and live r weight, microsomal 
protein and cytochrome P-450 concentrations, and NADPH-cytochrome 
c reductase, ethylmorphine N-demethylase, biphenyl 4- and cholesterol 
7a-hydroxylase activities from control levels were again evident 
(Table 5.3 )• This table also shows that the serum cholesterol 
concentration was once more significantly elevated in this group whilst 
no change in the live r cholesterol concentration was elic ited  from 
control values.
The Relative Effects of Vitamin D? + Cholesterol Administration and 
of Pair-Feeding on Cholesterol Metabolism and Hepatic Microsomal 
Cytochrome P-450 Concentration in Rats: Rats in the pair-fed group
maintained a constant body weight for the f ir s t  four days of the 
dosing period but over the remaining two days of this period their 
body weight began to decrease although i t  never dropped to the much 
lower level reached by the vitamin D2 plus cholesterol-dosed rats 
(Figure 5.9)* This smaller body weight decrease by the former group 
occurred even though their food consumption paralleled the progressively 
fa lling  consumption of the la tte r group (Figure 5.8). The body weight 
changes in these two groups were found to be significantly lower than 
the controls at the time of k illing  as shown by the data in Table 5.4. 
Furthermore, from this table i t  can be seen that there were also
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Figure 5.6. The Variation in Food Consumption in Control, and
Vitamin P3 + Cholesterol Dosed Rats During the Dosing Period.
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Figure 5.7. The Variation in Body Weight in Control, and Vitamin D$ + 
Cholesterol Dosed Rats During the Dosing Period.
a - a  Control
Vitamin D3 + Cholesterol
Table 5.3. The E ffect o f Vitamin P3 + Cholesterol Administration on
Hepatic Mixed-Function Oxidation and Cholesterol Metabolism
in Rats.
Figures in parentheses refer to the number of rats/group.
* P < 0.01; **  P < 0.001.
CONTROLS
(6)
VITAMIN D3 + 
CHOLESTEROL 
DOSED (3)
Body weight (g) 309 + 18 245+16*
Liver weight (g) 13.0 + 1.1. 9.1 + 0.6**
Microsomal protein 
(mg/total liver) 312 + 23 2 2 6 + 8 * *
Cytochrome P-450 
(nmol/total liver) 236 + 33 108 + 3**
NADPH-cytochrome c reductase 
(ymol/total liver/min) 1 4 . 8 + 3 . 3 5.9 + 0 . 4 *
Cholesterol 7a-hydroxylase 
(pmol/total liver/min) 113 + 35 39 + 33
.. ------------
Ethyl morphine N-demethylase 
(ymol/total liver/min) 2.3 +0 . 6 0.8 + 0 . 1 *
... . -----------
Biphenyl 2-hydroxylase 
(nmol/total liver/min) 12.1 + 3.1 8.4 + 5.7
Biphenyl 4-hydroxylase 
(ymol/total liver/min) 0.49 + 0.08 0.18 + 0.03**
Serum cholesterol 
(mg/dl) 66 + 9 121 + 13**
Liver cholesterol 
(mg/total liver) 26.8 + 3.5 23.3 + 3.8
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Figure 5.8. The Variation of Food Consumption in Control, Vitamin D?
+ Cholesterol, and Pair-Fed Rats During the Dosing Period,
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significant decreases in live r weight, cytochrome P-450 concentration 
and cholesterol 7a-hydroxylase activ ity  from the control levels in 
both the vitamin D2 plus cholesterol and pair-fed rat groups.
However, the serum cholesterol concentration was raised in only 
the vitamin D2 plus cholesterol-dosed rats, and also their 18,000 g 
supernatant free cholesterol level, taken as a measure of the 
substrate pool for cholesterol 7a-hydroxylase, was unaltered from the 
control levels whereas lower levels of this fraction were seen in 
the pair-fed group. The 18,000 g supernatant esterified cholesterol 
fraction was significantly decreased in both test groups, particularly  
in the pair-fed rats. The rats receiving the atherogenic regime 
again exhibited a mortality (13%) during the dosing period; no deaths 
were obtained in the other groups.
The Effect of Vitamin D? Addition i n  v i t r o  on Hepatic Mixed-Fuhction 
Oxidase A ctivity: Vitamin D2 at a concentration of 1 mM gave partial
inhibition of the control microsomal activities of cholesterol 7 a -  
and biphenyl 4-hydroxylases, and ethylmorphine N-demethylase when 
added in vitro (Table 5.5).  The magnitude of this inhibition was 
greatest on ethylmorphine N-demethylase activity (38% of control), 
and at lower levels on biphenyl 4-hydroxylase (63% of control) and 
cholesterol 7a-hydroxylase activities (80% of control). Vitamin 
D2 concentrations lower than 1 mM were without any significant effect 
on these enzymes.
The Binding of Vitamin D? i n  v i t r o  to Rat Liver Microsomes: Vitamin
D2 showed a Type I induced binding spectrum with control rat liv e r  
microsomes'with a peak at 385 nm, a trough at 420 nm and an isosbestic
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point at 403 nm (Figure 5.1o l. The value for the half-maximal 
binding constant, Ks, was calculated to be 67 + 31 yM from 12 
separate determinations.
Discussion
In this study mortalities were observed among rats given 
various vitamin D-containing regimes, vitamin D3 proving to be far 
more toxic in this respect than vitamin D2 at similar levels, so 
confirming similar observations made by Parke et al_. (1978) in the 
rat and lends support to their view that this is an unsuitable 
pharmacological model for the assessment of potential anti-athero­
sclerotic agents. Vitamin D toxicity in these rats was accompanied 
by weight loss, anorexia, weakness, coarse body coat and in some cases 
laboured breathing which were a ll symptoms that exactly documented 
those reported by Haschek & c;oworkers (1978) in the pig. Moreover, 
i t  was clear from the data of the pair-feeding study (Table 5.4} 
that the body weight loss could not be completely ascribed to the 
associated occurrence of anorexia in these rats. Extensive degenerative 
changes in the body induced by hypervitaminosis D, noted in the pig by 
Haschek & coworkers (1978), would seem a like ly  contributing mechanism 
towards this weight loss.
The production of hypercholesteraemia in the rat by an atherogenic 
regime comprising high doses of vitamin D2 and cholesterol, previously 
reported by several workers (Aubert et al_., 1974; Testa £ t al_., 1975; 
Douglas et al_., 1977), was confirmed in the present studies. Vitamin 
D2 administered alone was also found to be capable of generating this 
hypercholesteraemia whilst cholesterol given alone was without such
- 113 -
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Figure 5.10. The Vitamin Dp-Induced Binding Spectrum with Rat Liver
Microsomes.
Final vitamin Dz concentrations were:
A. 5 pM, B. 10 yMj C. 15 pM, D. 20 pM,
E. 25 pM, F. 30 pM.
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an effect indicating that i t  was the vitamin D component of the 
atherogenic regimes which was responsible for the serum cholesterol 
elevation.
Even though a ll the vitamin D containing regimes tested in vivo 
apparently had a pronounced detrimental effect on the functional 
capacity of the liver microsomal drug and cholesterol metabolising 
systems i t  was subsequently proven that this effect was almost or even 
entirely the result of the starvation experienced by these animals, as 
demonstrated by the results of the pair-feeding study (Table 5.4) .  A 
more pronounced lowering of cytochrome P-450 concentration in the 
vitamin D2 plus cholesterol group compared to that in the pair-fed group 
was apparent which may to some extent suggest that starvation was only 
partly the cause of the lowered drug-metabolising a b ility  found in rats 
dosed with vitamin D regimes, and that vitamin D might be responsible for 
an additional decrease in cytochrome P-450 to further depreciate drug- 
metabolising potential.
The lowering effect of starvation on cholesterol 7a-hydroxylase 
activ ity , originally recognised by Mitropoulos & associates (1972), along 
with the absence of hypercholesteraemia in the pair-fed group precludes 
the proposal made earlier that inhibition of this enzyme was the defect 
that gave raised serum cholesterol concentrations in these rats. Mo 
consistent decreases in the 18,000 g supernatant free cholesterol fraction, 
taken as a measure of the substrate pool level for cholesterol 7a-hydroxylati 
were found which might explain the lowered activity of this enzyme. On 
the other hand, the increased liver cholesterol concentration observed in 
the rats given cholesterol alone, but not in those given vitamin D plus 
cholesterol, points towards greater mobilisation of cholesterol from the 
tissues as an alternative mechanism for the hypercholesteraemia. Other 
possible mechanisms include increased gut absorption proposed by Huang &
coworkers (1977), and a higher rate o f endogenous synthesis o f cholesterol.
A type I binding spectrum was induced by vitamin D2 in vitro with 
rat liver microsomes which according to Schenkman et al_. (1967) and 
Remmer et £l_. (1969) can be attributed to the interaction of this compound 
with cytochrome P-450 in the microsomes. The mean binding constant value 
of 67 yM obtained was of the same order as the value of 7 yM reported by 
Cinti et (1976). Further in vitro addition experiments with vitamin 
D2 showed that i t  was capable of inhibiting known cytochrome P-450-mediated 
reactions such as ethylmorphine N-demethylation and biphenyl 4-hydroxylation 
in agreement with the findings of Cinti ,et a/L (1976). Moreover, these 
workers demonstrate that this inhibition was competitive in nature indicating 
that vitamin D2 binds at the substrate site of cytochrome P-450. The 
inhibitory consequences of such an interaction occurring in vivo cannot be 
considered totally  responsible for the lowering of activ ity  of the drug 
metabolising system observed, a more like ly  cause was the decreased cytochrome 
P-450 concentration in the microsomes which could have arisen from either 
decreased synthesis, or increased breakdown of this haemoprotein, or a 
combination of both. I t  would seem like ly  that vitamin D played a component 
part with starvation in this lowering of cytochrome P-450 as mentioned 
earlier. The depressing effect of starvation on hepatic drug-metabolising 
enzyme activities has been recognised for some time although the mechanism 
involved remains obscure (Campbell & Hayes, 1974).
Cholesterol 7a-hydroxylase activity was inhibited in vitro by 
vitamin D2> a finding which cannot be considered to contradict the previously 
held view that lowered activ ity  of this enzyme does not contribute towards 
the accumulation of hypercholesteraemia. Although the sim ilarity in 
response of this enzyme to vitamin D2> in comparison with the cytochrome P-450- 
mediated enzyme reactions also tested in v itro , does suggest an involvement
of cytochrome P-450 in the 7a-hydroxylation of cholesterol. This suggestion 
gains support from the similar modulations in cholesterol 7a-hydroxylase 
activity and cytochrome P-450 concentration noted in the in vivo studies. 
Furthermore, the in vitro inhibition of cholesterol 7a-hydroxylase by 
vitamin D25 a compound structurally similar to cholesterol, introduces the 
likelihood that this enzyme and cholecalciferol 25-hydroxylase are one and 
the same enzyme. Certainly the D vitamins would seem to satisfy some of 
the substrate specificity c rite ria  of cholesterol 7a-hydroxylase shown by 
Aringer (1978), namely a hydroxyl group at C3 and a similar side-chain 
structure to cholesterol.
\
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CHAPTER SIX
The Effects of Modulators of Hepatic Microsomal Cytochrome P-450 
-Mediated Mono-oxygenation on Cholesterol 7a-Hydroxylase A ctivity .
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Introduction
Since the cytochrome P-450-dependent mixed-function oxidase 
system of liver microsomes may be induced by a variety of compounds 
(Conney, 1967; Parke, 1975), several investi gators:-have used such 
compounds to evaluate the involvement of cytochrome P-450 in the enzymic 
7a-hydroxylation of cholesterol. The literature bears contradictory 
reports of the effect of phenobarbitone treatment on rat live r cholesterol 
7a-hydroxylase activ ity , some showing no stimulation (Boyd et aT. ,  1969;
Mellon et a1_., 1978) others showing an enhancement (Einarsson & Johansson, 
1968b; Wada et al_., 1968; Shefer ^ t aJ ., 1972; Cohen et jil_., 1975;
Brandau & Keup, 1976). Similar inconsistent findings have been documented 
for the administration of 3-methylcholanthrene to the rat (Brown & Boyd,
1974; Gielen. . e t a K j  1976; Wada jet , 1969; Mellon et a]_,, 1978). 
However, rats treated with the catatoxic steroid pregnenolone 16a-carbonitrile, 
yet another inducer of the hepatic drug mono-oxygenation system (Solymoss 
^ t al_., 1971; Japundzic et ^1_., 1974), have repeatedly shown a decrease 
in the activity of the cholesterol hydroxylase (Einarsson & Gustafsson,
1973; Honohan & Parkinson, 1975; Mason & Boyd, 1978).
Some suggestion of a cytochrome P-450 involvement in the 
7a-hydroxylation of cholesterol can be drawn from the effects of 
cholesterol supplementation in rat diet in that short-term (3-5 days) 
supplementation is known to enhance the activity  of cholesterol 7a- 
hydroxylase (Boyd et al_., 1969; Mitropoulos et al_., 1973; Si pat
et aV., 1977), whilst more long-term (4-5 weeks) supplementation induces 
the hepatic cytochrome P-450-dependent mixed-function oxidases (Lang &
Hanninen, 1977; Lang- e t a l . ,  1976; Laitinen, 1976; Hietanen et a l . ,
1978). However, the well recognised stimulation of rat live r cholesterol 
7a-hydroxylase by dietary cholestyramine (Boyd et siK, 1969; Johansson, 
1970) occurs without any change in liver microsomal cytochrome P-450 
concentration although the activ ity  of NADPH-cytochrome c reductase, a 
component of the hepatic drug mono-oxygenase system, is raised (Brown & 
Boyd, 1974; Mellon et aU , 1978).
The use of compounds such as SKF-525A, piperonyl butoxide, metyrapone, 
and 1-alkyl imidazoles to inhibit cytochrome P-450-dependent drug 
metabolism both in vivo and in vitro is well recognised (S titzel et a l . ,
1966; Anders, 1968; Liebman, 1969; Palmer & Cawthorne, 1974). Of these
SKF-525A and the 1-alkylimidazoles are known inhibitors of cholesterol 
biosynthesis (Holmes & Bentz, 1960; Atkin et a/L, 1972), whilst SKF-525A 
and metyrapone have been shown to inhibit mitochondrial sterol oxidation 
in the liver (Dean & Whitehouse, 1967). However, the effect of these 
compounds on the hepatic 7a-hydroxylation of cholesterol has not been 
examined.
In an attempt to c larify  the somewhat equivocal evidence for the 
involvement of cytochrome P-450 in the 7a-hydroxylation of cholesterol 
a more exhaustive examination of the effects of a number of cytochrome
P-450 inducers and inhibitors on the hepatic drug and cholesterol
metabolising mono-oxygenase systems was performed.
Materials and Methods
Materials: All materials have been previously described.
The Effects of Inducing Agents and Inhibitors on Cholesterol Metabolism 
and the Mixed-Function Oxidases of Rat Liver: The following compounds
were administered to rats as described in Chapter Two: phenobarbitone,
3-methylcholanthrene, pregnenolone 16a-carbonitrile, safrole, SKF-525A,
cholesterol and cholestyramine.
The effects of these compounds on general body parameters such 
as body and live r weights were examined. Also, hepatic mixed-function 
oxidation parameters including microsomal cytochrome P-450, protein 
concentrations, ethylmorphine N-demethylase, biphenyl 2- and 
4-hydroxylase, cholesterol 7a-hydroxylase, NADPH-cytochrome c reductase 
activities were determined. Lastly, in cases where cholesterol 
7a-hydroxylase activity was altered, serum and live r cholesterol 
concentrations were measured.
The Effects of Inhibitors on Rat Liver Cholesterol 7a- and Biphenyl 
4-Hydroxylase Activities vn vitro: The following compounds were examined
for inhibition of cholesterol 7a- and biphenyl 4-hydroxylases in v itro : 
a-naphthoflavone, SKF-525A, piperonyl butoxide, metyrapone, dodecylimidazole 
2-propylbenzimidazole and 2-methylbenzimidazole.
Results
The Effect of Phenobarbitone Pretreatment on the Rat Liver Mixed-Function 
Oxidase System: Rats treated with phenobarbitone exhibited enhanced
hepatic drug metabolising activ ity  characterised by 2-3 fold increases in 
ethylmorphine N-demethylase and biphenyl 4-hydroxylase, along with 
significant increases in the concentrations of the components of this 
system such as cytochrome P-450 and NADPH-cytochrome c reductase 
(Figure 6.1) .  Microsomal protein concentration and live r weight were also 
significantly increased in the phenobarbitone-treated rats. The increase 
in cytochrome P-450 concentration was similar to the increases in 
ethylmorphine N-demethylation and biphenyl 4-hydroxylation. However, no 
change in cholesterol 7a-hydroxylase activ ity occurred. Rats of both
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Figure 6.1. The Effect of Phenobarbitone Pretreatment on the Rat 
Liver Mixed-Function Oxidase System.
Values represent the mean + S.D. for 6 animals (expressed as 
percent of control); **  P < 0.001. The control values are given 
in Appendix 1.
A, Body weight; G, Cytochrome P-450;
B, Liver weight; H, NADPH-Cytochrome c reductase;
C, Ethylmorphine N-demethylase; I, Microsomal protein,
D, Biphenyl 2-hydroxylase;
E, Biphenyl 4-hydroxylase;
F, Cholesterol 7a-hydroxylase;
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phenobarbitone-treated and control groups consumed the same amount of 
food during the dosing period (data not shown).
The Effect of 3-Methylcholanthrene Pretreatment on the Rat Liver Mixed- 
Function Oxidase System: 3-Methylcholanthrene administration to the
rat also produced increases in the hepatic drug metabolising enzymes 
although biphenyl 4-hydroxylase and ethylmorphine N-demethylase ac tiv ities , 
and cytochrome P-450 (P-448) concentration were not so highly induced as 
with phenobarbitone (Figure 6.21. Moreover no increases in NADPH-  
cytochrome c reductase activ ity  or microsomal protein could be 
detected. However, a marked 25-fold enhancement of biphenyl 2-hydroxy- 
lation, a cytochrome P-448-mediated enzyme reaction, was evident. No 
significant change in cholesterol 7a-hydroxylase activity was found 
although the mean activ ity  did show a 40% decrease from the control 
value; serum and live r cholesterol concentrations in these rats 
remained unchanged. The food consumption of both treated and control 
groups were the same during the dosing period (data not shown).
The Effect of Pregnenolone 16a-carbonitrile Pretreatment on the Rat 
Liver Mixed-Function Oxidase System: The administration of pregnenolone
16a-carbonitrile to the rat resulted in some induction of the hepatic 
drug mixed-function oxidase system as indicated by significant increases 
in ethylmorphine N-demethylase and biphenyl 2-hydroxylase activ ities  
only (Figure 6.3). The enhancement of biphenyl 2-hydroxylase activ ity  
was much less than that seen with 3-methylcholanthrene whilst the ethyl­
morphine N-demethylase increase was of the same order as that with 3-methyl- 
cholanthrene. NADPH-cytochrome c reductase activ ity  and cytochrome P-450 
concentration in the rats dosed with pregnenolone 16a-carbonitrile both
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Figure 6.2. The Effect of 3-Methyl cholanthrene Pretreatment on the 
Rat Liver Mixed-Function Oxidase System.
Values represent the mean + S.D. for 6 animals (expressed as 
percent of control); **  P < 0.001. The control values are given
in Appendix 1.
A, Body weight:
B, Liver weight;
C, Ethylmorphine N-demethylase;
D, Biphenyl 2-hydroxylase;
E, Biphenyl 4-hydroxylase;
F, Cholesterol 7a-hydroxylase;
G, Cytochrome P-450;
H, NADPH-Cytochrome c reductase;
I, Microsomal protein;
J, Serum cholesterol; and 
K, Liver cholesterol.
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Figure 6.3. The Effect of Pregnenolone 16a-Carbonitrile Pretreatment 
on the Rat Liver Mixed-Function Oxidase System.
Values represent the mean + S.D. for 6 animals (expressed as 
percent of control); * P < 0.01; * *  P < 0.001. The control values 
are given in Appendix 1.
A, Body weight;
B, Liver weight;
C, Ethylmorphine N-demethylase;
D, Biphenyl 2-hydroxylase
E, Biphenyl 4-hydroxylase;
F, Cholesterol 7a-hydroxylase;
G, Cytochrome P-450;
H, NADPH-Cytochrome c reductase;
I, Microsomal protein.
-  125 -
showed some increase . No change of cholesterol 7a-hydroxylase activity  
occurred. Both treated and control rats consumed similar amounts of 
food during the dosing period (data not shown).
The Effect of Safrole Pretreatment on the Rat Liver Mixed-Function 
Oxidase System: Safrole treatment of rats produced significant increases
in the activities of biphenyl 2-hydroxylase, ethylmorphine N-demethylase 
and NADPH-cytochrome c reductase; microsomal cytochrome P-450 and 
protein concentrations were also increased (Figure 604).  The activ ity  
of cholesterol 7cx-hydroxylase in the safrole-treated rats showed no 
change from control. Food consumption in safrole-treated and control 
rats was similar (data not shown).
The Effect of -SKF-525A Presentment on the Rat Liver Mixed- 
Function Oxidase System: Rats treated with SKF-525A for 2 consecutive
days exhibited significantly increased biphenyl 2 - and cholesterol 
7a-hydroxylase activ ities , and increased microsomal cytochrome 
P-450 and protein concentrations (Figure 6.5). Mo changes in 
ethylmorphine N-demethylase, biphenyl 4-hydroxylase, or NADPH-cytochrome 
c reductase activities or serum and liver cholesterol concentrations 
were observed. The enhancement of biphenyl 2-hydroxylase activ ity  
noted in this study was similar to that previously shown with safrole 
treatment. The cytochrome P-450 obtained with SKF-525A treatment 
showed a typical absorbance maximum at 450nm for the carbon monoxide 
difference spectrum. The body weight of the treated rats was less than 
that of controls, as shown in Figure 6 . 6 . Food consumption data was 
not recorded for these rats.
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Figure 6.4. The Effect of Safrole Pretreatment on the Rat Liver 
Mixed-Function Oxidase System.
Values represent the mean + S.D. for 5 animals (expressed as 
percent of control); *  P < 0.01; **  P < 0.001. The control values
are given in Appendix 2.
A, Body weight;
B, Liver weight;
C, Ethylmorphine N-demethylase;
D, Biphenyl 2-hydroxylase;
E, Biphenyl 4-hydroxylase;
F, Cholesterol 7a-hydroxylase;
G, Cytochrome P-450;
H, NADPH-Cytochrome c reductase;
I, Microsomal protein.
Figure 6.5. The E ffect o f SKF-525A Pretreatment fo r  2 Consecutive Days
on the Rat Liver Mixed-Function Oxidase System.
Values represent the mean + S.D. for 4 animals (expressed as 
percent of control); *  P < 0.01; * *  P <0.001. The control values
are given in Appendix 1.
G, Cytochrome P-450;
H, NADPH-Cytochrome c reductase;
I, Microsomal protein;
J, Serum cholesterol; and 
K, Liver cholesterol.
A, Body weight;
B, Liver weight;
C, Ethylmorphine N-demethylase;
D, Biphenyl 2-hydroxylase;
E, Biphenyl 4-hydroxylase
F, Cholesterol 7a-hydroxylase;
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Figure 6 0 6 . The Variation of Body Weight in Control and SKF-525A Dosed 
Rats During the Dosing Period.
a —a  Control
SKF-525A
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Alternatively the administration of SKF-525A to rats 1 h before 
k illing  completely abolished ethylmorphine N-demethylase activ ity  and 
significantly lowered biphenyl 4-hydroxylase activ ity , although no 
lowering of cholesterol 7a- hydroxylase activ ity  was observed 
(Figure 6.7) .
The Effect of Dietary Supplementation with Cholesterol on the Rat 
Liver Mixed-Function Oxidase System: The inclusion of cholesterol
in the diet of rats was found to induce a small (30%) but significant 
rise in liver cholesterol 7a-hydroxylase activ ity  which was otherwise 
accompanied by non-significant increases in microsomal protein and 
cytochrome P-450 concentration only (Figure 6 . 8 ) .  No variation in 
serum cholesterol concentration from the control value could be 
detected although a small non-significant increase in 1 iver cholesterol 
concentration was present. A slightly higher food consumption among 
the cholesterol-fed rats was evident (Figure 6.9)  but there was no 
overall change in body weight gain in this group over the controls 
during the dosing period (Figure 6.10).
The Effect of Dietary Administration of Cholestyramine on the Rat 
Liver Mixed-Function Oxidase System: Rats treated with cholestyramine
exhibited a specific and marked enhancement of liver cholesterol 
7a-hydroxylase activ ity  which was associated with a small (30%), but 
s ta tis tica lly  non-significant rise in microsomal cytochrome P-450 
concentration, similar to that seen in the cholesterol-fed rats 
(Figure 6.11). No other changes in hepatic mixed-function oxidase 
activity or components were found. Liver cholesterol concentration 
remained unchanged by this regime but a small, significant decrease
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Figure 6.7. Ihe Effect of a Single Dose of SKF-525A on the Rat Liver 
Mixed-Function Oxidase System.
Values represent the mean + S.D. for 4 animals (expressed as 
percent of control); * P < 0.01; * *  P < 0.001. The control values 
are given in Appendix 1.
A, Body' weight;
B, Liver weight;
C, Ethylmorphine N-demethylase;
D, Biphenyl 2-hydroxylase;
E, Biphenyl 4-hydroxylase;
F, Cholesterol 7a-hydroxylase;
G, Cytochrome P-450;
K, NADPH-Cytochrome c reductase; 
I, Microsomal protein. .
Figure 6 . 8 . The E ffect of Cholesterol Administration on the Rat
Liver Mixed-Function Oxidase System.
Values represent the mean + S.D. for 4 animals (expressed as 
percent of control); * P < 0.01. The control values are given 
in Appendix 1.
A, Body weight; G, Cytochrome P-450;
B, Liver weight; H, NADPH-Cytochrome c reductase
C, Ethylmorphine N-demethylase; I, Microsomal protein;
D, Biphenyl 2-hydroxylase; J, Serum cholesterol; and
E, Biphenyl 4-hydroxylase; K, Liver cholesterol.
F, Cholesterol 7a-hydroxylase;
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Figure 6.9. The Variation of Food Consumption in Control and Cholesterol- 
Fed Rats Puri rig the Dosi ng Period.,
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Figure 6.10. The Variation of Body Weight in Control and Cholesterol- 
Fed Rats During the Dosing Period.
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Figure 6 .11. The Effect of Cholestyramine Administration on the 
Rat Liver Mixed-Function Oxidase System.
Values represent the mean + S.D. for 4 animals (expressed as 
percent of control); * P < 0.01; **  P < 0.001. The control 
values are given in Appendix 1.
A, Body weight;
B, Liver weight;
C, Ethylmorphine N-demethylase;
D, Biphenyl 2-hydroxylase;
E, Biphenyl 4-hydroxylase;
F, Cholesterol 7a-hydroxylase;
G, Cytochrome P-450;
H, NADPH-Cytochrome c reductase;
I , Microsomal protein;
J, Serum cholesterol; and 
K, Liver cholesterol.
(- 13°/) in serum cholesterol was apparent. Furthermore a significant 
lowering of liver weight was noted in these treated rats, although 
food consumption in both treated and control groups were normal 
(data not shown).
The Effect of the in vitro Addition of Various Mixed-Function Oxidase 
Inhibitors on Rat Liver Cholesterol 7a- and Biphenyl 4-Hydroxvlase 
Activities: From the data presented in Table 6.1 i t  can be seen that
the addition of either a-naphthoflavone, SKF-525A, piperonyl butoxide, 
metyrapone, or dodecylimidazole to rat liver microsomes in vitro was 
associated with inhibition of both cholesterol 7a- and biphenyl 
4-hydroxylase activ ities , often to quite similar degrees. Even though 
all five of these compounds led to significant inhibition of cholesterol 
7a-hydroxylase only SKF-525A, piperonyl butoxide and dodecylimidazole 
significantly inhibited biphenyl 4-hydroxylase. Of these SKF-525A was 
the strongest inhibitor of cholesterol 7a-hydroxylase activ ity  and 
likewise dodecylimidazole was the most active inhibitor of biphenyl
4-hydroxylase activ ity . The two 2-alkylbenzimidazoles also examined, 
namely, 2 -propyl- and 2 -methylbenzimidazole, showed very l i t t l e  
inhibition of the activ ities of these two enzymes.
Discussion
The data obtained in the present study revealed new evidence for 
the participation of cytochrome P-450 in the enzymic 7a-hydroxylation 
of cholesterol, in that a correlation between the rate of this reaction 
and the modulations of the hepatic monooxygenase system, implemented 
by various agents, was clear in several cases. Most noteworthy were 
the effects of SKF-525A; this agent demonstrated a marked a b ility  to 
increase the activity  of cholesterol 7a-hydroxylase in vivo as well as
Table 6.1. The Relative Effects o f the in  v itro  Addition o f
Cytochrome P-450 Inhibitors on Rat Liver Cholesterol 
7a- and Biphenyl 4-Hydrowlase Activities,,
Values represent the mean _j\S„D. for 3 determinations (expressed 
as percent inhibition of control ac tiv ity ). Each inhibitor was added in 
10 yl dimethylformamide to give a final concentration of TOO yM. Control 
cholesterol 7a-hydro*ylase activity -1 0 .2  + 0.1 pmol/g liver/m in, and 
biphenyl 4-hydroxylase activ ity  = 16.9 nmol/g liver/min.
Inhibitor
% Inhibition of Control Activity
Cholesterol j Biphenyl 
7a-Hydroxylase j 4-Hydroxylase
a-Naphthoflavone
j
21 + 1 * *  | 10 + 4
SKF-525A 5 0 + 3 * *  j 2 2 + 6 *
!
Piperonyl Butoxide 23 + 3 * *  j 58 + 3**
i
Metyrapone
i
21 + 3** ] 1 7 + 6
! Dodecylimidazole 4 3 + 1 * *  | 66 + 0**
2-Propylbenzimidazole 6 + 4 6 + 6 _  , '
j  2-Methylbenzimidazole
i . 
iL ....
oo
*  P < 0.01; * *  P < 0,001.
raising the microsomal cytochrome P-450 content. Moreover in vitro  
i t  showed inhibition of both cholesterol 7a-hydroxylase and the 
cytochrome P-450-mediated 4-hydroxylation of biphenyl although as 
an inhibitor in vivo lowering of biphenyl 4-hydroxylase and ethyl­
morphine N-demethylase activities only were evident. Cholestyramine 
also enhanced cholesterol 7a-hydroxylase activ ity  in vivo and was 
accompanied by an increase in the microsomal cytochrome P-450 content, 
whilst cholesterol administration in Vivo gave similar but smaller 
rises in cholesterol 7a-hydroxylase activity and cytochrome P-450 
content. Furthermore compounds such as a-napthoflavone, piperonyl 
butoxide, metyrapone and dodecylimidazole inhibited both cholesterol 
7a- and biphenyl 4-hydroxylase activities in v itro .
On the other hand, the administration of other known hepatic 
monooxygenase inducers in vivo was accompanied by an absence of 
cholesterol 7a-hydroxylase enhancement even though increases in the 
components and activ ities of the hepatic drug-metabolising monooxygenase 
system were apparent. In particular, no stimulation of cholesterol 
7a-hydroxylase was obtained with phenobarbitone treatment in agreement 
with the findings of Boyd et a! .(1969) and Mellon et al_.( 1978) in Wistar 
rats but contradictory to the inductive effects noted by Wada'et a l. 
(1968) in the Sprague-Dawley ra t, and by Shefer et a1_. (1972) and Cohen 
et a l. (1975) in the Wistar rat. These la tte r two groups also reported 
a Tack of response of this enzyme to phenobarbitone pretreatment in 
Sprague-Dawley rats. Shefer et al_. (1972) claimed that this inconsistency 
was the result of strain differences in the responsiveness of this enzyme, 
although the present data supported the view held by Mellon et al .(1978) 
that intrastrain differences must also exist.
Administration of the polycyclic hydrocarbon, 3-methylcholanthrene, 
to rats induces a microsomal haemoprotein referred to as cytochrome 
P-448 which differs in certain of its  physical and biochemical 
characteristics from the cytochrome P-450 of untreated and phenobarbitone 
treated rat liver microsomes (Alvares et £ l / ,  1967; Shoeman et al_., 1969) 
The non-significant lowering of cholesterol 7a-hydroxylase activ ity  by 
3-methylcholanthrene observed in the current investigation resembled 
the decreases in this enzyme activ ity  documented by Wada et aj_. (1969) 
in Sprague-Dawley rats and Mel!on et al_. (1978) in Wistar rats. The 
conclusions of Mellon et al_. (1978) that cytochrome P-448 was less 
capable than cytochrome P-450 of acting as the terminal oxidase for the 
7a-hydroxylation of cholesterol, or that some component or components 
of this enzyme system were adversely effected by this treatment would 
seem good explanations for this effect. However safrole, a compound 
similar to 3-methylcholanthrene in its  pattern of induction (Lake et 
al_., 1973) and formation of cytochrome P-448 (Elcombe et a l . ,  1975), 
showed no such lowering of cholesterol 7a-hydroxylase activ ity  in the 
present studies which would support only the la tte r suggestion that 
components other than cytochrome P-450 were affected. Pregnenolone 
16a-carbonitrile similar to phenobarbitone also failed to change the 
activ ity  of cholesterol 7a-hydroxylase, a finding which disagreed with 
the decreasing effect of this agent on cholesterol 7ct-hydroxylase 
activity.reported in the literature (Einarsson & Gustafsson, 1973;
Honohan & Parkinson, 1975; Mason & Boyd, 1978). Since Mason & Boyd 
(1978) used rats of the Wistar strain, and the former workers Sprague- 
Dawley rats then<the present discrepancy could be explained by the 
existence of strain and intrastrain differences in the responsiveness 
of this enzyme to prenenolone 16a-carbonitrile similar to those noted 
earlier for phenobarbitone.
The recognised stimulation of rat liv e r cholesterol 7cr-hydroxylase 
activity by dietary cholesterol (Boyd et al_., 1969; Mitropoulos et a l . ,  
1973; Sipat et al_., 1977) was confirmed in the current work. A non­
significant increase in liver cholesterol concentration was also found 
in these rats which agrees with the observed increase in cholesterol 
pool size reported by Mitropoulos et al_. (1973) and introduced the 
possibility that the enhanced activ ity of the cholesterol hydroxylase 
resulted from a greater substrate concentration. Alternatively, 
compositional changes in the microsomal membranes induced by cholesterol, 
as suggested by Hietanen et ja]_. (1978), may raise the functional 
capacity of this enzyme system, or the effect may be purely due to 
de novo protein synthesis. The enhancement of this enzyme by 
cholestyramine treatment was also confirmed, and occurred without any 
change in liver cholesterol concentration so supporting the finding 
of Mitropoulos et al_. (1973) that the substrate pool level was unaltered.
I t  is well known that cholestyramine produces this effect on cholesterol 
7crhydroxylase by decreasing the enterohepatic circulation of b ile  acids 
which subsequently lowers the magnitude of their normal feedback 
inhibition on cholesterol 7ct-hydroxylase (Myant & Mitropoulos, 1977).
Since the rise in enzyme activity produced by interruption of the entero­
hepatic circulation of bile acids can be prevented by the protein synthesis 
inhibitor actinomycin D (Einarsson & Johansson, 1968a) i t  would seem that 
induction of some component for this enzyme produces the observed stimu­
lation of activ ity . The present study pointed towards this component 
being cytochrome P-450. The serum cholesterol-lowering effect of 
cholestyramine is generally attributed to the higher rate of cholesterol 
catabolism to bile acids which may also be the mechanism by which the 
hypocholesteraemic effect of SKF-525A, seen over more long-term dosing 
(Dick et al_., 1960), is generated.
The daily administration of SKF-525A to rats is associated 
with the induction of cytochrome P-450 and the formation of a 
metabolically-inactive complex between this haemoprotein and SKF-525A 
in liver microsomes (Buening & Franklin, 1976) with a maximum increase 
in uncomplexed cytochrome P-450 of two-fold which was confirmed in 
the present investigations (Figure 6.5} and is associated with 
increases in cholesterol 7a- and biphenyl 2-hydroxylase activ ities .
The absence of any increase in liver cholesterol concentration in 
theserats discounted any suggestion that a greater substrate 
availab ility  for cholesterol 7a-hydroxylase produced the stimulation 
of this enzyme. A more like ly  cause is increased synthesis of 
some microsomal protein component for this enzyme coupled with a 
decrease in microsomal protein degradation, as proposed by Fernandez 
et aj_. (1978) for the inductive effect of this agent on the drug- 
metabolising enzymes, which would agree with the significant increase 
in microsomal protein concentration measured in these rats. Indeed 
i t  would seem from the present data that this component is cytochrome 
P-450.
In view of the similar modulations of cholesterol 7a-hydroxylase 
activity and cytochrome P-450 content shown by many of these studies 
and the current concepts of the multiple forms of cytochrome P-450 
(Lu & West, 1978) i t  would appear like ly  that a specific form of cyto­
chrome P-450 may exist in liver microsomes which preferentially  
catalyses the 7a-hydroxylation of cholesterol, and possibly a number 
of other steroid hydroxylations. Evidence for a sim ilarity between 
this form of the cytochrome and that involved in drug metabolism was
equivocal in that administration of inducers of the drug-metabolising 
cytochrome P-450 was not accompanied by an induction of cholesterol 
7a-hydroxylase although a correlation between the inhibition of 
biphenyl 4-hydroxylase and cholesterol 7a-hydroxylase by various compounds 
in vitro was demonstrated. Purification and characterisation of the 
specific cytochrome P-450 is needed to resolve this question.
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CHAPTER SEVEN
The Purification and Reconstitution of Rat Liver 
Cholesterol 7a-Hydroxylase Activity
Introduction
The purification and resolution of the liver mixed-function 
oxidase components and their subsequent use in reconstituted systems to 
study the properties of these enzymes has both advantages and disadvantages. 
One of the main advantages is that i t  is a means of establishing the 
essential components for mixed-function oxidase activ ity . Another 
advantage is that i t  is possible to determine whether multiple forms of 
cytochrome P-450 exist, and whether there is a specific form responsible 
for one or a group of substrate hydroxylations. One of its  limitations is 
that i t  may not be structurally identical to the intact membrane-bound 
mixed-function oxidase, and therefore may not be a true reflection of the 
in vivo system. In addition, the reconstituted system may not be suitable 
for establishing the total metabolic profile of a ll substrates due to 
either loss or inactivation of essential components during the isolation 
procedure.
A number of procedures now exist for the purification of the live r  
microsomal cytochrome P-450-dependent mixed-function oxidase system 
(Lu et al_., 1972; Imai & Sato, 1974; Haugen et a l . , 1975; Dignam & 
Strobe!, 1975; Yasukochi & Masters, 1976; Guengerich, 1977; West et a l . ,  
1979), some of which have been applied to the isolation of the liv e r  
microsomal cholesterol 7a-hydroxylase enzyme system. The purification of 
this enzyme in a partia lly  pure form was f ir s t  achieved by Bjdrkhem et a l . 
(1974) and more recently in a more refined form by Hansson & Wikvall (1979). 
These workers report that the activity  of cholesterol 7a-hydroxylase can 
be reconstituted using purified preparations of cytochrome P-450 and 
NADPH-cytochrome c (P-450) reductase, and a synthetic phospholipid.
Moreover, an absolute requirement for cytochrome P-450 and its  flavoprotein 
reductase was exhibited by this enzyme in experiments where these components 
were selectively omitted, whereas the requirement for phospholipid proved
more equivocal.
To investigate whether cholesterol 7a-hydroxylase is a cytochrome 
P-450-dependent enzyme, and to examine the role of NADPH-cytochrome c 
reductase and phospholipid in this reaction, purification and reconstitution 
of this mixed-function oxidase was performed.
Materials and Methods
Materials: All materials were obtained as previously described.
The Purification of Cholesterol 7a-Hydroxylase Activity from Rat Liver 
Microsomes: The procedure outlined in Figure 7.1 and given in detail in
Chapter Two was used to purify the cytochrome P-450 and NADPH-cytochrome c 
reductase fractions from the liver microsomes of cholestyramine-treated 
rats.
In addition, the absolute spectrum of the final cytochrome P-450 
fraction in the oxidised (fe rric ) state was recorded between 350 and 600 nm 
with the haemoprotein fraction diluted in 50 mM sodium phosphate buffer, 
pH 7.25, containing 25% glycerol in the sample cuvette and the buffer only 
in the reference.
The Reconstitution of Enzyme Activity: The reconstitution experiments were
performed according to the procedures given in Chapter Two.
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Figure 7.1. An outline of the procedure to purify the cytochrome P-450 
and NADPH-cytochrome c reductase components from__rat live r  
microsomes
The following abbreviations were used: P-450-cytochrome P-450,
b5-cytochrome b5, FPy-NADPH-cytochrome c reductase, FP -^NADH-cytochrome 
b5 reductase.
Results
Table 7.1 and 7.2 summarise the purification data for the isolation 
of the cytochrome P-450 and NADPH-cytochrome c reductase fractions. The 
solubilisation of these mixed-function oxidase components from the live r  
microsomal fraction achieved an increase in the specific content of 
cytochrome P-450 together with a high yield (83%), but the yield of 
NADPH-cytochrome c reductase activity was less certain since this enzyme 
was activated by the solubilisation detergent as indicated by the increased 
total activ ity . I t  was assumed that v irtually  a ll the activ ity  of this 
enzyme had been solubilised. On the other hand, a much lower yield and 
specific content of cholesterol 7a-hydroxylase activity in the solubilised 
preparation was observed.
Cytochrome P-450 was eluted from the DEAE-cellulose column in a broad 
band (Figure 7.2)*, the specific content of cytochrome P-450 was further 
improved by this chromatographic step to 1.46 nmol per mg of microsomal 
protein as compared to 1.18 nmol per mg of protein for the original 
microsomal fraction, and over 60% of the original microsomal haemoprotein 
was recovered (Table 7.1). Further chromatography on hydroxyapatite 
produced a concentrated cytochrome P-450 fraction (Figure 7.3) with a 36% 
yield and an even further increased specific content of 3.68 nmol per mg 
of protein. Removal of detergent by treatment of this fraction with 
Bio-Beads provided the final cytochrome P-450 preparation which amounted to 
an overall yield of 28% and a specific content of 3.65 nmol per mg of 
protein representing a three-fold purification of the microsomal cytochrome 
P-450. Only a trace of NADPH-cytochrome c reductase activity was detected 
in this final preparation.
Spectrally this purified cytochrome P-450 gave a characteristic
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Table 7.2. The a c t iv ity  o f cholesterol 7a-hydroxylase in the
microsomal fraction and the solubilisation supernatant.
FRACTION
CHOLESTEROL 7a-HYDR0XYLASE
*Units/
ml
*Units
Total
SPECIFIC CONTENT
Yield
%
*Units/ 
mg protein
*Units/ 
nmol P-450
Washed 
Mi crosomes 94 7250 2.14 1.81 100
tSolubilisation
Supernatant 2.9 2242 0.84 0 .6 8 30.9
* Units = pmol of 7a-hydroxy[4-14C]cholesterol/min.
t  The term 'solubilisation supernatant' refers to the supernatant obtained 
after centrifugation of the detergent-solubilised microsomal fraction at 
105,000 g for 1 h.
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reduced-carbon monoxide difference spectrum (Figure 7.4) with an 
absorbance maximum at 450 nm, only a minor inflection in this spectrum at 
420 nm was shown. In the oxidised (fe rric ) state this haemoprotein fraction 
again showed a typical spectrum of cytochrome P-450 (Figure 7.5) with a 
major Soret peak at 415 nm, and more minor a and 3 peaks at 566 and 533 nm 
respectively. \
Sodium dodecyl sulphate gel electrophoresis of the cytochrome P-450 
preparation showed the presence of 3-4 protein bands in the 45,000 - 55,000 
molecular weight range in which protein bands attributed to cytochrome 
P-450 are located (Plate 7.1). The intensity of both high and low molecular 
weight protein bands, located above and below the cytochrome P-450 region, 
were decreased compared to those in the original microsomal fraction, so 
verifying the purification of cytochrome P-450. A small contamination by 
cytochrome b5 may be indicated by the protein band at the bottom of the gel 
corresponding to a molecular weight of about 13,000.
The NADPH-cytochrome c reductase component eluted in a salt-gradient 
from the DEAE-cellulose column (Figure 7 .6 ), and further purified by a ffin ity  
chromatography and gel f iltra tio n  was obtained in high yield (72%) with a 
greatly improved specific activity of 2 0 .8  ymol per min per mg of protein 
as compared to 0.077 ymol per min per mg of protein for the microsomal 
preparation (Table 7.1). A greater loss in total activity of this enzyme 
than anticipated was encountered in the DEAE-cellulose fraction, but the 
addition of FMN to the purification buffers following this stage regenerated 
the activity in the later fractions. Even so, some loss of activ ity  was 
again obtained when FMN was omitted from the buffer during gel f ilt ra t io n .
No contamination of the final NADPH-cytochrome c reductase preparation by 
cytochrome P-450 was detected.
400 420 440 460 480 500
Wavelength, nm
Figure 7,4. The reduced-carbon monoxide difference spectrum of the 
purified cytochrome P-450.
The sample and reference cuvettes contained the purified haemoprotein 
(6.1 yM) in 50 mM sodium phosphate buffer, pH 7.25, containing 25% glycerol.
0.05 A
0.01 A
500 530 590560
Wavelength, nm
360 390 420
Wavelength, nm
450 480
Figure 7.5. The absolute oxidised spectrum of the purified cytochrome P-450
Cytochrome P-450 concentration = 3.05 yM.
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Plate 7.1. - The SDS-gel electrophoresis pattern o f the 
p u rified  cytochrome P-450.
A - molecular weight markers; B to E - increasing concentrations 
o f the p u rified  cytochrome P-450; F - normal control microsomes.
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Cholesterol 7a-hydroxylase activity was reconstituted in a system 
containing the purified cytochrome P-450 and NADPH-cytochrome c reductase, 
and a synthetic phospholipid at two substrate concentrations (Table 7.3).
At a substrate concentration of 4.5 yM, which was identical to that used 
in the microsomal determination, a lower specific activ ity of this 
hydroxylase was obtained (0 . 6 8  pmol per min per nmol of cytochrome P-450) 
relative to that in the microsomal fraction (1.81 pmol per min per nmol o f 
cytochrome P-450). However, with a substrate concentration of 45 yM in the 
reconstituted system a higher specific activ ity of cholesterol 7a-hydroxylase 
(10.4 pmol per min per nmol of cytochrome P-450) was obtained relative to 
the microsomal fraction. Omission of either the cytochrome P-450, or the 
NADPH-cytochrome c reductase components from the reconstituted system was 
accompanied by a concomitant loss of cholesterol 7a-hydroxylase activ ity , 
but the omission of the phospholipid produced only a partial loss of 
activity (Table 7.3).
The complete reconstituted system also actively supported the 
N-demethylation of ethylmorphine at a rate of 12.3 nmol of product per min 
per nmol of cytochrome P-450.
Table 7.3. The a c t iv ity  o f cholesterol 7a-hydroxylase in the microsomal
fraction, and in the reconstituted system.
r - .. — "
System Cholesterol 7a-Hydroxylase 
Activity (pmol/min/nmol
cytochrome P-450)
Microsomal fraction* 1.81
Complete reconstituted
system: a * 0 . 6 8
b + 10.4
Reconstituted systemt
minus:
cytochrome P-450 0 . 0
NADPH-cytochrome c 
reductase 0 . 2
phospholipid 5.3
* final concentration of exogenously added cholesterol = 4.5 yM 
t  final concentration of exogenously added cholesterol = 45 yM.
Discussion
The purification of cholesterol 7a-hydroxylase activity from rat 
liver microsomes of cholestyramine-treated rats has been previously 
achieved by a number of techniques. Bjdrkhem et (1974) used a 
procedure based on cholate solubilisation, and fractionation with 
polyethylene glycol and ammonium sulphate as described by Lu et al_. (1972).
However, this procedure gave a low cholesterol 7a-hydroxylase activ ity  and 
the extent of purification was small. The detrimental effect of cholate 
solubilisation was later confirmed and the use of non-ionic detergents 
proposed as a more favourable alternative (Hattersley & Boyd, 1975). More 
recently Hansson & Wikvall (1979), utilis ing non-ionic detergent solubilisation 
and a combination of DEAE-Sephadex and hydroxyapatite column chromatography 
and polyethylene glycol fractionation, and Boyd and Ozasa (1979) using a 
similar technique with the exception of the polyethylene glycol fractionation, 
have been more successful in isolating this enzyme system. The procedure 
reported here was similar to these la tte r two methods and confirmed the 
view that this type of technique is suitable for the purification of the 
cholesterol 7a-hydroxylase enzyme components from rat liver microsomes.
Treatment of the rats in this procedure with cholestyramine was chosen 
since i t  was demonstrated in Chapter 6 that cholestyramine enhanced the 
activity of cholesterol 7a-hydroxylase in the liver to a greater extent 
than other inducers of this enzyme such as cholesterol and SKF-525A.
The cytochrome P-450 specific content of 1.18 nmol per mg of microsomal 
protein for the liver microsomal fraction from the cholestyramine-treated 
rats was higher than that normally obtained with untreated rats (about 
0.8 nmol/mg of protein), and much higher than that reported by Hansson &
Wikvall (1979) for the liver microsomes of cholestyramine-treated rats 
(0.5 nmol/mg of protein). Since these la tte r workers used Sprague-Dawley
rats, and Wistar rats were used in the current work i t  would seem possible 
that a strain difference exists in the responsiveness of the liver  
microsomal cytochrome P-450 to cholestyramine treatment.
In view of the known inactivation and inhibition of cholesterol 
7a-hydroxylase activity by detergents and the critica l nature of the 
protein-detergent ratio for solubilisation (Hattersley & Boyd, 1975;
Hansson & Wikvall, 1979) i t  would seem like ly  that the marked loss of 
cholesterol 7a-hydroxylase activ ity during the solubilisation of the mixed- 
function oxidase components was due to either detergent inactivation or 
inhibition, or incomplete solubilisation of this enzyme.
The final cytochrome P-450 fraction had a reasonable degree of purity 
as shown by sodium dodecyl sulphate gel electrophoresis and a specific 
content of 3.65 nmol per mg of protein which was much the same as that 
obtained by Hansson & Wikvall (1979) for their purified preparation 
(3.6 nmol/mg of protein). The purified haemoprotein fraction exhibited 
the typical spectral features of cytochrome P-450 in respect of both its  
reduced-carbon monoxide spectrum, with an absorbance peak at 450 nm, and its  
absolute oxidised spectrum. Only a trace of cytochrome P-420 contaminated 
this preparation, as indicated by the minor inflection in the reduced-carbon 
monoxide difference spectrum at 420 nm. The absorbance maximum of the 
Soret peak at 415 nm in the oxidised spectrum lay close to the absorbance 
maximum at 418 nm noted for low-spin cytochrome P-450 as opposed to that of 
the high-spin state at about 390 nm (Jefcoate & Gaylor, 1969; Coon et a l . ,  
1975; Guengerich, 1977; Jefcoate, 1978; Gunsalus & Sligar, 1978), and 
denoted that the purified cytochrome P-450 was predominantly in the low-spin 
configuration.
I t  is well recognised that NADPH-cytochrome P-450 reductase contains a
number of FMN and FAD molecules associated with its  polypeptide structure 
(Dignam & Strobel, 1975; Yasukochi & Masters, 1976; Vermilion & Coon, 
1978a). Selective removal of FMN from this reductase by dialysis is 
accompanied by a concomitant loss in catalytic activity of this enzyme 
which can be restored by addition of FMN (Vermilion & Coon, 1978b). The 
depletion of NADPH-cytochrome c (P-450) reductase activ ity in the fraction 
from DEAE-cellulose chromatography and the regeneration of this activ ity  
in the la ter purification fractions of this enzyme by the addition of FMN 
to the buffers was consistent with the findings of these workers. The 
decrease in specific activity between the a ffin ity  column fraction and the 
final preparation can also be attributed to flavin depletion during gel 
filtra tio n .
The uncertainty surrounding complete equilibration of the exogenously 
added cholesterol with the substrate pool for cholesterol 7a-hydroxylase 
(Bjflrkhem & Danielsson, 1975; Myant & Mitropoulos, 1977) and the sub- 
microsomal existence of this pool (Mitropoulos et al_., 1978;
Balasubramaniam et al_., 1978) lim it the estimation of the substrate 
concentration for this enzyme such that its  absolute rate of metabolism 
cannot be accurately determined by methods which involve exogenous substrate 
addition. The isotope incorporation procedure is subject to such lim itations. 
I t  is therefore d iff ic u lt  to draw any firm conclusions regarding the 
efficiency of the purification of cholesterol 7a-hydroxylase from the 
specific activities measured in the microsomes and the reconstituted system. 
The lower specific activity of cholesterol 7a-hydroxylase measured in the 
reconstituted system relative to that in the original microsomal fraction, 
both at the same substrate concentration, would suggest that isolation of 
fractions low in cholesterol hydroxylating ab ility  only had been achieved. 
However, since optimisation of conditions for the reconstituted system, 
such as the concentrations of NADPH, substrate, phospholipid, cytochrome P-450
and NADPH-cytochrome c reductase, was not undertaken and the possibility that 
a loss of activity occurred during the detergent solubilisation then the 
chance that a higher activ ity  in the reconstituted system could be obtained 
at a substrate concentration of 4.5 yM cannot be discounted. On the other 
hand, the higher specific activity of cholesterol 7a-hydroxylase measured in 
the reconstituted system a t a substrate concentration of 45 yM relative to 
that obtained with the microsomal fraction, referred to previously, would be 
consistent with the view that purification of this hydroxylase was achieved.
A marked effect of substrate concentration on the activ ity  of the 
solubilised enzyme was also apparent in that a ten-fold increase in substrate 
concentration was accompanied by a much greater increase in cholesterol 
7a-hydroxylase activ ity  in the reconstituted system, and would suggest that 
cholesterol has an additional allosteric effect on this enzyme. Alternatively, 
since cholesterol is thought to modulate the mobility or flu id ity  of the 
phospholipid acyl chains in membranes, i t  may be that this effect resulted 
from changes in flu id ity  of the phospholipid in the reconstituted system 
induced by cholesterol. The concept developed by Stier (1976), that membrane 
phospholipid orientates the mixed-function oxidase components into an e ffic ien t 
functioning system, make this la tte r suggestion particularly attractive.
The 7a-hydroxylation of cholesterol exhibited the characteristics of a 
cytochrome P-450-dependent hydroxylation in that the activ ity  of this 
hydroxylase in the reconstituted system showed an absolute requirement for 
both the haemoprotein and its  flavoprotein reductase, whereas the reaction was 
only partia lly  dependent on the presence of phospholipid. Moreover, since 
phospholipid has been shown to be an absolute requirement for the reconstitution 
of cytochrome P-450-dependent hydroxylations from highly-purified and defatted 
components (Lu & West, 1978), i t  is probable that residual phospholipid
(or detergent) remaining in the preparations may have partia lly  fu lf il le d  
the lip id  requirement. These findings constitute further confirmation of 
the participation of cytochrome P-450 in the 7a-hydroxylation of cholesterol 
previously shown in reconstitution experiments by Bj&rkhem et al_. (1974), 
Hansson & Wikvall (1979) and Boyd & Osaza (1979).
The haemoprotein preparation also metabolised ethylmorphine in a 
reconstituted system signifying that the purified cytochrome P-450 also 
retained drug-metabolising activ ity . I t  would therefore appear like ly  that 
this haemoprotein preparation either possessed a broad substrate specificity  
that encompassed both cholesterol and drugs, or on the other hand, in view 
of the proposed existence of multiple forms of cytochrome P-450 (Haugen et 
a l . ,  1975; Guengerich, 1977; Lu & West, 1978; Ryan et a]_., 1979) i t  may 
consist of a mixture of the cytochrome responsible for both drug and 
cholesterol hydroxylations.
The existence of a cytochrome P-450 specific for cholesterol 7a- 
hydroxylation was not firmly established in the current investigations, 
clearly purification of the cytochrome P-450 to homogeneity is required \ 
to resolve this point.
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Final Discussion
Final Discussion
The metabolic conversion of cholesterol into bile acids that occurs 
in the live r forms a major catabolic route of cholesterol in the body, 
and since cholesterol 7a-hydroxylase functions as the main rate-lim iting  
enzyme in this pathway then i t  w ill have important ramifications on the 
disposal of cholesterol from the body, as discussed more fu lly  in the 
Introduction. For example, the serum cholesterol lowering effect obtained 
by administration of cholestyramine in the diet is generally attributed 
to the enhancement of cholesterol 7a-hydroxylase activ ity  produced by 
this agent. Furthermore, i t  is feasible that a low activ ity  of cholesterol 
7a-hydroxylase may be involved in the production of hypercholesteraemia 
in an individual, and would be consistent with the low level of faecal bile  
acid excretion noted in such individuals (Mietinnen et al_., 1967; Nestel 
& Hunter, 1974; Li et aK , 1979). The role of cholesterol 7a-hydroxylase 
activ ity  in hypercholesteraemia was investigated in the present study using 
two separate animal models of hypercholesteraemia which were the STR/1N 
mouse, and the vitamin D and cholesterol-fed rat. In the STR/1N mice no 
consistent lowering of cholesterol 7a-hydroxylase activ ity  could be 
established in association with the moderate degree of hypercholesteraemia 
found, whilst in the vitamin D and cholesterol-fed rat the decreased 
cholesterol 7a-hydroxylase activity that was in it ia l ly  found in association 
with hypercholesteraemia was later proven by a pair-feeding study not to be 
causal in the serum cholesterol accumulation.
Halloran et al_. 0978) have investigated the lipoprotein source of 
cholesterol for bile acid synthesis by administering HDL and LDL labelled 
with[3H]- o r[ltfC]cholesterol to a b ile  fistu la  patient, and found that the 
live r selectively utilised HDL cholesterol rather than LDL cholesterol for
bile acid synthesis. A low cholesterol 7a-hydroxylase activ ity  would 
perhaps be expected to be associated with a concomitant increase in 
the HDL cholesterol fraction of the blood. I t  may be that the increases 
in serum cholesterol concentration noted in the STR/1N mice and the 
vitamin D and cholesterol-fed rat were contained solely in the VLDL 
and LDL fractions without any increase in HDL cholesterol concentration, 
and could be tentatively proposed as an explanation for the absence of 
a correlation between the increased serum cholesterol concentration and 
a lowered cholesterol 7a-hydroxylase activ ity . Such a mechanism for the 
hypercholesteraemia in these animals would be consistent with an increased 
accumulation of cholesterol in the blood from either increased dietary 
absorption or increased endogenous synthesis, or a combination of both.
The HDL fraction of the blood is considered to derive its  cholesterol 
mainly from the peripheral tissues of the body, such as the arteria l wall, 
and transport this cholesterol to the live r for disposal (Glomset, 1968). 
Further evidence for such a role of the HDL has been recently suggested 
by the studies of Halloran et £l_. 0  978), mentioned above, and the finding 
of Schwartz et aiL 0  978} that HDL cholesterol is the preferred source 
of b ilia ry  cholesterol. Moreover, in a variety of cultured cell systems, 
including human fibroblasts and arterial smooth muscle cells , HDL has 
been noted for its  a b ility  to promote the efflux of cholesterol from these 
cells [Stein et aJ_., 1976; Stein & Stein, 1976). On the other hand, the 
lower density lipoproteins transport newly synthesised and dietary absorbed 
cholesterol to the tissues [Levy et a l . ,  1971; Lewis, 1971). The LDL 
cholesterol fraction has been particularly implicated in the accumulation 
of cholesterol in the arterial wall [Goldstein & Brown, 1977), whilst the 
HDL are considered to exert a protective effect against the formation of
atherosclerotic plaques in the arterial wall by preventing cholesterol 
accumulation, a suggestion supported by the finding that HDL fraction 
is a negative risk factor for the incidence of coronary heart disease 
in the population as a whole [M iller & M ille r, 1975; Gordon et a l . ,
1977a & b). Therefore, in view of the possible role of cholesterol 
7a-hydroxyl ase in HDL cholesterol turnover i t  cannot be discounted that 
the activity of this enzyme may be an important determinant towards the 
occurrence of atheroma and coronary heart disease in an individual.
Cholesterol 7a-hydroxylase demonstrates many of the properties 
characteristic of the liv e r microsomal drug-metabolising mono-oxygenases 
in that i t  requires NADPH and molecular oxygen for fu ll activ ity  in v itro , 
although evidence for the participation of cytochrome P-450 in this 
hydroxylation was more d iff ic u lt  to establish. The inhibition of this 
hydroxylation by carbon monoxide certainly suggested a cytochrome P-450 
involvement particularly when considered in view of the reversal o f this 
inhibition by monochromatic ligh t at 450 nm shown by Boyd et al_. (1973).
The additive effect on the NADPH-s up ported activ ity  of this enzyme by the 
addition of NADH to microsomal incubations provides evidence for a similar 
series of electron transfer reactions in this hydroxylation to those 
proposed by Estabrook et £l_. 0971) for the drug-metabol ising mono­
oxygenases. However, the administration of compounds that induce the drug 
mono-oxygenase components and ac tiv ities , such as phenobarbitone, 3-methyl- 
cholanthrene, pregnenolone 16a-carbonitrile, and safrole, did not induce 
the activity  of cholesterol 7a-hydroxylase.
Agents known to inh ib it the drug mono-oxygenases, such as SKF-525A, 
metyrapone, a-naphthoflavone and piperonyl butoxide, were found to inh ib it 
cholesterol 7a-hydroxylase activity in microsomal preparations to a
similar degree to the inhibition of the drug-metabolising enzyme biphenyl 
4-hydroxylase. This indicated some sim ilarity between cholesterol 
7a-hydroxylase and the drug-metabolising mono-oxygenases, and a probable 
involvement of cytochrome P-450 in the 7a-hydroxylation of cholesterol.
The lowering of drug-metabolising a b ility  observed in the obese/arthritic 
STR/1N mice could not be correlated with any consistent lowering of 
cholesterol 7a-hydroxylase activ ity , although the lowering of drug- 
metabolising a b ility  produced in the rat by treatment with vitamin D and 
cholesterol was associated with decreases in cholesterol 7a-hydroxylase 
activ ity .
Three compounds were noted for their a b ility  to induce cholesterol 
7a-hydroxylase activ ity , namely, SKF-525A, cholestyramine and cholesterol; 
in each case an increase in live r microsomal cytochrome P-450 concentration 
was also detected and contributed yet further evidence for the participation 
of this haemoprotein in the 7a-hydroxylation of cholesterol.
The purification and resolution of the liver microsomal mixed-function 
oxidase components and their subsequent use in reconstituted systems has 
proved a useful tool in the study of their properties. The isolation and 
reconstitution of these enzymes, f ir s t  reported by Lu & Coon (1968) and 
subsequently by several workers [Lu et a l . ,  1969, 1970 & 1972; Levin et a l .,  
1974; Van der Hoeven & Coon, 1974; Imai, 1976; Guengerich, 1977), has 
established that cytochrome P-450, NADPH-cytochrome c reductase and 
phospholipid are essential components of the live r mixed-function oxidase 
that catalyses the biotransformation of steroids, fatty acids and a variety 
of xenobiotics.
In an attempt to resolve the question of whether cytochrome P-450, 
NADPH-cytochrome c reductase and phospholipid are required for the 7a- 
hydroxylation of cholesterol, purification of the mixed-function oxidase
components from the live r microsomes of cholestyramine-treated rats by 
non-tonic detergent solubilisation and various chromatographic procedures, 
and their reconstitution in a system containing cholesterol and a synthetic 
phospholipid was undertaken. In the reconstituted system these purified 
mixed-function oxidase components catalysed the 7crhydroxylation of 
cholesterol. Moreover, selective omission of the essential components 
of liver mixed-function oxidation demonstrated that the 7a-hydroxylation 
of cholesterol has an absolute requirement for cytochrome P-450 and NADPH- 
cytochrome c reductase, and a partial requirement for phospholipid. These 
findings confirmed those reported earlier by Bjflrkhem e t  a l. (1974) for 
p artia lly  purified preparations of these components, and essentially those 
reported more recently by Hansson & Wikvall (.1979) although they were 
unable to show any phospholipid dependency for this hydroxylation. I t  is 
concluded from these present studies that cholesterol 7a-hydroxylase belongs 
to the class of live r microsomal mixed-function oxidases that u tilise  
cytochrome P-450 as their terminal oxidase and have a flavoprotein 
reductase, NADPH-cytochrome c reductase, catalysing the transfer of 
electrons from NADPH to cytochrome P-450. I t  would also appear like ly  
that the 7orhydroxylation of cholesterol proceeds by the same sequence 
of reaction steps involving these essential components that was originally  
proposed by Estabrook et al_. 0971) for cytochrome P-450-dependent 
hydroxyl at ions.
The partial effect of lip id  in the present study and the absence of 
such an effect in the studies of Hansson & Wikvall (1979) may well have 
been due to the presence of sufficient amounts of either lip id  or detergent 
in their preparations of cytochrome P-450 and NADPH-cytochrome c reductase 
that satisfied the lip id  requirement. Certainly when the levels of lip id  
and detergent in both preparations are depleted, all reconstituted mixed-
function oxidase systems to date show a significant lip id  dependency 
for catalytic activ ity  [Ingelman-Sundberg, 1977; Lu & West, 1978).
Strobe! et _a]_.[1970) have shown that phospholipid is essential for 
effic ien t electron transfer from NADPH to cytochrome P-450. In the 
absence of lip id , the rate and extent of cytochrome P-450 reduction 
by NADPH and NADPH-cytochrome c reductase are very low. The exact 
mode of action of the lip id  is s t i l l  unknown, but i t  appears that 
the phospholipid in some way facilita tes  electron transfer from 
NADPH-cytochrome c reductase to cytochrome P-450. Depierre & Dallner 
(1975) consider that the role of phospholipid (phosphatidylcholine) 
and certain other lip ids, such as cholesterol, in the endoplasmic 
reticulum is a physical one in which they form micelles with the mixed- 
function oxidase components that allows coupling of the cytochrome to 
its  reductase. Moreover, the studies of Stier (1976) have shown that 
the phospholipid in the immediate v ic in ity  of cytochrome P-450 is more 
highly organised than the majority of the membrane phospholipids. Stier 
goes on to suggest that this lip id  encloses the mixed-function oxidases 
components in a lip id  halo which may regulate the activ ity  of this system. 
He envisages two states of this system, f irs t ly  the normal physiological 
coupled state of cytochrome P-450 with its flavoprotein reductase, and 
secondly the decoupled state where the mode of hydroxylation changes, 
with the cytochrome functioning as a dioxygenase and the flavoprotein 
as a monooxygenase. This la tte r state would be consistent with a state 
of uncontrolled cellular oxygenation which may be the underlying defect 
in many diseased conditions, such as diabetes and cancer, and the cause 
of aging.
I t  is interesting at this point to consider whether there is a 
specific form of cytochrome P-450 present in live r microsomes that 
catalyses the 7a-hydroxylation of cholesterol. The existence of
multiple forms of cytochrome P-450 in live r microsomes that possess 
broad but overlapping substrate specificities has been reported by 
several workers ^Haugen et al_., 1975; Coon e t ^ K ,  1975; Imai & Sato,
1975; Guengerich, 1977; Lu & West, 1978; Pyan et al_., 1979), although 
the presence of a form of the haemoprotein which is specific for one 
particular substrate has not been clearly established. The concept 
of Stier (1976) that membrane lip id  modulates the mixed-function 
oxidase activity may well be a solution in its e lf  to the question 
of m ultip lic ity of the cytochrome. In a recent review, Parke (in press) 
considers that varying degrees of change in the lip id  envelope could 
modulate the different types of oxygenase activ ity  generating reaction 
products which give the false impression of m ultip lic ity . Moreover, 
modulations in the lip id  milieu could be induced by the lipophilic  
substrates themselves which might result in an apparent substrate- 
induced reaction specificity. The existence of a specific form of 
cytochrome P-450 for each substrate handled by the liv e r microsomal 
mixed-function oxidase system would seem an unattractive possibility  
particularly from the viewpoint of the vast numbers of cytochromes P-450 
this would involve. I f  m ultip licity of cytochrome P-450 is the case 
then a more favourable alternative is the existence of a few species of 
cytochrome P-450 which cooperatively catalyse the hydroxylation of a 
great number of substrates.
In the present study some evidence for the occurrence of a cholesterol- 
specific cytochrome P-450 was suggested in that some compounds when 
administered to the rat were found to increase the live r microsomal 
cytochrome P-450 concentration and cholesterol 7a-hydroxylase ac tiv ity , 
mostly without any changes in the other mixed-function oxidases measured.
For example, the administration of cholesterol or cholestyramine in the 
diet produced an enhancement of cholesterol 7a-hydroxylase activ ity
along with s ta tis tica lly  non-significant increases in microsomal 
cytochrome P-450 concentration. The use of SKF 525A as an inducer 
was found to elevate the microsomal cytochrome P-450 concentration 
with concomitant enhancements in the activities of cholesterol 
7<a-hydroxylase and biphenyl 2-hydroxylase only. I t  is interesting 
to consider that cholesterol 7a-hydroxylation, like biphenyl 2- 
hydroxylation, is a 'bay-region' hydroxylation, yet i t  is not catalysed 
by cytochrome P-448 which hydroxylates 'bay region1 positions nor 
is i t  increased by pretreatment with carcinogens, which are 
characterised by their increase of cytochrome P-448 and bay region 
hydroxylation. However, the cytochrome P-450 purified from the live r  
microsomes of cholestyramine-treated rats as well as catalysing the 
7a-hydroxylation o f cholesterol in a reconstituted system also showed 
a marked a b ility  to support the N-demethylation of ethylmorphine in a 
similar system. The presence of a cholesterol-specific cytochrome 
P-450 although suggested in some studies was not confirmed in the 
purified preparation and therefore leaves the matter open to speculation. 
Alternatively, the differences in response between the drug mono-oxygenases 
and cholesterol 7a-hydroxylase to various treatments which were observed 
in a number of cases, such as with phenobarbitone or 3-methylcholanthrene, 
may be explained by the existence of an additional regulatory component 
in the cholesterol 7a-hydroxylase enzyme system hitherto undiscovered.
Brown & Boyd C1974J have proposed the existence of an additional 
regulatory protein component of this system which is specific for 
cholesterol binding and transports cholesterol to the active site of 
the 7a-hydroxylase. Treatments which modulate the level of such a 
component w ill therefore be expected to change the activ ity  of cholesterol 
7a-hydroxylase. The purified preparation of cytochrome P-450 obtained 
in the present study was not sufficiently homogeneous to negate this
possibility. Further purification of the cytochrome P-450 from the 
live r microsomes of cholestyramine-treated rats to homogeneity, and 
a re-examination of both the absolute requirements of cholesterol 
7a-hydroxylase using this preparation, and the substrate specificity  
of the cytochrome P-450 are needed to resolve this matter.
The observations that NADH could support the 7a-hydroxylation 
of cholesterol to a limited extent when added to a microsomal 
suspension, and that i t  produced an additive effect on the rate of 
this reaction when combined with a sub-optimal concentration of 
NADPH indicated that NADH could act as an alternative electron donor 
in this reaction. This was a similar finding to those reported for 
other cytochrome P-450-dependent hydroxylations (Hildebrandt & Estabrook, 
1971; Cohen & Estabrook, 1971; Correia & Mannering, 1973), and is 
considered to indicate that NADH can act as an alternative donor of 
the second electron through cytochrome b  ^ in the reduction of the 
oxygenated-reduced cytochrome P-450-substrate complex that is thought 
to occur during the sequence of reactions involved in cytochrome P-450- 
dependent hydroxylation (Estabrook et 1971; Bjdrkhem, 1977) . This 
data provides further support for the earlier suggestion that the 7a- 
hydroxylation of cholesterol proceeds by a similar series of reaction 
steps to those proposed by Estabrook et al_. (1971), and introduces 
the possibility that cytochrome b^  may be an additional component of 
the cholesterol 7a-hydroxylase enzyme system. The observation that the 
purified cytochrome P-450 preparation probably contained traces of 
cytochrome b^  means that this possibility cannot be discounted by the 
current work. The finding that the cytochrome b,- free-cytochrome P-450 
preparation of Hansson & Wikvall 0 979) exhibited the same type of
necessary involvement in the 7a-hydroxylation of cholesterol as the 
current preparation of this ELaemoprotein opposes this view. Further 
purification of the cytochrome P-450 preparation to homogeneity is 
needed once again to resolve this matter. Even so, cytochrome fc>5 is 
not considered to be an obligate requirement for NADPH-supported 
hydroxylation in the reconstituted mixed-function oxidase system 
although i t  may modulate the reaction rate by interacting with the 
various components (Lu & West, 1978).
Finally, a marked effect of cholesterol concentration on cholesterol 
7a-hydroxylase activ ity  was noted in the reconstituted system possibly 
suggesting an additional allosteric effect of cholesterol on this enzyme. 
On the other hand, as cholesterol is a component of the membrane and is 
thought to modulate phospholipid and mixed-function oxidase ac tiv ity , i t  
is perhaps not surprising that the 7a-hydroxylase activ ity  should be 
affected by cholesterol quite apart from its  role as substrate.
References
Altman, R.F.A. (1973) Experientia, 29_, 256.
Alvares, A.P., Schilling, G., Levin, W. § Kuntzman, R. (1967) 
Biochem. Biophys. Res. Commun., 29_, 521-526.
Anders, M.W. (1968) Biochem. Pharmacol., 17, 2367-2370.
Aringer, L. (1978) J. Lipid Res., 19_, 933-944.
Arthur, J.R., Blair, H.A.F., Boyd, G.S., Hattersley, N.G. § 
Suckling, K.E. (1975) Biochem. Soc. Trans., _3, 963-964.
Atkin, S.D., Morgan, B., Baggaley, K.H. § Green, J. (1972) 
Biochem. J., 130, 153-157.
Atkin, S.D., Palmer, E.D., English, P.D., Morgan, B., Cawthorne, M.A.S 
Green, J. (1972) Biochem. J., 128, 237-242.
Aubert, D., Ferrand, J.C., Lacaze, B., Pepin, 0., Panak, E. § 
Podesta, M. (1974) Atheroscler., 20, 263-280.
Avigan, J. § Steinberg, D. (1965) J. Clin. Invest., 44, 1845-1856.
Back, P., Hamprecht, B. § Lynen, F. (1969) Arch. Biochem. Biophys.,
133, 11-21.
Balasubramaniam, S. § Mitropoulos, K.A. (1975) Biochem. Soc. Trans.,
3_, 964-967.
Balasubramaniam, S., Mitropoulos, K.A. § Myant, N.B. (1973)
Eur. J. Biochem., 34, 77-83.
Balasubramaniam, S., Mitropoulos, K.A. § Myant, N.B. (1975a) in
'Advances in Bile Acid Research' Vol. Ill, pp. 61-67 (Matern, S., 
Hackenschmidt, J., Back, P. § Gerok, W.,eds.), F.K.Schattauer Verlag, 
Stuttgart.
Balasubramaniam, S., Mitropoulos, K.A. § Myant, N.B. (1975b) Biochim. 
Biophys. Acta, 398, 172-177.
Balasubramaniam, S., Press, C.M., Mitropoulos, K.A., Magide, A.A. §
Myant, N.B. (1976) Biochim. Biophys. Acta, 441, 308-315.
Balasubramaniam, S., Venkatesan, S., Mitropoulos, K.A. § Peters, T.J. 
(1978) Biochem. J., 174, 863-872.
Bajvra, G.S., Morrison, L.M. § Ershoff, B.H. (1971) Proc. Soc. Exptl. 
Biol. Med., 138, 975-982.
Benditt, E.P. § Benditt, J.M. (1973) Proc. Natl. Acad. Sci., 70, 1753-1756.
*Berseus, 0., Danielsson, H. § Einarsson, K. 0969) in 'Methods in
Enzymology', Vol. XV, pp. 551-556 CColowick, S.P. § Kaplan, N.O., 
eds.) Academic Press, New York.
Bhattacharyya, A.K., Connor, W.E. § Spector, A.A. 0  972) J. Clin. Invest., 
51_, 2060-2070.
Bhattacharyya, M.H. § DeLuca, H.F. 0974) Arch. Biochem. Biophys., 160, 
58-62.
Bjflrkhem, I. Cl977) Pharmac. Ther., Pt. A 1, 327-348.
Bjdrkhem, I. § Danielsson, H. C1970) Eur. J. Biochem., 17, 450-459.
Bjdrkhem, I. $ Danielsson, H. 0-973) Biochem. Biophys. Res. Commun.,
51_, 766-774.
Bjdrkhem, I. § Danielsson, H. Q1975) Eur. J. Biochem., £3, 63-70.
Bjdrkhem, I., Danielsson, H. § Wikvall, K. 0974) Biochem. Biophys.
Res. Commun., 61, 934-941.
Bjdrkhem, I., Danielsson, H. § Wikvall, K. 0 9 7 5 ) Biochem. Soc. Trans.,
5_, 825-828.
Bjdrkhem, I., Hanson, R., Holmberg,I. § Wikvall, K.C1979)Biochem.Biophys .Res 
Commun., 90, 615-622.
Bjdrkhem, I ,  § Kallner, A. 09761 J. Lipid Res., 17,. 360-365.
Bjdrkhem, 1. § Lewenhaupt, A. 0979) J. Biol. Chem., 254, 5252-5256.
Bloch, K., Berg, B.N. § Rittenburg, D. C1943) J.Biol. Chem., 149, 511-517.
Blomstrand, R.,Gurtler, J. § Werner,B. 0 9 6 4 ) Acta Chem.Scand.,18,1019-1021.
Borgstrdm, B. 0 9 6 2 ) Gastroenterol., 43, 216-219.
Boyd, G'.S., Brown, M.J.G., Hattersley, N.G. £ Suckling, K.E. 0 9 7 4 )
Biochim. Biophys. Acta, 337, 132-135.
Boyd, G.S., Grimwade, A.M. § Lawson, M.E. 0 9 7 3 ) Eur. J. Biochem.,
37_, 334-340.
Boyd, G.S. & Lawson, M.E. 0976) FEBS Lett., 64, 435-439.
Boyd, G.S. § Ozasa, S. 0979) to be published in 'Microsomes and Drug 
Oxidations', 4th Tnt. Symp., Ann Arbor, Michigan.
Boyd, G.S., Scholan, N.A. § Mitton, J.R. 0 9 6 9 ) Adv. Exp. Med. Biol.,
£, 443-456.
Brandau, K. § Keup, U. 0976} Ameimittel-Forschung, 26, 1837-1842.
Brenner, R.R. 0 9 7 7 ) Drug Metab. Res., £, 155-212.
Briggs, M.H. $ Brotherton, J. 0 9 7 0 ) in 'Steroid Biochemistry § Pharmacology 
Ch. 3, pp. 52-85, Academic Press, London § New York.
Brown, M.J.G. § Boyd, G.S. 0-974) Eur. J. Biochem., 44, 37-47. 
Buening, M.K. § Franklin, M.R. 0 9 7 6 ) Drug Metab. Disp., 4, 244-255.
Campbell, T.C. § Hayes, J.R. 0974) Pharmacol. Rev., 26_, 171-197.
Carlson, L.A. § Bbttiger, L.E. 0972) Lancet 1_, 865-868.
Carlson, S.E., Mitchell, A.D. § Goldfarb, S. (1978) Biochim. Biophys. Acta, 
531, 115-124.
Cawthome, M.A., Palmer, E.D. § Green, J. (1976) Biochem. Pharmacol., 
25, 2683-2688.
Century, B. 0973) J. Pharm. Ther., 185, 185-194.
Cinti, D.L., Golub, E.E. § Bronner, F. 0976) Biochem. Biophys. Res. Commun. 
72, 546-553.
Cohen, B.S. § Estabrook, R.W. 0971) Arch. Biochem. Biophys., 143, 54-65.
Cohen, B.I., Raicht, R.F., Nicolau, G. § Mosbach, E.H. (1975) Lipids,
10, 168-174.
Conney, A.H. 0967) Pharmacol. Rev., 19_, 317-366.
Connor, W.E., Witiak, D.T., Stone, D.B. $ Armstrong, M.L. (1969)
J. Clin. Invest., 4£, 1363-1375.
Coon, M.J., Haugen, D.A., Guengerich, F.P., Vermilion, J.L. § Dean, W.L.
0976) in 'The Structural Basis of Membrane Function' pp. 409-427, 
(Hatefi, Y. § Djavadi-Ohaniance, L., eds.),Academic Press, New York.
Coon, M.J. § Lu, A.Y.H. 0969) in 'Microsomes and Drug Oxidations', 
pp. 151-166 (Gillette, J.R., Conney, A.H., Cosmides, G.J.,
Estabrook, R.W., Fouts, J.R. § Mannering, G.J., eds.), Academic 
Press, New York.
Coon, M.J., Nordblom, G.D., White, R.E. § Haugen, D.A. (1975) Biochem.
Soc. Trans., £, 813-817.
Cooper, D.Y., Levin, S., Narasimhulu, S., Rosenthal, 0. § Estabrook, R.W. 
0965) Science, 147, 400-402.
Correia, M.A. § Mannering, G.J. 0973) Molec. Pharmacol., 9, 455-469. 
Creaven, P.J., Parke, D.V. § Williams, R.T. (1965) Biochem. J., 96, 879-885
Danielli, J.F. § Davson, H. 0934) J. Cell. Comp. Physiol., £, 495-508. 
Danielsson, H. 0972) Steroids, 20, 63-72.
Danielsson, H. 0-973) in ’The Bile Acids', Vol. 2., pp. 1-32 (Nair, P.P.
§ Kritchevsky, D., eds.), Plenum Press, New York.
Danielsson, H. § Einarsson, K. Q964) Acta Chem. Scand., 18, 831-832.
Danielsson, H. § Einarsson, K. Q966) J. Biol. Chem., 241, 1449-1454.
Danielsson, H. § Einarsson, K. C1969) in 'The Biological Basis of Medicine*
Vol. 5, pp. 279-315 CBittar, E.E. § Bittar, N., eds.) Academic Press, 
London.
Danielsson, H., Einarsson, K. § Johansson, G. (1967) Eur. J. Biochem., 
£,44-49.
Danielsson, H. § Sjdvall, J. C1975) Ann. Rev. Biochem., 44, 233-253.
Dayton, S., Pearce, M.L., Hashimoto, S., Fakler, L.J., Hiscock, F. §
Dixon, W.J. 0962) New Eng. J. Med., 266, 1017-1023.
Dean, P.D.G. § Whitehouse, M.W. 0967) Biochem. Pharmacol., 16, 441-446.
Delvin, E.E., Arabian, A. § Glorieux, F.H. (1978) Biochem. J., 172, 417-422
DeLuca, H.F. Q 9 7 7 ) Clin. Endocrinol., 7_, Suppl. 1S-17S.
DePierre, J.W. § Dallner, G. 0975) Biochim. Biophys. Acta, 415, 411-472.
Dick, E.C., Greenberg, S.M., Herndon, J.F., Jones, M. § Van Loon, E.J. 
Q960) Proc. Soc. Exp. Med. Biol., 104, 521-526.
Dietschy, J.M. 0968) J. Clin. Invest., £7, 286-300.
Dietschy, J.M. 0972) Arch. Intern. Med., 130, 473-474.
Dietschy, J.M. § Siperstein, M.D. 0967) J. Lipid Res., £, 97-104.
Dietschy, J.M. $ Wilson, J.D. 09681 J. Clin. Invest., 47, 166-174.
Dietschy, J.M. $ Wilson, J.D. Q 9 7 0 a) New Eng. J. Med.., 282, 1179-1183.
Dietschy, J.M. § Wilson, J.D. 09705) New Eng. J. Med., 282, 1241-1249.
Dignam, J.D. § Strobel, H.W. 0975) Biochem. Biophys. Res. Commun.,
63, 845-852.
Douglas, B.H., Wilkinson, J.S. $ Ashburn, A.D. (1977) IRCS Med. Sci:Libr. 
Compend., £,22.
Einarsson, K. § Gustafsson, J.A. 0973) Eur. J. Biochem., 32, 197-206. 
Einarsson, K. $ Johansson, G. 0968a) FEBS Lett. £, 219-222.
Einarsson, K. § Johansson, G. 0968b) Eur. J. Biochem., 6, 293-298.
Elcombe, C.R., Bridges, J.W., Gray, T.J.B., Nimmo-Smith, R.H. § Netter, 
K.J. 0975) Biochem. Pharmacol., 2£, 1427-1433.
Ernster, L. § Orrenius, S. 0-965) Fed. Proc., 24, 1190-1199.
Estabrook, R.W., Hildebrandt, A.G., Baron, J., Netter, K.J. $ Leibman, K. 
(1971) Biochem. Biophys. Res. Commun., 42, 132-139.
Fennell, T.R., Dickens, M. § Bridges, J.W. 0979) Biochem. Pharmacol., 
28, 1427-1429.
Fernandez, G., Villarruel, M.C. § Castro, J.A. (1978) Toxicol. Appl. 
Pharmacol., 46, 315-321.
Folch, J., Lees, M. § SlOane Stanley, G.H. (1957) J. Biol. Chem., 226, 
497-509.
Fujii, K., Jaffe, H., Bishop, Y., Arnold, E., Mackintosh, D. § Epstein, 
S.S. 0970) Toxicol..Appl. Pharmacol., 1£, 482-494.
Garfinkel, D. 0  958) Arch. Biochem. Biophys., 77_, 493-509.
Gielen, J.E., Van Cantfort, J. $ Kremers, P. (1976) Arch. Toxicol. ,£6, 255-266.
Gielen, J., Van Cantfort, J. § Renson, J. (1968) Arch. Int. Physiol. Biochim.
7£, 930-932.
Gielen, J., Van Cantfort, J., Robaye, B. § Renson, J. (1969) C.R. Acad.
Sci. Paris, 269, 731-732.
Gielen, J., Van Cantfort, J., Robaye, B. § Renson, J. (1975) Eur. J. Biochem. 
5£, 41-48.
Gillette, J.R.., Davis, D.C. § Sasame, H.A. (1972) Ann. Rev. Pharmacol.,
■12, 57-84.
Ginter, E. 0976) Am. Lab., £, 21-29.
Ginter, E., Nem&c, R., Cerven, J. § Mikus, L. (1973) Lipids, £, 482-484.
Glomset, J.A. (1968) J. Lipid Res., £, 155-167.
Glomset, J.A. 0970) Am. J. Clin. Nutr., 23, 1129-1136.
Goldstein, J.L. § Brown, M.S. 0977) Ann. Rev. Biochem., 46, 897-930.
Gordon, T., Castelli, W.P., Hjortland, M.J., Kannel, W.B. § Dawber, T.R.
0977a) Am. J. Med., 62, 707-714.
Gordon, T., Castelli, W.P., Hortland, M.J., Kannel, W.B. § Dawber, T.R.
(1977b) Ann. Intern. Med., 87, 393-397.
Gotto, A.M., Yeshurun, D. § DeBakey, M.E. (1976) J. Chron. Dis., 29_, 677-681.
Gray, J.R. 0979) Ph.D. Thesis, University of Surrey.
Gresham, G.A. (1972) Proc. Nutr. Soc., 51, 303-305.
Grundy, S.M. § Ahrens, E.H., Jr. 0969) J. Lipid Res., 10, 91-107.
Guchait, R., Guha, B.C. § Ganguli, N.C. (1963) Biochem. J., 86, 193-197.
Guengerich, F.P. 0977) J. Biol. Chem., 252, 3970-3979.
Gunsalus, I.C. $ Sligar, S.G. 0978) Adv. Enzymol. 47_, 1-44.
Gustafsson, J.-A., Lisboa, B.P.L. § Sjdvall, J. (1968) Eur. J. Biochem.,
£, 437-449.
Halloran, L.G., Schwartz, C.C. Vlahcevic, Z.R., Nisman, R.M. § Swell, L.
(1978) Surgery, 84, 1-6.
Hansson, R. § Wikvall, K. 0979) Eur. J. Biochem. £3, 419-426.
Harper, H.A. Q975) in 'Review of Physiological Chemistry', 15th edition, 
p.234, Lange Medical Publications, Los Altos, California.
Harris, W.S., Kottke, B.A. § Subbiah, M.T.R. 0979) Am. J. Clin. Nutr.,
32, 1837-1841.
Haschek, W.M., Krook, L., Kallfelz, F.A. § Pond, W.G. 0978) The Cornell 
Veterinarian, b£, 324-364.
Hattersley, N.G. § Boyd, G.S. 0975) TEBS Lett. 53, 80-83.
Haugen, D.A., Van Der Hoeven, T.A. § Coon, M.J. (1975) J. Biol. Chem.,
250, 3567-3570.
Hietanen, E., Hhnninen, 0., Laitinen, M. § Lang, M. (1978) Pharmacol.,
17_3 163-172.
Higgins, J.M. § Fielding, C.J. 0975) Biochemistry, 14, 2288-2992.
Hildebrandt, A. § Estabrook, R.W. 0971) Arch. Biochem. Biophys., 143, 66-79. 
Hill, P. § Wynder, E.L. 0976} J. Am. Diet. Ass. 6£, 25-30.
Holmes, W.L. § Bentz, J.D. 0960) J. Biol. Chem. 235, 3118-3122.
Holt, P.R. 0972) Arch. Intern. Med., 130, 574-583.
Holtzman, J.L., Gram, T.E., Gigon, P.L. § Gillette, J.R. 0968) Biochem. J.
110, 407-412.
Honohan, T. § Parkinson, T.M. 0975} Biochem. Pharmacol., 24, 899-903.
Huang, W.Y., Kamio, A., Yeh, S.-J.C. § Kummerow, F.A. (1977) Artery, _3, 439-455.
Huber, J., Guder, W., Mttller, O.A., Latzin, S., Ganser, H. £ Hamprecht, _B. 
0974) Hoppe-Seyler’s Z. Physiol. Chem., 355, 669-674.
Imai, Y. 0976) J. Biochem. (Tokyo) 80, 267-276.
Imai, Y. § Sato, R. 0974) Biochem. Biophys. Res. Commun., 60, 8-14.
Ingelman-Sundberg, M. 0977) Biochim. Biophys. Acta, 488, 225-234.
Insull, W., Jr. $ Bartsch, G.E. 0966) J. Clin. Invest., 45, 513-523.
Jain, M.K. 0975) Curr. Top. Membr. Transp., £, 1-57.
Japundzic, I., Japundzic, M. § Szabo, S. (1974) Eur. J. Biochem., 4£, 79-85.
Jefcoate, C.R. 0978) in ’Methods in Enzymology', Vol. LII Biomembranes, 
pp. 258-278 (Pleischer, S. § Packer, L., eds.), Academic Press, New 
York § London.
Jefcoate, C.R.E. § Gaylor, J.L. 0969) Biochemistry, £, 3464-3472.
Johansson, G. 0970) Eur. J. Biochem., 17, 292-295.
Johansson, G. 0971) Eur. J. Biochem., ££, 68-79.
Kannel, W.B., Castelli, W.P., Gordon, T. § McNamara, P.M. (1971) Ann.
Intern. Med., 74, 1-12.
Karmen, A., Whyte, M. § Goodman, DeW. S. 0963) J. Lipid Res., £, 312-321.
Katayama, K. $ Yamasaki, K. 0968) Yonago Acta Med., £2, 103-109.
Keys, A. 0970) Circulation, ££, Suppl. I, 1-162.
Keys, A. 0975) Atherosclerosis, ££, 149-192.
Klingenberg, M. 0958) Arch. Biochem. Biophys., ££, 376-386.
Krause, R.F., Pallotta, M.A. § Voder, I.I. (1968) J. Atheroscler. Res.,
£, 277-289.
Kritchevsky, D. 0964) J. Atheroscler. Res., £, 103-105.
Kritchevsky, D. 0970) Am. J. Clin. Nutr., £3, 1105-1110.
Kritchevsky, D. 0976) Am. J. Pathol., 8£, 615-632.
Kritchevsky, D. 0978) Am. J. Clin. Nutr., 31, S65-S74.
Kritchevsky, D. § Story, J.A. 0974) J* Nutr., 104, 458-462.
Kritchevsky, D. § Tepper, S.A. 0965) Life Sci., £, 1467-1471.
Kritchevsky, D., Tepper, S.A., Kim, H.K., Story, J.A., Vesselinovitch, D.
§ Wissler, R.W. 0976) Exp. Mol. Pathol., 24, 375-391,*
Kudchodkar, B.J., Sodhi, H.S. § Horlick, L. 0972) Metabolism, 2£, 343-349.
Laemmli, U.K. 0970) Nature, Lond. 227, 680-685.
Laitinen, M. 0976) Acta Pharmac. Tox., 39_, 241-249.
Lake, B.G., Hopkins, R., Chakraborty, J., Bridges, J.W. § Parke, D.V.
0973) Drug Metab. Disp., £, 342-349.
Lambert, L. $ Wills, E.D. 0977) Biochem. Pharmacol., 26, 1423-1427.
Lang, M. 0976) Gen. Pharmac., £, 415-419.
Lang, M. § HSnninen, 0. 0977) in 'Microsomes and Drug Oxidations', Proc.
3rd Int. Symp., pp. 597-604 (Ullrich, V., Roots, I. § Hildebrandt, A., 
eds.)., Pergamon Press, Oxford.
Lang, M., Laitinen, M., Hietanen, E. § Vainio, H. (1976) Acta Pharmac. Tox. 
39, 273-288.
Levin, W., Ryan, D., West, S. § Lu, A.Y.H. (1974) J. Biol. Chem., 249, 
1747-1754.
Levy, R.I., Belheimer, D.W. § Eisenberg, S. (1971) Biochem. Soc. Symp.,
3£, 3-17.
Lewis, B. 0971) Biochem. Soc. Symp., 33, 19-28.
Li, J.R., Dinh, D.M., Ellefson, R.D. § Subbiah, M.T.R. (1979) Metabolism, 
£8, 151-156.
Liebman, K.C. 0969) Molec. Pharmacol., £, 1-9.
Linn, T.C. 0967) J. Biol. Chem., 242, 990-993.
Lowry, O.H., Rosebrough, N.J., Farr, A.A. § Randall, R.S. 0951) J. Biol. 
Chem., 193, 265-275.
Lu, A.Y.H. 0977) Fed. Proc., 3£, 2460-2463.
Lu, A.Y.H. § Coon, M.J. 0968) J. Biol. Chem;, 243, 1331-1332.
Lu, A.Y.H., Kuntzman, R., West, S., Jacobson, M. § Conney, A.H. (1972)
J. Biol. Chem., 247, 1727-1734.
Lu, A.Y.H., Strobel, H.W. § Coon, M.J. (1969) Biochem. Biophys. Res. Commun
36, 545-551.
Lu, A.Y.H., Strobel, H.W. § Coon, M.J. (1970) Molec. Pharmac., £, 213-220. 
Lu, A.Y.H. § West, S.B. 0978) Pharmac. Ther., Pt. A., 2, 337-358.
Lucy, J.A. (1974) FEBS Lett., 40, S105-S111.
Lutton, C. 0-976) Digestion, 14, 342-356.
Lutton, C. $ Chevallier, F. 0972a) Biochim. Biophys. Acta, 280, 116-130.
Lutton, C. § Chevallier, F. 0972b) Biochim. Biophys. Acta, 280, 131-144.
Lutton, C., Mathe, D. § Chevallier, F. (1973) Biochim. Biophys. Acta,
306, 483-496.
Madhok, T.C., Schnoes, H.K. § DeLuca, H.F. (1978) Biochem. J., 175, 479-482. 
Malmros, H. 0976) Acta Biol. Med. Germ., £5, 1151-1158.
Marshall, W.J. § McLean, A.E.M. 0971) Biochem. J., 122, 569-573.
Mason, H.S. 0957) Adv. Enzymol., £9, 79-233.
Mason, H.S. (1965) Ann. Rev. Biochem., 34, 595-634.
Mason, J.I. § Boyd, G.S. 0978) Steroids, 31, 849-854.
Mathe, D., D'Hollander, F. § Chevallier, F. (1972) Biochimie, 54, 1479-1481.
Mathur, P.P., Carr, G.S. § Smyth, R.D. (1978) Biochem. Pharmacol., 27 
1379-1380..
Mathur, P.P., Smyth, R.D., Witmer, C., Carr, G. § Reavey-Cantwell, N.H.
0977) J. Pharmac. Exp. Ther., 205, 169-183.
Mathur, P.P., Smyth, R.D., Witmer, C., Nuss, G.W. § Carr, G. (1976)
Fed. Proc., 55, 537.
Mayer, D. 0976) Arch. Toxicol., 3£, 267-276.
Mayer, D. § Voges, A. (1972) Hoppe-Seyler's Z. Physiol. Chem., 353, 1187-1188.
McElhaney, R.N., De Gier, J. § Van Der Neut-Kok, E.C.M. (1973) Biochim.
Biophys. Acta, 298, 500-512.
McIntyre, N. $ Isselbacher, K.J. (1973) Am. J. Clin. Nutr., £6, 647-656.
Mellon, W.S., Witiak, D.T. § Feller, D.R. (1978) Biochem. Pharmacol.,
£7, 1055-1062.
Miettinen, T.A., Pelkonen, R., Nikkilh, E.A. § Heinonen, 0. (1967) Acta 
Med. Scand., 182, 645-650.
Miller, G.J. $ Miller, N.E. 0-975) Lancet, £, 16-19.
Mitropoulos, K.A. § Balasubramaniam, S. Q972) Biochem. J., 128, 1-9.
Mitropoulos, K.A. § Balasubramaniam, S. 0976) Biochem. J., 160, 49-55.
Mitropoulos, K.A., Balasubramaniam, S., Gibbons, G.F. § Reeves, B.E.A. 
0972) FEBS Lett., 27, 203-206.
Mitropoulos, K.A., Balasubramaniam, S. § Myant, N.B. 0973) Biochim. 
Biophys. Acta, 326, 428-438.
Mitropoulos, K.A., Balasubramaniam, S., Venkatesan, S. § Reeves, B.E.A. 
0978) Biochim. Biophys. Acta, 530, 99-111.
Mitropoulos, K.A., Myant, N.B-., Gibbons, G.F., Balasubramaniam, S. §
Reeves, B.E.A. 0974) J. Biol. Chem., 249, 6052-6056.
Mitropoulos, K.A., Venkatesan, S., Balasubramaniam, S. § Peters, T.J.
0978) Eur. J. Biochem., £2, 419-429.
Mitton, J.R., Scholan, N.A. § Boyd, G.S. 0971) Eur. J. Biochem., 20, 
569-579.
Morton, D.M. § Chatfield, D.H. 0970) Biochem. Pharmacol., 1£, 473-481.
Mosbach, E.H., Rothschild, M.A., Bekersky, I., Oratz, M. § Mongelli, J. 
0971) J. Clin. Invest., 50y 1720-1730.
Myant, N.B. £ Eder, H.A. O 961) J* Lipid Res., 2_, 363-368.
Myant, N.B. § Mitropoulos, K.A. 0977) J. Lipid Res., 18_, 135-153.
Nash, T. 0953) Biochem. J., 55_, 416-421.
Nestel, P.J. § Hunter, J.D. 0974) Aust. N.Z. J. Med., £, 491-496.
Norred, W.P. § Wade, A.E. 0972) Biochem. Pharmacol., 21, 2887-2897.
Oldfield, E. $ Chapman, D. 0972) FEBS Lett., 23, 285-297.
Omura, T. § Sato, R. 0962) J. Biol. Chem., 237, 1375-1376.
Omura, T. § Sato, R. 0964) J. Biol. Chem., 239, 2370-2378.
Palmer, E.D. § Cawthorne, M.A. 0974) Xenobiotica, £, 209-217.
Parke, D.V. 0968) 'The Biochemistry of Foreign Compounds', Pergamon Press, 
New York.
Parke, D.V. O n press) in 'Concepts in Drug Metabolism' CJenn©r, P. § Testa, 
B., eds.), Marcel Dekker, Inc.
Parke, D.V., Sacra, P.J. § Thornton, P.C. (1978) Brit. J . Pharmacol.,
63, 346P.
Phillips, M.C. C1972) Prog. Surf. Memb. Sci., £, 139-221.
Pooling Project Research Group 0-978) J* Chron. Dis., 31, 201-306.
Preiss, B. § Block, K. 0964) J. Biol. Chem., 239, 85-88.
Redgrave, T.G. 0970) J. Clin. Invest., 49, 465-471.
Registrar General's Statistical Review of England § Wales, H.M. Stationery- 
Office (1971) .
Remmer, H., Schenkman, J.B. § Greim, H. 0969) in 'Microsomes and Drug
Oxidations', pp.371-386 (G il le t te , J.R.^ Conney, A.H., Cosmides, G.J., 
Estabrook, R.W., Fouts, J.R. § Mannering, G.J.,eds.), Academic Press,
New York.
Robbins, K.C. (1961) Fed. Proc., 20, 272.
Rodwell, V.W., McNamara, D.J. § Shapiro, D.J. 0973) Adv. Enzymol., 38, 373-412.
Rosenfeld, R.S., Fukushima, D.K., Heilman, L. § Gallagher, T.F. 0954)
J. Biol. Chem., 211, 301-311.
Ross, R. § Glomset, J.A. (1976) New Engl. J. Med., 295, 420-425. 
Ross, R. § Harker, L. 0976) Science, 193, 1094-1100.
Rudel, L.L. § Morris, M.D. 0973) J. Lipid Res., 14, 364-366.
Ryan, D.E., Thomas, P.E., Korzeniowski, D. § Levin, W. 0979) J. Biol. Chem., 
254, 1365-1374.
Sabine, J.R. 0977a} in 'Cholesterol', Ch. 2, p.7, Marcel-Dekker, Inc.,
New York.
Sabine, J.R. (1977b) in 'Cholesterol', Ch.6, pp.105-135, Marcel-Dekker, Inc.,
New York.
Scanu, A.M., Vitello, L. § Deganello, S. (1974) CRC Crit. Rev. Biochem.,
2_, 175-196.
Schenkman, J.B., Remmer, H . §  Estabrook, R.W. (1967) Molec. Pharmac., 3, 113-123.
Schwartz, C.C., Halloran, L.G., Vlahcevic, Z., Gregory, D.H. § Swell, L. 
(1978) Science, 200, 62-64.
Shapiro, D.J. § Rodwell, V.W. 0972) Biochemistry 11, 1042-1045.
Shefer, S., Hauser, S., Bekersky, I. § Mosbach, E.H. (1969) J. Lipid Res., 
10, 646-655.
Shefer, S., Hauser, S., Bekersky, I. § Mosbach, E.H. (1970) J. Lipid Res., 
U , 404-411.
Shefer, S., Hauser, S. § Mosbach, E.H. (1968) J. Lipid Res., £, 328-333.
Shefer, S., Hauser, S. § Mosbach, E.H. 0972) J. Lipid Res., L3, 69-70.
Shiratori, T. § Goodman, DeW. S. (1965) Biochim. Biophys. Acta, 106, 625-627
Shoeman, D.W., Chaplin, M.D. § Mannering, G.J. (1969) Molec. Pharmac.,
5_, 412-419.
Singer, S.J. § Nicholson, G.L. (1972) Science, 175, 720-731.
Sipat, A.B., James, M.J. § Sabine, J.R. (1977) Proc. Aust. Biochem. Soc.,
10, 53.
Siperstein, M.D. § Fagan, V.M. 0966) J. Biol. Chem., 241, 602-609.
Smith, E.B. (1965) J. Atheroscler. Res., 5_, 224-240.
Sokoloff, L. (1956) A.M.A. Arch. Pathol., 62, 118-128.
Sokoloff, L., Crittenden, L.B., Yamamoto, R.S. § Jay, G.E., Jr. (1962) 
Arthritis § Rheumatism, £, 531-546.
Sokoloff, L. $ Jay, G.E., Jr. 0956) A.M.A. Arch. Pathol., 6£, 129-135.
Sokoloff, L., Mickelsen, 0., Silverstein, E., Jay, G.E., Jr. § Yamamoto,R.S. 
(1960) Amer. j. Physiol., 198, 765-770.
Solymoss, B., Werringloer, J. § Toth, S. (1971) Steroids, 17, 427-433.
Spritz, N., Ahrens, E.H., Jr. § Grundy, S. (1965) J. Clin. Invest., 44, 
1482-1493.
Stein, Y. § Stein, 0. 0976) Triangle, 15_, 63-69.
Stein, 0., Vanderhoek, J. § Stein, Y. (1976) Biochim. Biophys. Acta, 431, 
347-358.
Stier, A. (1976) Biochem. Pharmacol., £5, 109-113.
Stier, A., KHhnle, W. § Rdsen, R. (1976) in ’Microsomes and Drug Oxidations’ 
pp.1-8 (Proceedings of the 3rd International Symposium, Berlin)
Pergamon Press, London.
Stitzel, R.E., Anders, M.W. § Mannering, G.J. 0966) Molec. Pharmac.,
2, 335-340.
Strasser, T. (1972) W.H.O. Chron., 2£, 7-11.
Strobel, H.W., Lu, A.Y.H., Heidema, J. § Coon, M.J. (1970) J. Biol. Chem.,
245, 4851-4854.
Sylven, C. § BorgstrtJm, B. 0968) J. Lipid Res., £, 596-601.
Tai, H. § Bloch, K. 0972) J. Biol. Chem., 247, 3767-3773.
Takeuchi, N.,Ito, M. § Yamamura, Y. 0974) Atherosclerosis, 20, 481-494.
Testa, R., Canestrini, C. § Oldani, C. 0975) J. Pharm. Pharmac., 27_, 699-700.
Tomkins, G.M. $ Chaikoff, I.L. (1952) J. Biol. Chem., 196, 569-573.
Turley, S.D., West, C.E. § Horton, B.J. (1976) Atherosclerosis, 2£, 1-18.
Turpeinen, 0. 0979) Circulation, 59_, 1-7.
.Van Cantfort, J. 0972) Life Sci., 11, 773-780.
Van Cantfort, J. § Gielen, J. 0975) Eur. J. Biochem., S5_, 33-40.
Van Cantfort, J., Renson, J. § Gielen, J. 0975) Eur. J. Biochem., ££, 23-31.
Van Deenen, L.L.M., DeGier, J. § Demel, R.A. (1972) Biochem. Soc. Symp.,
3£, 377-382.
Van DerH.oeven, T.A. § Coon, M.J. 0974) J. Biol. Chem., 249, 6302-6310.
Vela, B.A. § Acevedo, H.F. 0969) J. Clin. Endocrinol., 29, 1251-1258.
Vermilion, J.L. § Coon, M.J. 0978a) J. Biol. Chem., 253, 2694-2704.
Vermilion, J.L. $ Coon, M.J. 0978b) J. Biol. Chem., 253, 8812-8819.
Virchow, R.L.K. (1856) in ’Cellular Physiology as Based upon Physiological 
§ Pathological Histology’ (English translation by F. Chance), pp.230- 
254, Dover Publications, New York (1971).
Wada, F., Hirata, K., Nakao, K. § Sakamoto, Y. (1968) J. Biochem.(Tokyo)
64, 415-417.
Wada, F., Hirata, K., Nakao, K. § Sakamoto, Y. (1969) J. Biochem.(Tokyo)
6£, 699-703.
Wada, F., Shibata, H., Goto, M. § Sakamoto, Y. (1968) Biochim. Biophys. Acta, 
162, 518-524.
Weight, M.J., Kotze, J.P., Deklerk, W.A. § Weight, N. (1974) Int. J. Biochem. 
5, 287-291.
West, S.B., Huang, M.-T., Miwa, G.T. § Lu, A.Y.H. (1979) Arch. Biochem. 
Biophys., 193, 42-50.
White, C.P. Cl908) Med. Chron., 47, 403-421.
Whitehouse, M.W. & Beck, F.J. (1973) Drug Metab. Disp., 1_, 251-255.
Wilhelmsen, L., Wedel, H. § Tibblin, G. (1973) Circulation, 4£, 950-958.
Williams, C.H., Jr. § Kamin, H. (1962) J. Biol. Chem., 237, 587-595.
Windmueller, H.G., Lindgren, F.T., Lassow, W.J. § Levy, R.I. (1970)
Biochim. Biophys. Acta, 202, 507-516.
Wood, P.D.S., Shioda, R. § Kinsell, L.W. (1966) Lancet II, 604-607.
Yamamoto, R.S., Crittenden, L.B., Sokoloff, L. § Jay, G.E., Jr. (1963)
J. Lipid Res., 4, 413-418.
Yasukochi, Y. § Masters, B.S.S. (1976) J. Biol. Chem., 251, 5337-5344.
Zamenhof, S. (1957) in ’Methods in Enzymology’, Vol. 3., p.702 (Colowick,
S.P. § Kaplan, N.O., eds.), Academic Press, New York.
Zannoni, V.G. (1977) Acta Vitaminol. Enzymol., 31, 17-29.
Ap
pe
nd
ix 
1. 
Th
e 
co
nt
ro
l 
va
lu
es
 
fo
r 
the
 
he
pa
tic
 
cy
to
ch
ro
m
e 
P-
45
0 
sy
ste
m 
in
du
ce
r 
and
 
in
hi
bi
to
r 
st
ud
ie
s.
u r— '_) VU \_1
<C 'r-
+ 1id  4-> +  | +  | +  1 +  1 +  | +  | +  1 +  | 1 1
CM *r-
LD JO 'O’ i— r— r - . CO 00 cn r—
1 T - cn • r— CO CM r— r— cn •
Ll_ X I T— cn . • • ■Sf
SX C o o o CM
CO •—<
CO co co
co o 1— r— CO CO
e • o o • o •
<  o CO o o o i— cvj CM o o ID  O
ID  *i—
+  1C\J 4-5 +  1 +  1 +  1 +  | +  1 +  | +  1 +  1 +  | + |ID  O
1 =5 r— r^ . CO *3- r— o CM CO to  o
u_ -o 1— • CM o ■5J- CM CM 0 0 • .
iX  e CM cn • . • o CM
CO t—i o r " o CM
cu
oS E CM cn o
• r - O CM p— r — CM
r -  E • - • • • • •
O  <C cn o o o CO CM r — o ID  O
S- S-
+  1 +  1 +  1 + 1<1) > , +  | +  | +  1 +  1 ■+■1 +  1 +  14-5 4-5
CO to i—■ 0 0 ID ID CO r^ . cn 0 0  r—
CU (U CO • p— CO CM r — r-* . r> .
r— i— CM r— • o • o CM
o  o r— o o o CM
XT x :
o  o
cu
r -
•r— CO ID to
S- o o ■cJ* o
CU 4-5 • o # • - •
E c— r— o O r"> CO o i—
O  C
+  1 +  1 +  1r—  O +  | +  1 + 1 +  | + 1 + 1 1 1o  xo
e  S- ID cn CO CO cn CO ID CO r --
CU fO 00 • CM o CM p— CM o •
e  o 00 • a •
CJ) 1 o CM r— CM
o  e
S- CO
D_ 1—
cu
E CM cn
CU CO o p— C". CM
u o • • • • • •i—  x i r— o o O ■si- ID CM o o to  o
> ,  +->
+ 1-C  E +  1 +  1 +  1 +  1 +  | +  | +  | 1 +  1 + 14-5 <13
CU r— J— CM CM CO cn cn O  I—
2 1  O CM • CM <n CO n— r— o • 00
i x : CM o • • • ID CM
CO C_5 o o n— CM
CU
E  .
O
4-5 «vt* CO CO
•p- r» . o I— p— 00
X I • • • • •
S- o o o CO o O
fO
+ 1-Q + 1 ■+■1 +  1 +  1 + 1 +  | +  | +  1 1 1O
E CO ID o 00 00 CO 0 0 cn CO
CU o • t— CM CO CM r—— o •
x : CM O • • • r- -
D_ 1 o o 1 CM
T
1 '—' s.
X I E CU CU >> c CU4-5 •r— to to X  T - >CU E co CO O E •!“
E  \ 1— I— \ r—cu s~ •o  s- o E"O cu X c X  E >> cu cn •r- r—■ r—-N 1 > O *p- O -r- X I > o cu \ CU o op—* cn 21 -r- i -  E i-  E 1 *r- ID E  r- 4-5 s- S-cn -—p -a \ ~o \ 8  r— -—. o o O cu cuv_P CU >> S- >5 S- r^ s 1 %~ s- E %. 4-5 4-54-5 e  cn s z  cu XI cu cn O- cu SZ p. C L '—' cn cn ---
4-5 XI •r- \ 1 > 1 > p— 's , -> ------- S- cu ^ cu s-xr cn x= i— CM -r- *0" *i— O r— <U •!— o I— cu r— r— p— cucn •r- Q. o i— . r— %- o E  •— 4-5 CU <0 > O E o >•r— cu E r— p— CU E o >> cn E  •«- x : XI •r—’<U 5 O 73. >, cn >, cn 4-5 a . s- cn C_5 <0 O r— o  o CJr—
E E  \ E  \ to — XI \ 1 4-5 in os~ r~ CU r— CU 1— cu a  r— 3 0  O p—% o  cn E  r - S- cn
> ) <u cu XT O x : o 1— cu o  o Cu 13 E £ - \ 13 \ cu■o > XI to Q- E a .  e O to 4-5 E a  -a •r- cj cn s_ cn > cn
o •r* 4-5 <d •r- E •r- E XT <0 > 5  £= «=C CU E •r -  E cu E •1“ E00 _ 1 LU r— CO----- CO —- O  1— c_> — - 21 O I CO * —1*«—1
Me
an 
+ 
st
an
da
rd
 
de
vi
at
io
n 
giv
en
 
in 
ea
ch
 
ca
se
.
Appendix 2. The control values fo r  the safro le induction study.
Body weight, g
Liver weight, g
Ethylmorphine N-demethylase 
ymol/total liver/min
Biphenyl 2-hydroxylase 
nmol/total liver/min
Biphenyl 4-hydroxylase 
ymol/total liver/min
Cholesterol 7a-hydroxylase 
pmol/total liver/min
Cytochrome P-450 
nmol/total liver
NADPH-Cytochrome c reductase 
ymol/total liver/min
Microsomal protein 
mg/total liver
199 + 11 
9.4 + 1.2
2 . 2 + 0 . 2  
6.9 + 2.0 
0.28 + 0o04
f
224 + 75 
232 + 21 
9.8 + 2.0 
238 + 17
Mean + standard deviation given in each case.
